



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/




Meeting Housekeeping and Rules

Revised April 13, 2021

Disclaimers

- This meeting is being conducted in a hybrid format – In Person and via Zoom.
- Video, audio, and Chat Box input is being recorded and will become part of the public record.
- For virtual participants with video capability, you can choose to have it on or off. You are not required to be on video at anytime during the meeting.



← *Video is off. Click to turn on.*

- Meeting materials were distributed prior to the meeting via AIDSNET at <http://aidsnet.org/meeting-documents/>.
- Zoom help can be found at <https://support.zoom.us/hc/en-us>

Setting the Meeting Environment

- All participants should place cell phones on mute/vibrate to reduce interruptions and feedback.
- Zoom participants should turn off external devices such as televisions, radios, etc.
- Zoom participants will be placed on mute and can unmute or be unmuted when acknowledged by the chair.

The Agenda

- The meeting will follow the Agenda which was distributed in advance.
- Some Agenda items have been modified for the hybrid meeting platform.
- Roll call will be conducted to indicate who is present at the meeting.
- The Agenda and supporting documents will be projected by staff and seen both in the meeting room or via Zoom Shared Screen mode.
- The Chair will lead the meeting per the Agenda and will recognize other participants named on the Agenda in order.

Roll Call

An officer or staff will read each **member's** name:


- If physically at the meeting, members will verbally “Here”, or
- If participating by Zoom, members will **Chat** “Here” to have participation recorded.

Staff will announce the names in-person and Zoom guests and staff.

Notes

- Anyone who has not been recognized during Roll Call should advise staff in-person or via Zoom chat.
- Zoom participants: If your name appears only as a phone number or other name, your attendance may not be recorded **UNLESS YOU CHAT.**

Chat Box



- Zoom participants may send comments or questions via the Chat Box.
- Only the moderator (staff) will see the chat box input.
- All chat input should be relevant to the item being discussed.
- Instead of using the “Hand Up” function, you may chat “**Hand Up**” to be added to the queue.
- The moderator will maintain a queue and the Chair will call on participants in order.

Special Notes for Members Attending In Person


COVID-19 Protocol

- Please leave your chair where it is positioned to ensure social distancing.
- Please keep your mask on at all times, covering your nose and mouth.

Microphones

- Participants in the Library each have their own microphone.
- When using the microphone:
 1. Turn the volume button to on (**Green**)
 2. Speak as close to the microphone as possible
 3. State your name so that Zoom attendees know who is speaking
 4. Turn the volume button to off (**Red**) when finished speaking

Voting and Motions via Zoom



Make a Motion

- Chat “**Motion**” or raise hand to make motion.
- The Chair will recognize you and you can make the motion.



Raise Hand

Second a Motion

- Chat “**Second**” or indicate second of motion.
- The Chair will read the name of member who seconds the motion.

The Chair will call for Discussion

- Chat “**Hand Up**” or click **Raise Hand** to be recognized by the Chair.
- Discussion should be limited to the current motion/Agenda item only.
- The Chair may impose time limits for discussion.

After discussion, the Chair will call for a Vote

- Voting is for Committee Members only.
- If you are **VOTING AGAINST** a Motion, Chat “**Opposed**”
- The member(s) voting against the motion will be read into the record.
- All members without a Chat of “Opposed” will be counted as **VOTING IN FAVOR** of the motion.

Voting and Motions In-Person

Make a Motion

- Raise your hand.
- The Chair will recognize you and you can make the motion.

Second a Motion

- State “Second”.
- The Chair will restate the name of the member who seconds the motion.

The Chair will call for Discussion

- Raise your hand to be recognized by the Chair.
- Discussion should be limited to the current motion/Agenda item only.
- The Chair may impose time limits for discussion.

After discussion, the Chair will call for a Vote

- Voting is for Committee Members only.
- Raise your hand - either for or against the motion - when the vote is called.





MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



Roll Call

Please indicate “present” or “here” when your name is called.

If participating via Zoom, please CHAT your name when your name is called to be included in today’s meeting attendance list.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

Floor Open to the Public

“Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any item on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns.

“BSR has a dedicated phone line and email for statements to be read into the record. No statements were received.”



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



**Medical Care Subcommittee Meeting
Miami-Dade Public Library, Auditorium
101 West Flagler, Miami, FL 33130 and Zoom
January 22, 2021**

#	Members	Physically Present	Virtually Present	Absent	Guests	
1	Baez, Ivet	x			Wendy Beauchamp	
2	Bauman, Dallas		x		Kimberly Wolak-Clark	
3	Cortes, Wanda	x			Brad Mester	
4	Dougherty, James			x	Ana Nieto	
5	Goubeaux, Robert		x		Angela Ortiz	
6	McFeely, John		x		Ray Sawaged	
7	Palacios, Carlos	x				
8	Pinero, Carmen	x				
9	Romero, Javier		x			
10	Torres, Johann		x			
11	Thornton, Darren	x				
12	Valle-Schwenk, Carla	x				
13	Vasquez, Silvana	x			Staff	
Quorum: 6					Christina Bontempo	Marlen Meizoso

Note that all documents referenced in these minutes were accessible to members and the public prior to (and during) the meeting, at www.aidsnet.org/meeting-documents. This meeting was held in a hybrid format with some members and guests participating via Zoom while other members maintained physical quorum.

I. Call to Order/Introductions

Carlos Palacios, the acting Chair, called the meeting to order at 9:40 a.m. He welcomed everyone and indicated some agenda items have been modified for a virtual format.

II. Meeting Housekeeping

Marlen Meizoso reviewed the Meeting Housekeeping and Rules presentation (copy on file), which reviewed the revised steps for hybrid meetings to ensure a good meeting environment.

III. Roll Calls

Members names were called, and they indicated their presence by voice for those physically at the meeting or chatting "Here" or "Present" in the chat box for members on Zoom. Guest names were called and indicated they were present either via chat or by voicing their presence.

IV. Review/Approve Agenda

The Subcommittee reviewed the agenda and voted to accept it as presented.

Motion to accept the agenda.

Moved: Carla Valle-Schwenk

Second: Ivet Baez

Motion: Passed

V. Floor Open to the Public

Mr. Palacios read the following: *“Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any item on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns.”*

“BSR has a dedicated phone line and email for statements to be read into the record. No statements were received.”

There were no comments, so the floor was closed.

VI. Review/Approve Minutes of October 23, 2020

Members reviewed the minutes of October 23, 2020 and accepted them with no changes.

Motion to accept the minutes of October 23, 2020.

Moved: Wanda Cortes

Second: Carla Valle-Schwenk

Motion: Passed

VII. Reports-Question and Answer

Carlos Palacios indicated that with the streamlined meeting process, reports will not be reviewed at the meeting. The Ryan White Part A, ADAP and Vacancy reports have been posted online at aidsnet.org. Questions regarding the report were requested but there were none. If anyone has any questions after the meeting, these can be forwarded to staff.

XI. Standing Business

- Letters of Medical Necessity Review

All

Mrs. Meizoso explained that at the last meeting the Letters of Medical Necessity were identified as needing updating. Staff forwarded suggested revisions to all ten letters of medical necessity. A memo accompanied the suggestions, explaining what was requested of the Subcommittee along with utilization data (copies on file). The Subcommittee addressed each letter and made motions to either delete or modify the letters.

The Subcommittee first decided to make uniform the introductory statement to the letters. They opted with the phrase “medical practitioner for” on the letters. Updates were suggested (copies on file) which included the signature lines inclusion of D.O.,P.A. and A.P.R.N. next to M.D. and updating the Ryan White Program client information system from SDIS to Provide. The Subcommittees adopted these changes to the six letters which remained (Antiretroviral Assay, Neupogen, Procrit/Epogen, Roxicodone, Testosterone, and Highly Sensitive Tropism).

Motion to accept the revisions to the Antiretroviral Assay Letter for Phenotype as discussed.

Moved: Carla Valle-Schwenk

Second: Dr. Robert Goubeaux

Motion: Passed

The Subcommittee reviewed utilization data for the last five years and noted the letter for Aptivus, Fuzeon and Sporonox had not been used. Sporonox is now available in generic. The Subcommittee voted to remove the need for a letter of medical necessity for those four medications. These medications will still be on the formulary unless specifically removed.

Motion to delete the Letter of Medical Necessity for Aptivus.

Moved: Carla Valle-Schwenk

Second: Wanda Cortes

Motion: Passed

Motion to delete the Letter of Medical Necessity for Fuzeon.

Moved: Carla Valle-Schwenk

Second: Dr. Darren Thornton

Motion: Passed

Motion to delete the Letter of Medical Necessity for Sporonox.

Moved: Dr. Robert Goubeaux

Second: John McFeely

Motion: Passed

In addition, on the Neupogen, Procrit or Epogen letters of medical necessity, it was recommended to remove the list of pharmacies at the bottom. Additional language was added to request documentation be attached to the LOMN document as indicated.

Motion to accept the revisions to the Letter of Medical Necessity for Neupogen.

Moved: Carla Valle-Schwenk

Second: Wanda Cortes

Motion: Passed

Motion to accept the revisions to the Letter of Medical Necessity for Procrit or Epogen.

Moved: Wanda Cortes

Second: Ivet Baez

Motion: Passed

In addition to the general changes previously discussed in the other letters, updated Florida Code language was included in the letter of medical necessity for Roxicodone, since there was revision to the code. These changes were accepted. The revised language will be verified with the County Attorney.

Motion to accept the revisions to the Roxicodone the Letter of Medical Necessity.

Moved: Ivet Baez

Second: Dr. Darren Thornton

Motion: Passed

The Subcommittee approved the changes recommended to the letter but indicated they may want to review at a future meeting why the letter of medical necessity was originally created, and if is still needed.

Motion to accept the revisions to the Letter of Medical Necessity for Testosterone Supplementation.

Moved: Ivet Baez

Second: Dr. Darren Thornton

Motion: Passed

On the letter for the Highly Sensitive Tropism Assay, since language on the ViiV Healthcare program that pays for the test is obsolete, it was recommended to strike that and any mention of ViiV on the letter. So, the revised sentence would now read "... is not eligible for any other payment source".

Motion to accept the revisions to the Highly Sensitive Tropism Assay required to prescribe Maraviroc (Selsentry).

Moved: Dr. Robert Goubeaux

Second: Dallas Bauman

Motion: Passed

Since nutritional supplements are no longer covered by the Ryan White Program, per HRSA guidance, the letter was recommended for deletion.

Motion to delete the Ryan White Program Nutritional Supplemental Referral two-page letter.

Moved: Carla Valle-Schwenk

Second: Dr. Ivet Baez

Motion: Passed

XII. New Business

▪ **Officer Elections**

Mrs. Meizoso reviewed the elections memo (copy on file). A chair and vice-chair will be needed to be elected. Carlos Palacios indicated he was interested in the chair position, and Dr. Robert Goubeaux indicated he was interested in the vice-chair position.

Motion to accept Carlos Palacios as chair and Dr. Robert Goubeaux as vice-chair.

Moved: Silvana Vasquez

Second: Dallas Bauman

Motion: Passed

Staff indicated that there were a few business items left to discuss and an extension of time would be needed in order to complete the items. The Subcommittee made a motion to extend the meeting until business was concluded.

Motion to extend the meeting until business is concluded.

Moved: Carla Valle-Schwenk

Second: Ivet Baez

Motion: Passed

▪ **Work Plan Review**

Mrs. Meizoso reviewed the current workplan items for this year (copy on file). With the current pandemic and data needs she suggested the Subcommittee address the standards of care during the summer when new data should be updated. She suggested taking the language in the separate file of other standards and adding these to the document so all the items can be found in one document. The Subcommittee agreed to the edits.

▪ **Annual Disclosure forms**

Mrs. Meizoso reviewed the annual disclosure forms that need to complete (copy on file). The form will be emailed to members either Friday or Monday. In the next month or so, the annual source of income forms will also need to be completed. Staff will forward those items upon receipt. If there are any questions on how to complete any forms, members may call the office or email her.

▪ **Discussion on medroxyprogesterone acetate**

Mrs. Meizoso indicated Carla Valle-Schwenk wanted to discuss medroxyprogesterone acetate. In 2015, the Partnership restricted access to J1050 (Depo-Provera-medroxyprogesterone acetate injectable) under Outpatient/Ambulatory Health Services as a prevention therapy that also was available through a Patient Assistance Program. Sometime after MCSC made the restriction to J1050 in 2015, the HRSA Policy Clarification Notice 16-02 (PCN 16-02 RWHAP Services Eligible Individuals and Allowable Uses of Funds (hrsa.gov) allows for preventive care under Outpatient/Ambulatory Health Services. Dr. Beal gave his opinion that Depo-Provera should be considered preventive care. This affects the current restriction for J1050 (Depo-Provera) under Outpatient/Ambulatory Health Services (OAHS). The Subcommittee decided to unrestrict its usage.

Motion to remove the restriction on J1050 under Outpatient Ambulatory Health Services.

Moved: Wanda Cortes

Second: John McFeely

Motion: Passed

The formulary allows for all formulations unless restricted. The Subcommittee indicated that all the formulations of medroxyprogesterone acetate should be included along with the brand names.

Motion to modify the Ryan White Program prescription drug formulary to include all formulations of medroxyprogesterone acetate, including injectables, and to add brand names.

Moved: Dr. Darren Thornton

Second: Ivet Baez

Motion: Passed

XIII. Announcements

Mrs. Meizoso announced that all announcements were posted online at www.aidsnet.org

XIV. Next Meeting

The next meeting is scheduled for February 26, 2021. The Subcommittee was asked if the 9:30 a.m. time worked and they indicated the new time was fine. For subsequent meetings, the meetings will be calendared from 9:30 a.m. to 11:30 a.m.

XV. Adjournment

Motion to adjourn.

Moved: Wanda Cortes

Second: Dr. Darren Thornton

Motion: Passed

Mr. Palacios adjourned the meeting at 11:15 a.m.

DRAFT



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

RYAN WHITE PART A GRANT AWARD (BU0330)
EARMARK ALLOCATION AND EXPENDITURE RECONCILIATION SCHEDULE YR30
FORMULA AND SUPPLEMENTAL FUNDING
Per Resolution #s: R-1125-19, R-246-20, R-247-20, AND R-817-19

This report includes YTD paid reimbursements for FY 2020 Part A service months up to January 2021, as of 3/4/2021. This report reflects reimbursement requests that were due by 2/20/2021 and have been paid thus far. Pending Part A reimbursement requests that have been received and are in process total \$1,981,950.69.

GRANT #: BU0330	AWARD AMOUNTS	GRANT DETAILS
Grant Award Amount Formula	15,610,424.00	01FORM
Grant Award Amount FY'18 Formula	1,632.00	01FOR2
Grant Award Amount Supplemental	7,612,515.00	01SUPP
Grant Award Amount FY'18 Supplemental	697,021.00	01SUP2
Carryover Award FY'19 Formula	707,084.00	01CYOV
Total Award	\$ 24,628,676.00	23,921,592.00 W/out CO

CONTRACT ALLOCATIONS/ FORMULA & SUPPLEMENTAL AWARDS

DIRECT SERVICES:

Core Medical Services	Allocations	
Outpatient/Ambulatory Health Svcs	8,661,870.00	
AIDS Pharmaceutical Assistance	66,007.00	
Oral Health Care	2,888,975.00	
Health Insurance Services	459,450.00	
Mental Health Therapy/Counseling	123,257.00	
Medical Case Management	5,745,493.00	
Substance Abuse - Outpatient	44,128.00	17,989,180.00

Support Services	Allocations	
Emergency Financial Assistance	0.00	
Food Bank	1,303,799.00	
Other Professional Services	154,449.00	
Medical Transportation	150,649.00	
Outreach Services	264,696.00	
Substance Abuse - Residential	1,773,744.00	3,647,337.00

DIRECT SERVICES TOTAL: \$ 21,636,517.00

Total Core Allocation	17,989,180.00	
Target at least 80% core service allocation	17,309,213.60	
Current Difference (Short) / Over	\$ 679,966.40	
Grantee Admin. (GC, ACMS, BSR Staff)	\$ 2,392,159.00	
Quality Management	\$ 600,000.00	
(+) Unobligated Funds / (-) Over Obligated:	2,992,159.00	24,628,676.00
Unobligated Funds (Formula & Supp)	\$ -	
Unobligated Funds (Carry Over)	\$ -	Check: \$0.00

Core medical % against Total Direct Service Allocation (Not including C/O):	
Cannot be under 75%	83.14% Within Limit

Quality Management % of Total Award (Not including C/O):	
Cannot be over 5%	2.51% Within Limit

OMB-GC Administrative % of Total Award (Cannot include C/O):	
Cannot be over 10%	10.00% Within Limit

CURRENT CONTRACT EXPENDITURES

DIRECT SERVICES:

S/O	Core Medical Services	Expenditures	Carryover Expenditures
60661	Outpatient/Ambulatory Health Svcs	4,709,759.13	
49212	AIDS Pharmaceutical Assistance	3,725.50	
21610	Oral Health Care	1,258,057.57	
22353	Health Insurance Services	223,525.02	
11404	Mental Health Therapy/Counseling	54,417.81	
21110	Medical Case Management	4,014,995.30	
21612	Substance Abuse - Outpatient	4,593.50	10,269,073.83

S/O	Support Services	Expenditures	Carryover Expenditures
22430	Emergency Financial Assistance	0.00	
49225	Food Bank	529,484.80	606,925.80
21210	Other Professional Services	124,510.50	1,136,410.60
60240	Medical Transportation	5,529.40	
22470	Outreach Services	49,629.82	
22413	Substance Abuse - Residential	1,198,110.00	2,514,190.32

TOTAL EXPENDITURES DIRECT SVCS & %: \$ 12,783,264.15 59.08%

Formula Expenditure %	93.99%
Grantee Administration	1,946,044.86
Quality Management	550,000.00 2,496,044.86
Grant Unexpended Balance	9,349,366.99
Total Grant Expenditures & %	\$ 15,279,309.01 62.04%

Core medical % against Total Direct Service Expenditures (Not including C/O):	
Cannot be under 75%	84.34% Within Limit

Quality Management % of Total Award (Not including C/O):	
Cannot be over 5%	2.30% Within Limit

OMB-GC Administrative % of Total Award (Cannot include C/O):	
Cannot be over 10%	8.14% Within Limit

RYAN WHITE PART A GRANT AWARD (BU0330)
EARMARK ALLOCATION AND EXPENDITURE RECONCILIATION SCHEDULE YR30
MINORITY AIDS INITIATIVE (MAI) FUNDING
 Per Resolution #s: R-1125-19, R-246-20, R-247-20, AND R-817-19

This report includes YTD paid reimbursements for FY 2020 MAI service months up to January 2021, as of 3/4/2021. This report reflects reimbursement requests that were due by 2/20/2021 and have been paid thus far. Pending MAI reimbursement requests that have been received and are in process total \$342,832.07.

GRANT #: BU0330	AWARD AMOUNTS	GRANT DETAILS
Grant Award Amount MAI	2,688,357.00	02MAIA
Grant Award Amount FY'18 MAI	23,133.00	02MAI2 2,711,490.00
Carryover Award FY'19 MAI	382,451.00	02MAIC W/out C/O
Total Award	\$ 3,093,941.00	

CONTRACT ALLOCATIONS

DIRECT SERVICES:

Core Medical Services	Allocations	
Outpatient/Ambulatory Health Svcs	1,491,992.00	
AIDS Pharmaceutical Assistance		
Oral Health Care		
Health Insurance Services		
Mental Health Therapy/Counseling	18,960.00	
Medical Case Management	1,156,338.00	
Substance Abuse - Outpatient	8,058.00	2,675,348.00
Support Services	Allocations	
Emergency Financial Assistance	0.00	
Food Bank		
Other Professional Services		
Medical Transportation	7,628.00	
Outreach Services	39,816.00	
Substance Abuse - Residential		47,444.00
DIRECT SERVICES TOTAL:	\$ 2,722,792.00	

Total Core Allocation	2,675,348.00	
Target at least 80% core service allocation	2,178,233.60	
Current Difference (Short) / Over	\$ 497,114.40	
Grantee Admin. (OGC)	\$ 271,149.00	
Quality Management	\$ 100,000.00	
(+) Unobligated Funds / (-) Over Obligated:	371,149.00	3,093,941.00
Unobligated Funds (MAI)	\$ -	
Unobligated Funds (Carry Over)	\$ -	Check: 0.00

Core medical % against Total Direct Service Allocation (Not including C/O):		
Cannot be under 75%	98.26%	Within Limit

Quality Management % of Total Award (Not including C/O):		
Cannot be over 5%	3.69%	Within Limit

OMB-GC Administrative % of Total Award (Cannot include C/O):		
Cannot be over 10%	10.00%	Within Limit

CURRENT CONTRACT EXPENDITURES

DIRECT SERVICES:

S/O	Core Medical Services	Expenditures	Carryover Expenditures
60661	Outpatient/Ambulatory Health Svcs	178,839.81	0.00
49212	AIDS Pharmaceutical Assistance		
21610	Oral Health Care		
22355	Health Insurance Services		
11404	Mental Health Therapy/Counseling	7,584.00	
21110	Medical Case Management	212,468.04	7,352.75
21612	Substance Abuse - Outpatient	0.00	
			406,244.60
S/O	Support Services	Expenditures	Carryover Expenditures
22430	Emergency Financial Assistance	0.00	
49225	Food Bank		
21210	Other Professional Services		
60240	Medical Transportation	0.00	
22470	Outreach Services	0.00	
22413	Substance Abuse - Residential		
			0.00
TOTAL EXPENDITURES DIRECT SVCS & %		\$ 406,244.60	14.92%

Grantee Administration	139,567.75	
Quality Management	91,666.63	231,234.38
Grant Unexpended Balance	2,456,462.02	
Total Grant Expenditures & % (Including C/O):	\$ 637,478.98	20.60%

Core medical % against Total Direct Service Expenditures (Not including C/O):		
Cannot be under 75%	100.00%	Within Limit

Quality Management % of Total Award (Not including C/O):		
Cannot be over 5%	3.38%	Within Limit

OMB-GC Administrative % of Total Award (Cannot include C/O):		
Cannot be over 10%	5.15%	Within Limit

**Miami-Dade County
Ryan White Part A/MAI Program Update
for March 2021 Partnership & Committee meetings
As of 03/10/2021**

Number of Unduplicated Clients Served

- Part A/MAI clients served:
 - Approximately 7,913 unduplicated clients were served from March 1, 2020 through January 31, 2020.

ACA Update

- FDOH is supporting 27 ACA Marketplace health plans in 2021; 6 of them are new, replacing a couple of plans that were discontinued.
- For plan year 2021, as of 3/5/2021:
 - 2,253 clients are enrolled in ADAP-sponsored ACA health insurance plans
- Special Enrollment Period:
 - February 15 through May 15
 - We are using same local process with American Exchange as we do with the normal open enrollment period

Part A/MAI Expenditures Report

- Most current version is in the meeting handouts:
 - Pending invoice totals as of 3/4/2021:
 - Part A: \$1,981,950.69
 - MAI: \$342,832.07
- Status of amendments for FY 2020:
 - All 21 subrecipient amendments (Part A/MAI/CARES Act) were executed by grant fiscal year end, February 28th.
 - We have already paid most of the Advance Payment Methodology payments.
 - REMINDER: delays were caused by development of new contracts (including 4 new subrecipients) resulting from the RFP awards approved by Board of County Commissioners in March 2020; implementation of new MIS data management system; and COVID-19.
- A review of the current Earmark Allocation and Expenditure Schedule shows the recipient's core medical expenditure percentage above the 75% limit.

- Taking into consideration the additional drawdowns that will be made as a result of the subrecipients selecting the APM, it is projected that the recipient will be able to reach the 95% Formula minimum expenditure requirement. We are current at approximately 91%
- Despite the low expenditure rate on the current award (FY 2020), the recipient plans to prioritize the use of the carryover funds recently awarded and request a carryover of all *eligible* funds for use during FY 2021.

Test & Treat / Rapid Access (TTRA)

- TTRA clients served between July 2, 2018 and March 4, 2021: 1,740
 - 642 New to Care
 - 394 New to RW Care
 - 702 Returned to Care
 - 2 Referral category not specified
 - 1,310 (75%) of those enrolled were on antiretroviral (ARV) medications
 - 1,136 (65%) of those enrolled are virally suppressed
 - IMPORTANT NOTE: These numbers are subject to change.

Administrative

- Ending the HIV Epidemic (EHE):
 - Part A Request for Proposals document for Ending the HIV Epidemic was issued February 8, 2021, with responses due March 8, 2021. County is currently under the Cone of Silence for this process.
 - In March 2021, hiring process is underway to fill the Special Projects Administrator 2 position for this grant.
- COVID-19:
 - All County Ryan White (Recipient) staff members continue working from home, as directed by the County Mayor and Interim Department Director. All Recipient staff have access to Remote Desktop and have ongoing contact with their assigned subrecipients. Contracts Officers continue to handle client calls placed to the office; mostly from existing or potential clients requesting assistance with connecting to care.
 - Subrecipient sites are open; but some of their staff are still working remotely. Those working onsite continue to follow CDC guidelines to help limit the spread of COVID-19.
 - CARES Act (COVID-19) amendments are fully executed for Personal Protective Equipment (PPE) (face masks/coverings) and hand sanitizer to distribute to clients and clients' immediate household members; as well as, to purchase appropriate PPE (face masks, face shields, gloves, gowns, etc.) to be used by front-line staff and clients during onsite provision of services.
- The County Ryan White staff continue to keep subrecipients and the Partnership (through its staff support) informed of federal, state, and local guidance on coronavirus by electronic mail with links to webinars and online information. In addition, we update them on state and federal business assistance programs and grant opportunities. BSR was copied on these notifications for distribution to the Partnership and the community.

- The County Ryan White staff continues to coordinate with FDOH staff and Part A/MAI subrecipients to address urgent/emergent client issues.

Other Planning Activities

- Part A/MAI Recipient staff continue to participate in:
 - Florida Comprehensive Planning Network (FCPN) Ending the HIV Epidemic (EHE) Workgroup meetings
 - Medication Access Committee meetings
 - Florida Part A / Part B coordination meetings:
 - Part A, Part B and FDOH are in the planning stages for the anticipated rollout of the new long-acting injectable antiretroviral medication, Cabenuva®
 - Planning meetings for data sharing and matching with Florida Department of Health and Georgetown University related to the statewide HRSA 19-039 Communities of Practice: Data to Care project

Mission:

To protect, promote & improve the health of all people in Florida through integrated state, county & community efforts.



Vision: To be the Healthiest State in the Nation

Ron DeSantis
Governor

Scott A. Rivkees, MD
State Surgeon General


March 2021

ADAP Miami-Dade / Preliminary Summary Report – FY 2020/2021

FY 20/21	First Enrollments	6-mo. Re-Enrollments	TOTAL OPEN	CHD Pharmacy Expenditures	RXs	Patients	RX/Pt	Premium Payments	Number of Premiums	Average Premium
Apr-20	60	340	6,352	\$4,333,133.87	8,271	2,815	2.9	\$1,956,513.58	2228	\$ 878.15
May-20	61	548	6,401	\$1,434,289.65	2,605	1,014	2.6	\$1,969,923.35	2248	\$ 876.30
Jun-20	49	1,143	4,414	\$2,895,422.35	5,514	1,882	2.9	\$1,646,967.06	1868	\$ 881.67
Jul-20	58	1,469	4,813	\$2,615,961.21	4,097	1,442	2.8	\$1,709,454.62	1956	\$ 873.95
Aug-20	78	1,012	5,329	\$3,907,327.65	5,302	1,800	2.9	\$1,710,234.89	1986	\$ 861.15
Sep-20	78	815	5,505	\$2,348,591.65	3,512	1,189	3.0	\$1,748,953.44	2042	\$ 856.49
Oct-20	73	794	5,762	\$2,020,011.87	3,210	1,094	2.9	\$1,815,989.33	2115	\$ 858.62
Nov-20	51	653	5,815	\$3,308,569.45	4,863	1,559	3.1	\$1,820,370.09	2121	\$ 858.26
Dec-20	76	995	5,765	\$2,476,310.34	3,827	1,300	2.9	\$1,818,513.05	2122	\$ 856.98
Jan-21	55	1,072	5,769	\$2,096,849.84	3,211	1,110	2.9	\$2,278,320.06	2195	\$ 1,037.96
Feb-21	66	1,074	5,773	\$2,727,812.49	4,256	1,371	3.1	\$2,270,017.21	2214	\$ 1,025.30
Mar-21	90	1,064	5,766	\$2,679,073.95	4,010	1,368	2.9	\$2,369,904.49	2300	\$ 1,030.39
TOTAL	795	10,979	5,766	\$32,843,354.32	52,678	17,944	2.9	\$23,115,161.17	25,395	\$ 910.22

ADAP-Miami @ West Perrine – not included in report

- Estimate for ~300 Direct Dispense clients served through CVS Specialty (\$4.5-5.5 million/TBC)



PROGRAM UPDATE

- 01/28 – Federal Executive Order: Special Enrollment Period into ACA-MP (February 15 – May 15)
- 02/24 – ADAP clients with COBRA or High Utilization rates, eligible to apply for ACA-MP insurance (FLADAP approved plans)
- 02/26 – Executive Order: Suspension of CD4 and Viral Load requirement, extended to April 27, 2021
- 03/23 – Extension of Special Enrollment Period into ACA-MP (February 15 – August 15)
- 03/25 – ADAP Program & CHD Pharmacy completed 1 year of Emergency Operations (Drive-Thru & Walk-Up services; 18,000+ clients served)

For additional information: www.ADAPMiami.com or ADAP.FLDOHMDC@flhealth.gov



Executive Committee Report to Committees April 2020

Supporting documents related to motions in this report are available online at aidsnet.org/meeting-documents/, or from staff at Behavioral Science Research Corp. (BSR). Contact hiv-aidsinfo@behavioralscience.com for assistance.

The scheduled Partnership meeting of March 17, 2021 failed to reach quorum. The Executive Committee was convened on April 12, 2021 and reviewed and approved the following Committee motions:

Care and Treatment Committee

1. Motion to accept ten (10) motions proposed by the Medical Care Subcommittee related to revisions and deletions of Letters of Medical Necessity:
 - a. Motion to accept the revisions to the Antiretroviral Assay Letter for Phenotype as discussed.
 - b. Motion to accept the revisions to the Letter of Medical Necessity for Neupogen.
 - c. Motion to accept the revisions to the Letter of Medical Necessity for Procrit or Epogen.
 - d. Motion to accept the revisions to the Roxicodone the Letter of Medical Necessity.
 - e. Motion to accept the revisions to the Letter of Medical Necessity for Testosterone Supplementation.
 - f. Motion to accept the revisions to the Highly Sensitive Tropism Assay required to prescribe Maraviroc (Selsentry).
 - g. Motion to delete the Letter of Medical Necessity for Aptivus.
 - h. Motion to delete the Letter of Medical Necessity for Fuzeon.
 - i. Motion to delete the Letter of Medical Necessity for Sporonox.
 - j. Motion to delete the Ryan White Program Nutritional Supplemental Referral two-page letter.
2. Motion to remove the restriction on J1050 under Outpatient/Ambulatory Health Services.
3. Motion to modify the Ryan White Part A Program Prescription Drug Formulary to include all formulations of medroxyprogesterone acetate, including injectables, and to add brand names.

Community Coalition Committee

4. Motion to direct staff to write a letter to Mayor Daniella Levine Cava to:
 - a. Introduce the Miami-Dade HIV-AIDS Partnership;
 - b. Request guidance on how we can speed up the process of new member appointments to the Partnership; and
 - c. Request assistance with filling Partnership vacancies for Miami-Dade County Public Schools Representative; Federally Recognized Indian Tribe Representative; Former inmate of local, state, or federal prison released from custody of penal system during the preceding three years and HIV-positive as of release date, or a representative of HIV-positive incarcerated persons; Ex-officio Representative of the Office of the MDC Mayor; and Ex-officio Representative of the Board of County Commissioners.

Strategic Planning Committee

5. Motion to accept the 2020 Annual Report, as presented.

Membership

6. Motion to appoint Angela Machado to the Strategic Planning Committee.

Details on future meetings are online at <http://aidsnet.org/calendar/> (Partnership Website) and <https://www8.miamidade.gov/global/calendar/global.page> (County Website).



Vacancy Report

April 21, 2021

The Miami-Dade HIV/AIDS Partnership (Partnership) is the advisory board for HIV/AIDS to the Miami-Dade County Mayor and the MDC Board of County Commissioners. In addition to the advisory board, the Partnership is comprised of five (5) committees and one (1) subcommittee. If you meet the qualifications for membership, you are encouraged to apply.

Qualifications for Membership

Members must have a reputation of integrity and community service, and possess the knowledge, skills and expertise relevant to the position for which they are applying and, as applicable, be currently employed in the field of expertise they wish to represent. Members must be committed to working toward the Partnership's vision: *To eliminate disparities and improve health outcomes for all people living with or at risk for HIV/AIDS.*

Miami-Dade HIV/AIDS Partnership Qualifications:

- Devote at least four (4) hours per month to Partnership and committee activities;
- Be a resident of and a registered voter in Miami-Dade County (MDC) (some seats are exempt from this requirement);
- Agree to undergo a criminal background check conducted by the Office of the Mayor of MDC; and
- Complete additional training and Partnership and County documents and forms as required.

Committee or Subcommittee Qualifications:

- Devote at least three (3) hours per month to committee activities;
- Be a resident of and a registered voter in Miami-Dade County; and
- Complete additional training and Partnership and County documents as required.

Miami-Dade HIV/AIDS Partnership Vacancies

39 Members; 3 Alternates; 2 Ex-Officio Members

14 Member vacancies

Goal: 8 Members and 3 Alternates

- Representative of the Affected Community
 - *Member representatives of affected communities that include individuals with HIV disease, who are not affiliated or employed by a Part A funded provider and are recipients of Part A services, and historically underserved groups and subpopulations that reflect the demographics of the population within the EMA*

Goal: 1 Member

- Federally Recognized Indian Tribe Representative
 - *Representative of a federally recognized Indian tribe as represented in the population from the affected community*

Goal: 1 Member

- Representative Co-infected with Hepatitis B or C

Goal: 1 Member

- Mental Health Provider Representative

Goal: 1 Member

- Former Inmate of local, state, or federal prison

Goal: 1 Member

- Miami-Dade County Public Schools Representative

Goal: 1 Member

- Non-Elected Community Leader, not an HIV provider
 - *Non-elected community leader who does not provide HIV related health care services subject to funding under the Partnership programs*

Miami-Dade HIV/AIDS Partnership's Committee & Subcommittee Vacancies

24 Members sit on each Committee and Subcommittee
Multiple Vacancies

Care and Treatment Committee – 9 Vacancies

This committee conducts the annual needs assessment, reviews Ryan White Part A/MAI standards of care and sets and recommends Ryan White Part A/MAI Program service and funding priorities to the Partnership.

Goal: 3 Members

- Representative of the Affected Community

Goal: 6 Members

- Non-assigned seats

Medical Care Subcommittee – 11 Vacancies

This subcommittee of the Care and Treatment Committee reviews the Ryan White Prescription Drug Formulary and medical treatment guidelines for the Ryan White Part/MAI Program.

Goal: 7 Members

- Representative of the Affected Community

Goal: 2 Members

- Nurse/Medical Case Manager

Goal: 1 Members

- Licensed Medical Providers (MD, DO, APRN, PA) *(1 application pending)*

Goal: 1 Members

- General Seat

Community Coalition Committee – 15 Vacancies

This committee conducts outreach on behalf of the Partnership and recruits, pre-screens, and recommends new members for appointment to the Partnership.

Goal: 15 Members

- Non-assigned seats

Housing Committee – 14 Vacancies

This committee works with the City of Miami HOPWA program to address housing challenges for PLWHA.

Goal: 5 Members

- Representative of the Affected Community

Goal: 9 Members

- Non-assigned seats

Prevention Committee – 4 Vacancies

This committee works with the Florida Department of Health in Miami-Dade County to address HIV/AIDS prevention challenges.

Goal: 4 Members

- FDOH contracted seats and/or non-assigned seats *(1 application pending)*

- 1 Outgoing Member *(1 application pending)*

Strategic Planning Committee - 9 Vacancies

This committee works on drafting, implementing, and monitoring Miami-Dade's Integrated HIV Prevention & Care Plan; produces an annual report on HIV/AIDS in MDC, and evaluates the Ryan White Part A/MAI Program administration.

Goal: 4 Members

- Representative of the Affected Community

Goal: 5 Members

- Non-assigned seats

Membership applications are available on AIDSNET.org, at every Partnership meeting, or by contacting Staff Support at (305) 445-1076 or hiv-aidsinfo@behavioralscience.com.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

**RYAN WHITE PROGRAM
LETTER OF MEDICAL NECESSITY FOR
ANTIRETROVIRAL PHENOTYPE RESISTANCE ASSAYS FOR EXPERIENCED PATIENTS
COVERAGE IS LIMITED TO A MAXIMUM OF ONE PHENOTYPE IN ANY CONSECUTIVE 12-MONTH PERIOD.
*(NOT REQUIRED FOR VIRTUAL PHENOTYPE TESTS)***

Date: _____

As the medical practitioner for _____ it is my considered opinion that he/she requires HIV phenotypic resistance testing. The following criteria have been met:

1. The patient at any time in the past has failed two (2) or more antiretroviral (ARV) regimens;
2. Results of at least one, preferably more, prior genotype(s) must be available in the chart and Resistance to two or more drugs per class in at least two classes of ARVs is present on prior genotype(s);

AND ONE OF THE FOLLOWING (check-off the appropriate condition below):

Prior genotype(s) show(s) resistance to at least 2 PIs other than ritonavir and use of a PI is being considered;

OR

Lopinavir/ritonavir is being considered in a PI-experienced patient with four or more mutations associated with resistance to lopinavir/ritonavir on a prior genotype;

OR

Four or more mutations at codons associated with PI cross-resistance are present;

OR

M184V mutation is present in the presence of 3 or more NRTI-associated mutations (NAMs);

OR

K65R mutation is present, or other mutations associated with NRTI cross-resistance (69 insertion complex or I51 complex);

OR

Rescue ARV regimens guided by results of two or more prior genotypes have failed to suppress viral replication, whether mutations present or not, and the patient has been determined to be adherent on re-evaluation. (Requires a minimum of two prior genotypes.)

I understand HIV phenotypic resistance testing for experienced patients may only be ordered under the following conditions:

1. The above criteria have been met and are fully documented in the patient's medical record;
2. Adherence has been discussed with the patient on an on-going basis as part of his/her medical treatment, and it has been determined that the patient is fully adherent with his/her current ART regimen;
3. The patient's plasma HIV RNA (viral load) at the time of testing must be at least 1000 co/ml within the past month (attach copy to letter of medical necessity);
4. The patient must be on antiretroviral medications at the time of testing.

Sincerely, _____, M.D./D.O./P.A./A.P.R.N.

Print M.D./D.O./P.A./A.P.R.N name

Florida Medical License # (ME#)

Patient's 10 digit Medicaid # (if applicable)

Patient's CIS # (assigned by the Ryan White Program Provide System)

Please note: All questions should be directed to the Office of Management and Budget-Grants Coordination/Ryan White Program, at (305) 375-4742. Requests for information/clarification of a clinical nature will be forwarded by Miami-Dade County to the Miami-Dade HIV/AIDS Partnership Medical Care Subcommittee and/or a qualified member of the Subcommittee (physician, nurse, registered dietitian, etc.). Pursuant to the most current Professional Service Agreement for Ryan White Program-funded services, the service provider must make available to Miami-Dade County access to all client charts (including electronic files), service utilization data, and medical records pertaining to this Agreement during on-site verification or audit by County personnel and/or authorized individuals to confirm the accuracy of all information reported by the service provider.

Rev. x/x/20xx

LOMN Phenotype Staff Notes

April 2021

In March 2021, the County consulted with Dr. Beal regarding phenotypes. Locally, a letter of medical necessity is needed for phenotypes. Data regarding utilization was shared at the prior meeting and is attached. Dr. Beal wanted to share some comments regarding the letter for consideration by the Subcommittee, as indicated below.

My first comment is to ask whether your data shows there are enough Phenotypes ordered to require Practitioners complete this form. I prefer to implement forms based upon abusive practices and not make all of the expert Practitioners justify their requests. Should you see a Practitioner ordering phenotypes frequently, then review their practice charts.

If keeping the form is the preference of the Medical Care Subcommittee I would offer the suggestion to simplify the form stating the phenotype is ordered when: A practitioner is not able to construct an antiretroviral regimen consisting of two fully suppressive antiretroviral drugs from two separate classes documented by resistance pattern, tropism assay, or documented medication intolerance.

Last Five Year Utilization for
Current Letters of Medical Necessity

	FY 2016-2017					FY 2017-2018					FY 2018-2019				
	Und. Clients	Total Rx/Svc	Total Cost for Rx/Svc	% of Total Expenditure	Total FY Expenditure for LAPD/OAHS	Und. Clients	Total Rx/Svc	Total Cost for Rx/Svc	% of Total Expenditure	Total FY Expenditure for LAPD/OAHS	Und. Clients	Total Rx/Svc	Total Cost for Rx/Svc	% of Total Expenditure	Total FY Expenditure for LAPD/OAHS
Antiretroviral Assay Letter for Phenotype Test (87903, 87904)	25	54	\$23,157.43	0.376%	\$6,158,906.00	13	25	\$13,005.23	0.190%	\$6,847,772.00	17	33	\$14,825.32	0.163%	\$9,112,521.00
Aptivus (tipranavir TPV) (RX0314)															
Fuzeon (enfuvirtide ENF, T-20) (RX0301)															
Neupogen (filgrastim) (Rx0701)															
Procrit or Epogen (erythropoietin/epoetin alpha) (RX0700)	1	1	\$1,196.07	0.153%	\$782,605.00										
Roxicodone (oxycodone) (RX0103)	1	3	\$31.50	0.004%	\$782,605.00	1	2	\$775.28	0.176%	\$441,202.00	1	10	\$126.63	0.147%	\$86,210.00
Sporonox (itraconazole) oral solution (RX0523)															
Delatestryl (testosterone enanthate injection) (RX1204)															
High Sensitive Tropism Assay for Maraviroc (Selzentry) (553100, 829670) These are not included in the SDIS list, used 9940134 for Tropism Assay instead															

Last Five Year Utilization for
Current Letters of Medical Necessity

	FY 2019-2020					FY 2020-2021				
	Und. Clients	Total Rx/Svc	Total Cost for Rx/Svc	% of Total Expenditure	Total FY Expenditure for LAPD/OAHS	Und. Clients	Total Rx/Svc	Total Cost for Rx/Svc	% of Total Expenditure	Total FY Expenditure for LAPD/OAHS
Antiretroviral Assay Letter for Phenotype Test (87903, 87904)	23	45	\$15,993.22	0.170%	\$9,391,615.00	3	6	\$2,241.41	0.054%	\$4,187,479.41
Aptivus (tipranavir TPV) (RX0314)										
Fuzeon (enfuvirtide ENF, T-20) (RX0301)										
Neupogen (filgrastim) (Rx0701)	1	3	\$1,024.47	1.771%	\$57,843.00					
Procrit or Epogen (erythropoietin/epoetin alpha) (RX0700)										
Roxicodone (oxycodone) (RX0103)	10	14	\$158.37	0.274%	\$57,843.00	1	1	\$4.64	0.019%	\$24,680.45
Sporonox (itraconazole) oral solution (RX0523)										
Delatestryl (testosterone enanthate injection) (RX1204)										
High Sensitive Tropism Assay for Maraviroc (Selzentry) (553100, 829670) These are not included in the SDIS list, used 9940134 for Tropism Assay instead										



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

RYAN WHITE PROGRAM

Letter of Medical Necessity (LOMN) for Testosterone Supplementation

(A LOMN must accompany each prescription*)

* *Exclusion: This form is not required for clients with gender dysphoria who are prescribed testosterone. Please ensure a related notation is included in the medical record and on the prescription.*

Date: _____

As the medical practitioner for _____, I intend to place this patient on testosterone supplementation (duration may NOT exceed 12 months). I have educated the patient on the consequences of testosterone supplementation and have explained the risks associated with this therapy, including venous blood clots, increased risk of heart attacks and strokes, worsening of undiagnosed prostate cancer and benign prostatic hyperplasia. Hemoglobin levels must be monitored and documented in the patient chart.

I certify that the patient (mark all that apply):

___has a documented low (<350 ng/dL) testosterone lab level at initiation of therapy or low level of free testosterone.

OR

___has a documented history of testosterone therapy but has discontinued therapy for 60 calendar days to re-evaluate levels and still has a documented low (<350 ng/dL) testosterone lab level;

AND/OR

___has primary hypogonadism, in which there is low testosterone accompanied by increased follicle-stimulated hormone and increased luteinizing hormone. Common causes include: Klinefelter’s syndrome, anorchism, undescended testicles, mumps orchitis, hemochromatosis, injury to testicles, cancer treatment, and normal aging;

AND/OR

___has secondary hypogonadism, in which there is low testosterone accompanied by low to normal follicle-stimulated hormone and luteinizing hormone. Common causes include: Kallmann syndrome, pituitary disorders, inflammatory diseases, HIV/AIDS, medications, obesity, and stress-induced hypogonadism;

AND

___is physically symptomatic (e.g. malaise, fatigue, lethargy, muscle loss, depression, decreased bone mass or bone mineral density, etc.).

The following restriction is placed on the medications: Maximum dose is **400 mg per month** unless clinically indicated per labs. **Labs (testosterone: total and free, CBC, PSA) must be submitted to the pharmacy with this letter, and if medication is continued, every 6 months thereafter.**

_____, M.D./D.O./P.A./A.P.R.N.

Print M.D./D.O./P.A./A.P.R.N. name

Florida medical license # (MEO #)

Patient’s 10-digit Medicaid # (if applicable)

Patient’s CIS # (assigned by the Ryan White Program Provide System)

Please note: All questions should be addressed to Office of Management and Budget-Grants Coordination/Ryan White Program, at (305) 375-4742. Requests for information/clarification of a clinical nature will be forwarded by Miami-Dade County to the Miami-Dade HIV/AIDS Partnership Medical Care Subcommittee and/or a qualified member of the Subcommittee (physician, nurse, registered dietician, etc.). Pursuant to the most current Professional Service Agreement for Ryan White Program-funded services, the service provider must make available to Miami-Dade County access to all client files (including electronic files), service utilization data, and medical records pertaining to this Agreement during on-site verification or audit by County personnel and/or authorized individuals to confirm the accuracy of all information reported by the service provider.

LOMN Testosterone Staff Notes

April 2021

At the last meeting, the Subcommittee suggested reviewing the history of the testosterone letter of medical necessity. A letter of medical necessity has existed since before 2003; revisions to the letter have been made in 2003, 2009, 2015, 2018, 2019/2020 and 2021. The primary concern is to ensure that only clients who meet clinical criteria receive the medications. There were issues in the past with high utilization. Currently, utilization is low.

The Medicaid program does not require a letter of medical necessity for this medication. The only restrictions relate to usage for 18 years and older.



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

**Medical Care Subcommittee
Calendar of Activities 2021**

Month	Activities							Notes
	Officer Elections	Conflict of Interest Forms/Financial Disclosure Forms	Outpatient/Ambulatory Medical Care Standards	Allowable Medical Conditions, as needed	Ryan White Prescription Drug Formulary, as needed	Oral Health Care Items	Committee Items (items added as needed)	
January	x	x					x	elections, disclosures, letters of medical necessity (LOMN)
February	N	N	N	N	N	N	N	
March	N	N	N	N	N	N	N	
April							x	LOMN phenotype and testosterone, Cabenuva update, Anchor Study update, substance use disorder
May						x	x	members will review standards and forward recommendations ; information will be forward a end of month
June	N	N	N	N	N	N	N	members will review standards and forward recommendations
July								members will review standards and forward recommendations, Long Acting ARVS
August			x			x	x	
September			x				x	
October			x				x	
November			x			x	x	
December	N	N	N	N	N	N	N	

Comments:
N=no meeting



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Please use the [Cabenuva NASTAD-HIVMA-AAHIVM Resource](#) and the [ViiVConnect site](#) for the latest industry information.

Based on Ryan White provider feedback on potential barriers to long acting injectable antiretrovirals (L-AI ARVs), we have gathered the following resources, suggestions, and best practices.

Patient Adherence Issues:

Area of concern	Suggestions and best practices
Problems with tracking patient follow-up	<p>Use overbook appointment spots or walk-in appointment spots as a failsafe on rescheduled appointments.</p> <p>A best practice is to create a spreadsheet to track patients on Cabenuva (and shipments) when current appointment systems are unable to set up reminders and follow-up appointments (or flag Cabenuva users).</p> <p>ViiVConnect provides Cabenuva-specific support services for providers and clients.</p>
Problems with drug delivery	<p>Contact CVS for lost and delayed shipments, damaged or unusable medications due to shipping, broken vials noted on or right after delivery or indications that temperature has not been maintained during shipping.</p> <p>Contact a ViiV reimbursement manager if a Cabenuva vial shatters on use or if the product appears discolored or contains particulate matter. Please note, Cabotegravir vial is tinted. At present, there is no timeframe available for replacement medication delivery.</p> <ul style="list-style-type: none"> • For North Florida through Tampa, contact Stephanie Meade, FRM, at Stephanie.d.meade@viivhealthcare.com or 813-734-5370. • For South Florida and Orlando, contact Marvin Poole, FRM, at Marvin.x.poole@viivhealthcare.com or 407-516-0534.
Oral medication	<p>For initial oral lead in a practitioner would place order for initiation of Cabenuva through ViiVConnect. A prescription needs to be sent to TheraCom for Vocabria (cabotegravir) and Edurant (rilpivirine).</p> <p>For planned missed injection The current process is to contact ViiVConnect to get information to send the prescription to TheraCom for Vocabria (the cabotegravir portion of the oral medication). The Edurant (rilpivirine) portion of the oral regimen is available for order at the client's retail pharmacy.</p>



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Staff Training Issues:

Area of concern	Suggestions and best practices
Staff training specific to Cabenuva and Z-track injection	<p>Please see the Cabenuva package insert for detailed injection instructions.</p> <p>There is also an injection video on the Cabenuva website.</p>
Possible issues with re-scheduling appropriately for the injection	<p>Clinical support staff should be made aware of the +/- seven-day window limitation to schedule for Cabenuva injections. Include front desk staff in training on the importance of rescheduling patients receiving Cabenuva in a timely manner.</p> <p>If a patient cannot be reached or cancels their appointment – refer to internal processes and include seeking county health department support to locate the patient (through a linkage and engagement specialist or disease intervention specialist).</p>
Clinical considerations for Cabenuva temperature control and administration	<p>DO NOT TAKE THE MEDICATION OUT OF THE FRIDGE UNTIL THE PATIENT ARRIVES. Please wait 15 minutes for the medication to warm up at room temperature prior to injection administration.</p> <p>If you need a larger administration needle to accommodate for body size, contact Fisher Healthcare for the two-inch safety needle.</p>

Transportation Issues:

Area of concern	Suggestions and best practices
Transportation access limits ability to present to clinic for follow up	<p>Local areas are to determine how to address transportation needs within their jurisdictions. Transportation issues are not unique to this drug and are handled differently in different areas based on available resources.</p> <p>Consider ride-share services available in your area. Other possible transportation services may be available through local volunteer organizations, elder care services organizations, and community and religious centers.</p>



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Medication Costs:

Area of concern	Suggestions and best practices
Coverage for those not eligible for the AIDS Drug Assistance Program (ADAP)	<p>Please see the cost sharing and patient assistance information on the NASTAD-HIVMA-AAHIVM Resource.</p> <p>The Patient Assistance Program (PAP) CANNOT BE USED IF THE CLIENT IS ON ADAP.</p> <p>To be eligible for PAP, the patient MUST:</p> <ul style="list-style-type: none"> • Live in one of the 50 states, the District of Columbia, or Puerto Rico • Have a household income less than or equal to 500 percent of the Federal Poverty Level based on household size • Not be eligible for Medicaid or Puerto Rico's Government Health Plan, Mi Salud • Meet one of the following: <ul style="list-style-type: none"> • Have no prescription drug coverage • Have a Medicare Part B, Medicare Part D, or Medicare Advantage Plan and have spent at least \$600 on out-of-pocket prescription expenses during the current calendar year • Have a private insurance plan limited to generic-only coverage, outpatient use only, or therapeutic class exclusion (non-coverage) of drug <p>The PAP decision will be provided after all information is confirmed.</p> <p>The PAP is in Section 8 of the ViiV enrollment form.</p>

Billing:

Area of concern	Suggestions and best practices
Administration costs	<p>Administration costs for the Cabenuva injection range from \$20 to \$25.08 based on current Medicare rates.</p> <p>Associated billing code for Cabenuva: CPT injection code 96372 for each intramuscular injection provided by a nurse under the direct supervision of a provider</p> <p>Please also see the Cabenuva Criteria per Medicaid.</p>



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|---|--|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | <ul style="list-style-type: none">Letters of Medical Necessity for PhenotypesLetter of Medical Necessity for TestosteroneWork Plan Revision | All
All
All |
| IX. | New Business | |
| | <ul style="list-style-type: none">Cabenuva UpdateAnchor Study UpdateSubstance Use Disorder | Carla Valle-Schwenk
John McFeely
All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

Substance Use Trend

March 2021

Overdose Deaths Escalate during COVID-19 Pandemic

The COVID-19 pandemic was declared a national emergency on March 13, 2020.¹ Daily life in the United States changed dramatically with varying restrictions issued by April to help prevent the spread of COVID-19.¹ The pandemic may have had unintended consequences for substance use and overdose.² Job losses, limited social and family interactions, changes in substance use disorder treatment center services, and the pandemic itself provoking anxiety/depression have affected people with addiction and substance use disorder.¹

Drug Overdoses in the U.S. during COVID-19

The pandemic may have led to an increase in drug overdose deaths.¹ Provisional data from the Center for Disease Control and Prevention (CDC) recorded over 81,000 drug overdose deaths in the United States, the highest number of overdose deaths in a 12-month period, ending in May 2020.¹ Although overdose deaths were increasing before COVID-19 pandemic, the latest data suggest overdose deaths have escalated during the pandemic.² Synthetic opioids, primarily illicit fentanyl has been the reason for increases in overdose deaths with a 38.4% increase as of May 2020 compared to data from the previous year.¹ July 2019 to July 2020 shows a 24.2% change increase for drug overdose deaths in the United States.² The predicted number of deaths within this same time period estimates 86,000 drug overdose deaths in the United States.²

Drug Overdoses in Florida during COVID-19

In Florida, predicted cases of drug overdose deaths in 2019 was 5,127 deaths but had a 38.4% increase to 7,098 provisional drug overdose deaths for the current 12-months reporting period from July 2019 to July 2020.² Figure 1 indicates states with over

20% of all fatal drug overdoses from June 2019 to May 2020 in red.³ Provisional data in Florida indicates an increase in suspected non-fatal drug overdoses during the pandemic months of April through September 2020 with 25,048 non-fatal drug overdoses compared 19,191 non-fatal drug overdoses from April through September of 2019.⁴




Figure 1: Percent change in 12-months ending provisional data on all fatal drug overdoses. June 2019-May 2020. Source: [CDC](#)

Recommendations

The COVID-19 pandemic has overshadowed the access and availability of treatment and policies to combat the opioid epidemic.⁵ The CDC suggests expanding distribution and use of naloxone and overdose prevention education, spread awareness about the access and availability of treatment for substance use disorders, intervene early with individuals who are at high risk for overdose, and improve effective response to overdose outbreaks.¹ For more information, please visit the following websites:

Additional Information Sources:

[COVID-19 Resources for Organization Working with Persons Who Use Drugs or Have Substance Use Disorder](#)

[COVID-19 Questions and Answers: For People Who Use Drugs or Have Substance Use Disorder](#)

[I Save Florida](#)

References

1. Niles, J. K., Gudin, J., Radcliff, J., & Kaufman, H. W. (2021). The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020. *Population Health Management*, 24(S1), S-43.
<https://doi.org/10.1089/pop.2020.0230>
2. Center for Disease Control and Prevention. (2020). Overdose Deaths Accelerating During COVID-19. Retrieved February 26, 2021, from <https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html>
3. Center for Disease Control and Prevention. (2021). Products - Vital Statistics Rapid Release - Provisional Drug Overdose Data. Retrieved February 26, 2021, from <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
4. Florida Department of Health (2020). Opioid Use Dashboard. Retrieved February 28, 2021, from <http://www.flhealthcharts.com/ChartsReports/rdPage.aspx?rdReport=ChartsProfiles.OpioidUseDashboard>
5. Alexander, G. C., Stoller, K. B., Haffajee, R. L., & Saloner, B. (2020). An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. *Annals of Internal Medicine*, 173(1), 57–58.
<https://doi.org/10.7326/m20-1141>

Patterns and Characteristics of Methamphetamine Use Among Adults — United States, 2015–2018

Christopher M. Jones, PharmD, DrPH¹; Wilson M. Compton, MD²; Desiree Mustaquim, MPH³

Methamphetamine is a highly addictive central nervous system stimulant. Methamphetamine use is associated with a range of health harms, including psychosis and other mental disorders, cardiovascular and renal dysfunction, infectious disease transmission, and overdose (1,2). Although overall population rates of methamphetamine use have remained relatively stable in recent years (3), methamphetamine availability and methamphetamine-related harms (e.g., methamphetamine involvement in overdose deaths and number of treatment admissions) have increased in the United States* (4,5); however, analyses examining methamphetamine use patterns and characteristics associated with its use are limited. This report uses data from the 2015–2018 National Surveys on Drug Use and Health (NSDUHs) to estimate methamphetamine use rates in the United States and to identify characteristics associated with past-year methamphetamine use. Rates (per 1,000 adults aged ≥18 years) for past-year methamphetamine use were estimated overall, by demographic group, and by state. Frequency of past-year use and prevalence of other substance use and mental illness among adults reporting past-year use were assessed. Multivariable logistic regression examined characteristics associated with past-year use. During 2015–2018, the estimated rate of past-year methamphetamine use among adults was 6.6 per 1,000. Among adults reporting past-year methamphetamine use, an estimated 27.3% reported using on ≥200 days, 52.9% had a methamphetamine use disorder, and 22.3% injected methamphetamine. Controlling for other factors, higher adjusted odds ratios for past-year use

were found among men; persons aged 26–34, 35–49, and ≥50 years; and those with lower educational attainment, annual household income <\$50,000, Medicaid only or

INSIDE

- 324 Nonfatal Violent Workplace Crime Characteristics and Rates by Occupation — United States, 2007–2015
- 329 Tuberculosis Preventive Treatment Scale-Up Among Antiretroviral Therapy Patients — 16 Countries Supported by the U.S. President's Emergency Plan for AIDS Relief, 2017–2019
- 335 Genotyping and Subtyping *Cryptosporidium* To Identify Risk Factors and Transmission Patterns — Nebraska, 2015–2017
- 339 COVID-19 in a Long-Term Care Facility — King County, Washington, February 27–March 9, 2020
- 343 Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
- 347 Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020
- 353 Notes from the Field: Ongoing Cluster of Highly Related Disseminated Gonococcal Infections — Southwest Michigan, 2019
- 355 Notes from the Field: Nationwide Hepatitis E Outbreak Concentrated in Informal Settlements — Namibia, 2017–2020
- 359 QuickStats

* <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/12568NFLISdrugMethamphetamine.pdf>.

Continuing Education examination available at https://www.cdc.gov/mmrw/mmw_r_continuingEducation.html



no insurance, those living in small metro and nonmetro counties,[†] and those with co-occurring substance use and co-occurring mental illness. Additional efforts to build state and local prevention and response capacity, expand linkages to care, and enhance public health and public safety collaborations are needed to combat increasing methamphetamine harms.

Data are from 171,766 adults participating in the 2015–2018 NSDUHs, managed by the Substance Abuse and Mental Health Services Administration.[§] NSDUHs collected information about the use of drugs, alcohol, and tobacco through in-person interviews with noninstitutionalized U.S. civilians aged ≥12 years. An independent, multistage area probability sample design for each state and the District of Columbia allows for production of national and state estimates. The average overall weighted response rate for the 2015–2018 NSDUHs

was 51%. NSDUH variables included sex, age, race/ethnicity, urbanization status of county, education, annual household income, insurance status, and self-reported substance use, mental illness status, and receipt of substance use treatment. Self-reported substance use in NSDUHs included lifetime and past-year use of methamphetamine; past-year use of cocaine and heroin; past-year misuse of prescription opioids, sedatives, tranquilizers, and stimulants; past-month binge drinking (i.e., drinking five or more [men] or four or more [women] drinks on the same occasion on ≥1 day within the past month); and past-month nicotine dependence as determined using the Nicotine Dependence Syndrome Scale (6). NSDUHs assessed past-year substance use disorders for specific substances (e.g., methamphetamine) using self-reported responses to questions based on the individual diagnostic criteria from the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV). Using a predictive model, past-year any mental illness and serious mental illness[¶] were determined for each adult NSDUH respondent.

[†]The Rural-Urban Continuum Codes are hierarchical, mutually exclusive classifications for all U.S. counties created by the U.S. Department of Agriculture. All population counts are from the 2010 Census representing the resident population. Large metro = counties in metro areas with a population ≥1 million persons. Small metro = counties in metros areas with populations between 250,000–1,000,000; counties in metro areas with populations <250,000. Nonmetro = counties with urban populations ≥20,000 adjacent to a metro area; urban populations ≥20,000 not adjacent to a metro area; urban populations 2,500–19,999 adjacent to a metro area; urban populations 2,500–19,999 not adjacent to a metro area; rural or <2,500 urban populations adjacent to a metro area; and rural or <2,500 urban population not adjacent to a metro area. <https://seer.cancer.gov/seerstat/variables/countyattribs/ruralurban.html>.

[§]<https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>.

[¶]Any mental illness is defined as currently or at any time within the past year having had a diagnosable mental disorder (excluding developmental disorders and substance use disorder) of sufficient duration to meet DSM-IV diagnostic criteria. Serious mental illness is defined as currently or at any time within the past year having had a mental disorder (excluding developmental disorders and substance use disorder) of sufficient duration to meet DSM-IV diagnostic criteria, which resulted in serious functional impairment substantially interfering with or limiting one or more major life activities. <https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>.

The MMWR series of publications is published by the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Control, U.S. Department of Health and Human Services, Atlanta, GA 30333-1627.

Suggested citation: *Morbidity and Mortality Weekly Report*. (2020). *2017 National Survey on Drug Use and Health: Key findings*. *Morbidity and Mortality Weekly Report*. Available from <https://www.cdc.gov/mmwr>.

Centers for Disease Control and Prevention
 Robert F. Daubert, MD, Director
 Anne Schuchat, MD, Principal Deputy Director
 Christine L. Ribicich, MD, MPH, Deputy Director for Public Health Systems and Surveillance
 Robert Hancock, PhD, MPH, Deputy Director for Science
 Adina Compton, PhD, Acting Director, Office of Science Quality, Office of Science
 Michael P. Slaughter, PhD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services

MMWR Editorial and Production Staff (Weekly)

Charlotte K. Ross, PhD, MPH, Editor in Chief	Harriet E. Brown, Lead Visual Information Specialist
Isaac Quinn-Gentles, MD, Editor	Stephanne A. Lamb, PhD, C. Buchanan
Paul P. Kung'u, MPH, MPH, Senior Associate Editor	Debra J. Scriggs, Tang Tang
John Lee, PhD, MPH, Associate Editor	Visual Information Specialist
John F. Partridge, Managing Editor	Quang M. Doan, MPH, Philip H. Yang
Stephanie W. Woodruff, Lead Technical Writer/Editor	George M. Johnson, Susan Tang
Glenn Wagner, Scientific Coordinator, PhD, Teresa H. Flood, MS, Editorial Writer/Editor	Information Technology Specialist

MMWR Editorial Board

Michael H. Beach, MPH	Thomas R. Frieden, MD, MPP	Thomas R. Frieden, MD, MPP
Sharon L. Stroup, MD, MPH	Jonathan E. Pechoff, MD, MPH, MPP	Frank L. Brinkman, MD, MPH
Candice Brackbill, MD, MPA	Thomas R. Frieden, MD, MPP	Cheryl Rupp, MS, MPH
De C. Shaha, MD	Thomas R. Frieden, MD, MPP, MPH	William Schaffner, MD
Virginia A. Caine, MD	David M. Rubin, MD, MPH, MPP	Wagner Bockor, M.D.
	Jill M. Nadler, PhD	

Using public-use-file data** from combined 2015–2018 NSDUHs, weighted counts, annual average rates per 1,000 adults, and corresponding 95% confidence intervals (CIs) were estimated for lifetime methamphetamine use and past-year methamphetamine use overall and by demographic, substance use, and mental illness variables. Estimates and 95% CIs for frequency of methamphetamine use and prevalence of past-year methamphetamine use disorder, methamphetamine injection, receipt of substance use treatment, other substance use, and mental illness among adults reporting past-year use were determined. Multivariable logistic regression examined characteristics associated with past-year methamphetamine use, controlling for demographic, substance use, and mental illness variables. Results are presented as adjusted odds ratios and 95% CIs. No multicollinearity or potential interaction effects between examined variables in the final model were observed. Restricted access 2017–2018 NSDUH data were used to estimate state rates of past-year methamphetamine use per 1,000 adults. NSDUHs use 2010 census-based population estimates (3). Stata (version 15.1; StataCorp) was used to account for the NSDUH complex survey design and sample weights.

During 2015–2018, the estimated annual average rate of lifetime methamphetamine use was 59.7 per 1,000 adults, or 14,686,900 adults on average each year. The estimated rate of past-year use was 6.6 per 1,000, or 1,626,200 adults on average each year (Table 1). Estimated rates of past-year use were 8.7 for men and 4.7 for women. The highest estimated rates were among adults aged 26–34 (11.0), 18–25 (9.3), and 35–49 (8.3) years and among non-Hispanic whites (7.5), Hispanics (6.7), and non-Hispanic other races (5.6). Estimated rates of past-year use also varied by the other demographic, substance use, and mental illness variables assessed. During 2017–2018 rates of past-year methamphetamine use ranged from 2.76 in New York to 13.98 in Nevada; generally, rates were higher in the western United States than in the East (Supplementary Figure, <https://stacks.cdc.gov/view/cdc/85704>).

Among adults reporting past-year methamphetamine use, an estimated 36.2%, 19.2%, 17.2%, and 27.3% reported using methamphetamine 1–29 days, 30–99 days, 100–199 days, and ≥200 days, respectively; 22.3% reported injecting methamphetamine (Figure). Approximately one half (52.9%) of adults who reported past-year methamphetamine use met diagnostic criteria for past-year methamphetamine use disorder. Among those with past-year methamphetamine use disorder, an estimated 31.5% received any substance use treatment within the past year.

Among adults using methamphetamine within the past year, estimated prevalences of past-year use or misuse of other

substances included cannabis use (68.7%), prescription opioid misuse (40.4%), cocaine use (30.4%), prescription sedative or tranquilizer misuse (29.1%), prescription stimulant misuse (21.6%), and heroin use (16.9%). Past-month binge drinking was reported by an estimated 46.4% and nicotine dependence by 44.3%. Mental illness was common also; of persons who used methamphetamine, an estimated 57.7% reported any mental illness, and 25.0% reported serious mental illness during the past year.

Multivariable logistic regression analysis found increased odds of past-year methamphetamine use among men; persons aged 26–34, 35–49, and ≥50 years (versus persons aged 18–25 years); persons with less than a high school diploma, a high school diploma, and some college or associate's degree (versus college graduates); those with annual household income <\$20,000 or \$20,000–\$49,999 (versus ≥\$75,000); persons having Medicaid only or being uninsured (versus private or other insurance); persons living in small metro and nonmetro counties (versus large metro counties); persons reporting past-month nicotine dependence; those reporting past-year use of cannabis, cocaine, and heroin; persons reporting misuse of prescription opioids, sedatives, tranquilizers, or stimulants; and persons reporting past-year mental illness but not serious mental illness or past-year serious mental illness (versus no past-year mental illness). Non-Hispanic black race/ethnicity was associated with lower odds of past-year methamphetamine use compared with non-Hispanic white race/ethnicity (Table 2).

Discussion

In the United States during 2015–2018, approximately 1.6 million adults, on average, used methamphetamine each year, and nearly 25% of those reported injecting methamphetamine. In addition, approximately 50% of persons using methamphetamine in the past year met diagnostic criteria for past-year methamphetamine use disorder, yet fewer than one third of adults with past-year methamphetamine use disorder received substance use treatment in the past year. Particularly concerning were high rates of co-occurring substance use or mental illness among adults using methamphetamine.

These findings provide new insights into populations to prioritize for prevention and response efforts, such as men, middle aged adults, and rural residents. Identification of higher rates of methamphetamine use in small metro and nonmetro areas are important given difficulties in delivering services to rural populations who might be disproportionately affected by methamphetamine use. Attention has been drawn to infectious disease transmission associated with opioid injection in these areas (7); the long-standing challenges with lower economic resources, prevalent substance use, and limited treatment availability also place these areas at risk for infectious disease

** <https://datafiles.samhsa.gov/info/browse-studies-nid3454>.

TABLE 1. Methamphetamine use among adults aged ≥18 years by demographic, substance use, and mental health characteristics — United States, 2015–2018

Characteristic	Past-year methamphetamine use	
	Annual average no. of adults aged ≥18 years (weighted)	Annual average rate per 1,000 adults aged ≥18 years (95% CI)
Overall lifetime use	14,686,900	59.7 (58.1–61.4)
Overall past-year use	1,626,200	6.6 (6.1–7.1)
Past-year use by demographic characteristic		
Sex		
Women	598,300	4.7 (4.2–5.2)
Men	1,027,900	8.7 (7.9–9.5)
Age group (yrs)		
18–25	320,000	9.3 (8.3–10.4)
26–34	431,200	11.0 (9.7–12.5)
35–49	507,900	8.3 (7.3–9.5)
≥50	367,100	3.2 (2.8–3.9)
Race/Ethnicity		
White, non-Hispanic	1,180,200	7.5 (6.9–8.2)
Black, non-Hispanic	72,000	2.5 (1.8–3.4)
Other, non-Hispanic	113,000	5.6 (4.4–7.2)
Hispanic	260,900	6.7 (5.5–8.1)
Education level		
Less than high school diploma	394,600	12.4 (10.8–14.3)
High school graduate	563,300	9.2 (8.1–10.4)
Some college or associate's degree	527,300	6.9 (6.1–7.9)
Bachelor's degree or higher	141,000	1.8 (1.3–2.5)
Annual household income		
<\$20,000	640,700	15.6 (13.8–17.7)
\$20,000–49,999	552,000	7.6 (6.6–8.6)
\$50,000–74,999	169,100	4.3 (3.4–5.5)
≥\$75,000	264,300	2.9 (2.4–3.4)
Insurance status		
Private or other insurance (including Medicare)	704,900	3.6 (3.1–4.1)
Medicaid only	524,600	20.9 (18.5–23.5)
Uninsured	396,700	16.4 (13.9–19.2)
County type of residence*		
Large metro	711,200	5.2 (4.6–5.8)
Small metro	583,100	7.9 (6.6–9.5)
Nonmetro	331,900	9.5 (8.2–11.0)
Substance use†		
Past-month binge drinking	753,900	11.6 (10.2–13.0)
Past-month nicotine dependence	719,900	39.0 (35.1–43.4)
Past-year marijuana use	1,118,000	30.6 (27.9–33.6)
Past-year cocaine use	493,500	94.7 (83.5–107.1)
Past-year heroin use	275,600	315.7 (267.8–367.8)
Past-year prescription opioid misuse	657,100	63.2 (56.4–70.9)
Past-year prescription sedative/tranquilizer misuse	473,400	74.0 (66.9–81.7)
Past-year prescription stimulant misuse	350,900	69.6 (61.2–79.0)
Mental health		
No past-year mental illness	688,300	3.4 (3.1–3.8)
Past-year mental illness but not serious mental illness‡	531,900	15.3 (13.5–17.3)
Past-year serious mental illness¶	406,000	37.6 (32.1–43.9)

Source: National Surveys on Drug Use and Health, 2015–2018, using 2010 U.S. Census–based population estimates.

Abbreviations: CI = confidence interval; DSM-IV = *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*.


* The Rural-Urban Continuum Codes are hierarchical, mutually exclusive classifications for all U.S. counties created by the U.S. Department of Agriculture. All population counts are from the 2010 Census representing the resident population. *Large metro* = counties in metro areas with a population ≥1 million persons. *Small metro* = counties in metro areas with populations between 250,000–1,000,000; counties in metro areas with populations <250,000. *Nonmetro* = counties with urban populations ≥20,000 adjacent to a metro area; urban populations ≥20,000 not adjacent to a metro area; urban populations 2,500–19,999 adjacent to a metro area; urban populations 2,500–19,999 not adjacent to a metro area; rural or <2,500 urban populations adjacent to a metro area; and rural or <2,500 urban population not adjacent to a metro area. <https://seer.cancer.gov/seerstat/variables/countyattrs/ruralurban.html>.

† Among adults engaging in substance use behavior.

‡ Any mental illness is defined as currently or at any time within the past year having had a diagnosable mental disorder (excluding developmental disorders and substance use disorders of sufficient duration to meet DSM-IV diagnostic criteria). <https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>. For this analysis where the variable was defined as past-year mental illness, not serious mental illness, persons meeting criteria for serious mental illness were not included.

¶ Serious mental illness is defined as currently or at any time within the past year having had a mental disorder (excluding developmental disorders and substance use disorders of sufficient duration to meet DSM-IV diagnostic criteria, which resulted in serious functional impairment substantially interfering with or limiting one or more major life activities). <https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>.

FIGURE. Methamphetamine injection, use disorder, frequency of use, receipt of substance use treatment,* other substance use,[†] and mental illness among adults aged ≥18 years reporting past-year methamphetamine use — United States, 2015–2018[§]



Source: National Surveys on Drug Use and Health, 2015–2018, using 2010 U.S. Census–based population estimates.

* Receipt in past year among those with a methamphetamine use disorder; all other percentages are among adults reporting past-year methamphetamine use.

[†] Binge drinking and nicotine dependence reported within the past month; all other substances are within the past year.

[§] Weighted percentages; error bars represent 95% confidence intervals.

outbreaks associated with methamphetamine injection. Expansion of evidence-based substance use treatment, syringe services programs, and other community-based interventions aimed at reducing use, including injection, are needed.

Given the high rates of co-occurring substance use identified, along with trends of increasing opioid-related overdose deaths and treatment admissions that involve methamphetamine (4,5), prevention and treatment efforts will need to be comprehensive and broad-based. Universal preventive interventions such as Promoting School-Community-University Partnerships to Enhance Resilience (PROSPER) have resulted in lasting protective effects on youth substance use generally, and for methamphetamine use and opioid misuse specifically (8). Promising treatment strategies for methamphetamine use disorder are those that use evidence-based psychosocial approaches (e.g., community reinforcement or cognitive-behavioral therapy)

combined with contingency management, where rewards are provided to reinforce positive behavior (9). The finding of increased odds of methamphetamine use among adults with lower socioeconomic indicators underscores the importance of recovery support services and linkage to social service providers.

The overlap of methamphetamine use with mental illness, especially serious mental illness, suggests an important role for mental health providers to engage in care with this population, in coordination with addiction and other health care providers. Treatment of co-occurring mental and substance use disorders has been a recognized gap in the system of care (10) and persons who use methamphetamine might be particularly affected.

The findings in this report are subject to at least four limitations. First, NSDUH data are self-reported and subject to recall and social desirability biases. Second, because the survey is cross-sectional and different persons were sampled

TABLE 2. Characteristics associated with past-year methamphetamine use among adults aged ≥18 years — United States, 2015–2018

Characteristic	Adjusted odds ratios* (95% CI)
Sex	
Women	Reference
Men	1.68 (1.43–1.96)
Age group (yrs)	
18–25	Reference
26–34	1.67 (1.36–2.05)
35–49	2.49 (2.01–3.07)
≥50	1.72 (1.31–2.25)
Race/Ethnicity	
White, non-Hispanic	Reference
Black, non-Hispanic	0.29 (0.20–0.42)
Other, non-Hispanic	1.07 (0.78–1.47)
Hispanic	1.08 (0.85–1.37)
Education level	
Less than high school	3.28 (2.13–5.06)
High school graduate	2.65 (1.78–3.93)
Some college or associate's degree	2.04 (1.38–3.02)
Bachelor's degree or higher	Reference
Annual household income	
<\$20,000	2.09 (1.59–2.74)
\$20,000–49,999	1.42 (1.11–1.82)
\$50,000–74,999	1.06 (0.77–1.46)
≥\$75,000	Reference
Insurance status	
Private or other insurance (including Medicare)	Reference
Medicaid only	2.01 (1.55–2.61)
Uninsured	1.70 (1.31–2.22)
County type of residence[†]	
Large metro	Reference
Small metro	1.32 (1.01–1.72)
Nonmetro	1.54 (1.25–1.90)
Substance use[§]	
Past-month binge drinking	1.06 (0.86–1.30)
Past-month nicotine dependence	2.14 (1.75–2.62)
Past-year cannabis use	4.61 (3.67–5.80)
Past-year cocaine use	2.72 (2.12–3.50)
Past-year heroin use	5.10 (3.63–7.17)
Past-year prescription opioid misuse	2.17 (1.66–2.84)
Past-year prescription sedative/tranquilizer misuse	1.85 (1.45–2.35)
Past-year prescription stimulant misuse	1.91 (1.43–2.55)
Mental health	
No past-year mental illness	Reference
Past-year mental illness but not serious mental illness [¶]	2.18 (1.82–2.60)
Past-year serious mental illness ^{**}	3.34 (2.53–4.40)

Source: National Surveys on Drug Use and Health, 2015–2018, using 2010 U.S. Census–based population estimates.

Abbreviations: CI = confidence interval; DSM-IV = *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*.

* Odds ratios are adjusted for all other variables in the model.

[†] The Rural-Urban Continuum Codes are hierarchical, mutually exclusive classifications for all U.S. counties created by the U.S. Department of Agriculture. All population counts are from the 2010 Census representing the resident population. *Large metro* = counties in metro areas with a population ≥1 million persons. *Small metro* = counties in metro areas with populations between 250,000–1,000,000; counties in metro areas with populations <250,000. *Nonmetro* = counties with urban populations ≥20,000 adjacent to a metro area; urban populations ≥20,000 not adjacent to a metro area; urban populations 2,500–19,999 adjacent to a metro area; urban populations 2,500–19,999 not adjacent to a metro area; rural or <2,500 urban populations adjacent to a metro area; and rural or <2,500 urban population not adjacent to a metro area. <https://seer.cancer.gov/seerstat/variables/countyattribs/ruralurban.html>.

[§] Reference group is no use (misuse) within the past month (past year).

[¶] Any mental illness is defined as currently or at any time within the past year having had a diagnosable mental disorder (excluding developmental disorders and substance use disorder of sufficient duration to meet DSM-IV diagnostic criteria). <https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>. For this analysis where the variable was defined as past-year mental illness, not serious mental illness, persons meeting criteria for serious mental illness were not included.

^{**} Serious mental illness is defined as currently or at any time within the past year having had a mental disorder (excluding developmental disorders and substance use disorder of sufficient duration to meet DSM-IV diagnostic criteria, which resulted in serious functional impairment substantially interfering with or limiting one or more major life activities). <https://www.samhsa.gov/data/report/2017-methodological-summary-and-definitions>.

Summary**What is already known about this topic?**

Methamphetamine is a highly addictive central nervous system stimulant. In recent years, methamphetamine availability and methamphetamine-related harms have been increasing in the United States.

What is added by this report?

During 2009–2018, an estimated 1.6 million U.S. adults aged ≥18 years, on average, reported past-year methamphetamine use; 43.2% had a methamphetamine use disorder, and 43.1% reported injecting methamphetamine within the past year.

Co-occurring substance use and mental illness were common among those who used methamphetamine within the past year.

What are the implications for public health practice?

Efforts to build state and local prevention and response capacity, expand linkages to care, and enhance public health and public safety collaborations are needed to combat rising methamphetamine availability and related harms.

each year, inferring causality from the observed associations between the predictors examined and self-reported past-year methamphetamine use is not possible. Third, NSDUHs do not include homeless persons not living in shelters, active duty military, or persons residing in institutions such as those who are incarcerated; thus, substance use estimates in this study might not be generalizable to the total U.S. population. Finally, NSDUHs provide estimates of persons meeting diagnostic criteria for methamphetamine use disorder based on self-reported responses to the individual questions that make up the DSM-IV diagnostic criteria for methamphetamine use disorder, not estimates of the number of persons receiving a diagnosis from a health care provider; thus, gaps between meeting diagnostic criteria and receiving treatment might be incorrectly estimated.

Methamphetamine use and related harms represent a substantial U.S. public health concern. Additional efforts to support prevention and response capacity in communities, expand linkages to care for substance use and mental health, and enhance collaborations between public health and public safety are needed.

Corresponding author: Christopher M. Jones, fjr0@cdc.gov, 404-498-0756.

¹Office of Strategy and Innovation, National Center for Injury Prevention and Control, CDC; ²National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland; ³Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Wilson M. Compton reports long-term stock holdings in General Electric Co., 3M Companies, and Pfizer, Inc., outside the submitted work. No other potential conflicts of interest were disclosed.

References

1. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. *J Psychiatry Neurosci* 2006;31:301–13.
2. Degenhardt L, Sara G, McKetin R, et al. Crystalline methamphetamine use and methamphetamine-related harms in Australia. *Drug Alcohol Rev* 2017;36:160–70. <https://doi.org/10.1111/dar.12426>
3. Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2019. <https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables>
4. Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. *Addiction* 2020;115:347–53. <https://doi.org/10.1111/add.14812>
5. Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 states, July–December 2017 to January–June 2018. *MMWR Morb Mortal Wkly Rep* 2019;68:737–44. <https://doi.org/10.15585/mmwr.mm6834a2>
6. Shiffman S, Waters A, Hickcox M. The nicotine dependence syndrome scale: a multidimensional measure of nicotine dependence. *Nicotine Tob Res* 2004;6:327–48. <https://doi.org/10.1080/1462220042000202481>
7. Havens JR, Walsh SL, Korhuis PT, Fiellin DA. Implementing treatment of opioid-use disorder in rural settings: a focus on HIV and hepatitis C prevention and treatment. *Curr HIV/AIDS Rep* 2018;15:315–23. <https://doi.org/10.1007/s11904-018-0402-3>
8. Spoth R, Redmond C, Shin C, Greenberg MT, Feinberg ME, Trudeau L. PROSPER delivery of universal preventive interventions with young adolescents: long-term effects on emerging adult substance misuse and associated risk behaviors. *Psychol Med* 2017;47:2246–59. <https://doi.org/10.1017/S0033291717000691>
9. De Crescenzo F, Ciabattini M, D'Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. *PLoS Med* 2018;15:e1002715. <https://doi.org/10.1371/journal.pmed.1002715>
10. Han B, Compton WM, Blanco C, Colpe LJ. Prevalence, treatment, and unmet treatment needs of US adults with mental health and substance use disorders. *Health Aff (Millwood)* 2017;36:1739–47. <https://doi.org/10.1377/hlthaff.2017.0584>

COVID-19 is an emerging, rapidly evolving situation.

- Get the latest public health information from CDC »
- Get the latest research information from NIH »
- NIH staff guidance on coronavirus (NIH Only) »

NEWS RELEASES

Wednesday, January 13, 2021

Combination treatment for methamphetamine use disorder shows promise in NIH study

A combination of two medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with moderate or severe methamphetamine use disorder in a double-blind, placebo-controlled Phase III clinical trial. The findings suggest this combination therapy may be a promising addition to current approaches to treatment, such as cognitive behavioral therapy and contingency management interventions, for a very serious condition that remains difficult to treat and overcome. The research, published today in *The New England Journal of Medicine*, was conducted at multiple sites within the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN). NIDA is part of the National Institutes of Health.

"The opioid crisis and resulting overdose deaths in the United States are now well known, but what is less recognized is that there is a growing crisis of overdose deaths involving methamphetamine and other stimulants. However, unlike for opioids, there are currently no approved medications for treating methamphetamine use disorder," said NIDA Director Nora D. Volkow, M.D. "This advance demonstrates that medical treatment for methamphetamine use disorder can help improve patient outcomes."

The study known as the Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder study, or ADAPT-2, was conducted from 2017 to 2019 at clinics in multiple community treatment programs nationwide and enrolled 403 adult volunteers ages 18 to 65 years with moderate to severe methamphetamine use disorder. All participants wished to reduce or cease use of the drug and were randomly assigned to the treatment or control group.

In each of two six-week stages, volunteers in the treatment group were given an injection of extended-release naltrexone, a drug used to treat opioid and alcohol use disorders, every three weeks and took daily extended-release tablets of bupropion, an antidepressant also used as a treatment to aid nicotine cessation. Those in the control group were given matched injectable and oral placebos over the same time periods. Investigators performed four urine drug screens at the end of each stage of the trial. Participants were considered to have responded to treatment if at least three of four urine screens were negative.

Overall, participants responded at a significantly higher rate in the treatment group. When screened during weeks five and six, 16.5% of



Dr. Madhukar Trivedi and staff of UT Southwestern Medical Center conduct lab research. *UT Southwestern Medical Center*

those given the naltrexone/bupropion combination responded, compared to only 3.4% of those in the control group. Similarly, when screened in weeks 11 and 12, 11.4% of the treatment group responded, compared to 1.8% of the control group. Researchers calculated that the number needed to treat (NNT) was 9. NNT is a way to describe the utility of a medical intervention that indicates the number of people who would need to receive a treatment for it to benefit one person. The investigators reported that, with an NNT of 9, naltrexone/bupropion's benefit as a treatment for methamphetamine use disorder is similar to most medical treatments for mental health disorders, including antidepressants prescribed for depression or naltrexone prescribed for alcohol use disorder.

Participants in the treatment group were assessed to have fewer cravings than those in the placebo group and reported greater improvements in their lives as measured by a questionnaire called the Treatment Effectiveness Assessment. Importantly, there were no significant adverse effects associated with the dual medication treatment. Adherence to treatment was encouraged by adherence counseling and mobile app reminders and remained high at 77.4% and 82.0% in the treatment and placebo groups, respectively, in the final six weeks of the study.

"Long-term methamphetamine misuse has been shown to cause diffuse changes to the brain, which can contribute to severe health consequences beyond addiction itself," said Madhukar H. Trivedi, M.D., of the University of Texas Southwestern Medical Center, Dallas, who led the trial. "The good news is that some of the structural and neurochemical brain changes are reversed in people who recover, underscoring the importance of identifying new and more effective treatment strategies."

Methamphetamine use disorder is a serious illness often associated with severe medical and mental health complications and a risk of fatal overdose. Methamphetamine is a potent stimulant, and, like other addictive drugs, it hijacks the reward pathways in the brain by raising levels of dopamine, a brain chemical associated with repeating actions that cause pleasurable feelings.

Finding treatments that disrupt these processes has been challenging for scientists. Research suggests bupropion may alleviate dysphoria associated with methamphetamine withdrawal by acting on the dopamine and norepinephrine systems. Alleviating dysphoria may in turn reduce cravings and help prevent return to methamphetamine use. Naltrexone may reduce the euphoric effects and cravings associated with taking methamphetamine. In previous clinical studies, however, both bupropion and naltrexone administered alone showed limited, inconsistent efficacy in treating methamphetamine use disorder. Now, in combination, these compounds seem to have an additive or synergistic effect.

While there are U.S. Food and Drug Administration-approved medications for other substance use disorders, no medications have yet received FDA approval for methamphetamine use disorder. The effectiveness of this medication combination is progress toward improving treatment of this addiction.

The investigators recommend that future research build on this work by testing if longer naltrexone/bupropion treatment or concurrent behavioral therapy, such as contingency management, brings still better responses. Contingency management, which uses motivational incentives and tangible rewards to help a person attain their treatment goals, has demonstrated to be the most effective therapy for stimulant use disorders but is not widely used, stemming in part from a policy limiting the monetary value of incentives allowable as part of treatment.

About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.drugabuse.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health®

References

Trivedi MH, *et al.* Trial of Bupropion and Naltrexone in Methamphetamine Use Disorder. *New England Journal of Medicine*. January 14, 2020.

###

Institute/Center

National Institute on Drug Abuse (NIDA)

Contact

NIDA Press Office
301-443-6245

Connect with Us

[Subscribe to news releases](#)

[RSS Feed](#)

NIH...Turning Discovery Into Health®

National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892

U.S. Department of Health and Human Services

EVIDENCE-BASED RESOURCE GUIDE SERIES

Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders



SAMHSA
Substance Abuse and Mental Health
Services Administration

Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders

Acknowledgments

This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), under contract number HHSS283201700001/75S20319F42002 with SAMHSA, HHS. Donelle Johnson served as contracting officer representative.

Disclaimer

The views, opinions, and content of this publication are those of the authors and do not necessarily reflect the views, opinions, or policies of SAMHSA. Nothing in this document constitutes a direct or indirect endorsement by SAMHSA of any non-federal entity's products, services, or policies, and any reference to non-federal entity's products, services, or policies should not be construed as such.

Public Domain Notice

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS.

Electronic Access

This publication may be downloaded from <http://store.samhsa.gov>

Recommended Citation

Substance Abuse and Mental Health Services Administration (SAMHSA). *Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders*. Publication No. PEP20-06-03-001 Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration, 2020.

Originating Office

National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, Publication No. PEP20-06-03-001. Released 2020.

Nondiscrimination Notice

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, ni edad.

Publication No. PEP20-06-03-001
Released 2020



**MESSAGE FROM THE ASSISTANT SECRETARY
FOR MENTAL HEALTH AND SUBSTANCE USE,
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**

As the first U.S. Department of Health and Human Services Assistant Secretary for Mental Health and Substance Use at the Substance Abuse and Mental Health Services Administration (SAMHSA), I am pleased to present this new resource: *Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders*.

In response to the charge of the 21st Century Cures Act to disseminate information on evidence-based practices and service delivery models, the National Mental Health and Substance Use Policy Laboratory has developed the Evidence-Based Resource Guide Series focused on the prevention and treatment of substance use disorders (SUD) and mental illnesses. With this specific guide, SAMHSA's goal is to inform health care practitioners and administrators, policy makers, and community members about strategies to prevent and treat HIV among individuals who have mental illness and/or SUD.

Established in 2019, the federal initiative "Ending the HIV Epidemic: A Plan for America" aims to reduce new HIV infections in the United States by 90 percent by the year 2030. It encourages implementation of HIV prevention, diagnosis, treatment, and outbreak response through effective programs, practices, and resources. Supporting the needs of people at risk for and with HIV who have co-occurring mental illness and/or SUD is key to meeting the initiative's goals. People with mental illness and/or SUD are particularly vulnerable to HIV. SUD, in particular, can hasten the progress of HIV.¹ More specifically, injection drug use increases the risk of getting or transmitting the disease,² and the risk of getting HIV is 4 to 10 times greater for people with mental illness.³

This guide reviews effective programs and practices to prevent HIV and increase adherence to and retention in care. I encourage you to use this guide to become informed about the populations experiencing mental illness and/or SUD with or at risk for HIV; to review the current evidence on the effectiveness of programs and practices to prevent HIV among this population; and to develop and implement appropriate and effective programming in your communities. Ultimately, your efforts will help meet the goals of ending the HIV epidemic over the next decade.

Elinore F. McCance-Katz, MD, PhD

Assistant Secretary for Mental Health and Substance Use
U.S. Department of Health and Human Services

- 1 National Institute on Drug Abuse. (2020, April 10). *Common comorbidities with substance use disorders research report*. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-3-connection-between-substance-use-disorders-hiv>
- 2 National Institute on Drug Abuse. (2020, April 10). *ibid*
- 3 Remien, R. H., Stirratt, M. K., Nguyen, N., Robbins, R. N., Pala, A. N., & Mellins, C. A. (2019). Mental health and HIV/AIDS: The need for an integrated response. *AIDS*, 33(9), 1411-1420. doi: 10.1097/QAD.0000000000002227

Evidence-Based Resource Guide Series Overview

The Substance Abuse and Mental Health Services Administration (SAMHSA), and specifically, the National Mental Health and Substance Use Policy Laboratory (Policy Lab), is pleased to fulfill the charge of the 21st Century Cures Act to disseminate information on evidence-based practices and service delivery models to prevent substance misuse and help people with substance use disorders (SUD), serious mental illnesses (SMI), and serious emotional disturbances (SED) get the treatment and support they need.

Treatment and recovery for SUD, SMI, and SED can vary based on a number of geographic, socio-economic, cultural, gender, race, ethnicity, and age-related factors, which can complicate evaluating the effectiveness of services, treatments, and supports. Despite these variations, however, there is substantial evidence to inform the types of resources that can help reduce substance use, lessen symptoms of mental illness, and improve quality of life.

This Evidence-Based Resource Guide Series contains a comprehensive set of modules with information to improve health outcomes for people at risk for developing, living with, or recovering from mental illness and/or SUD. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.

A priority topic for SAMHSA is preventing human immunodeficiency virus (HIV) among people with mental illness and/or SUD and linking people with HIV and co-occurring mental illness and/or SUD to HIV care. This guide reviews research findings and literature related to this issue, examines emerging and best practices, and identifies challenges and strategies for implementation.

SAMHSA's Policy Lab developed this guide between 2019 and 2020, prior to and during the COVID-19 pandemic. The practices and programs included in Chapter 2 were studied prior to the onset of COVID-19 and may require adaptation to accommodate the unique challenges of delivering health care during the pandemic. Implementation strategies, outlined in Chapter 3, may also need to account for COVID-19 conditions in each community, county, and state. Finally, the practices and programs highlighted in Chapter 4 are examples of implementation prior to and at early phases of the pandemic. It is possible these organizations and programs have modified their service delivery to include telehealth and other ways of providing services due to the COVID-19 public health emergency.

Expert panels of federal, state, and non-governmental participants provided input for each guide in this series. The panels included accomplished scientists, researchers, service providers, community administrators, federal and state policy makers, and people with lived experience. Members provided input based on their knowledge of healthcare systems, implementation strategies, evidence-based practices, provision of services, and policies that foster change.

Research shows that implementing evidence-based practices requires a comprehensive, multi-pronged approach. This guide is one piece of an overall approach to implement and sustain change. Readers are encouraged to visit the [SAMHSA website](#) for additional tools and technical assistance opportunities.

Content of the Guide

This guide contains a foreword and five chapters. The chapters stand alone and can be read in any order. Each chapter is designed to be brief and accessible to healthcare practitioners, healthcare system administrators, community members, policy makers, and others working to meet the needs of people at risk for developing, experiencing, or recovering from mental illness and/or SUD.

The goal of this guide is to review the literature on preventing and treating HIV for people with mental illness and/or SUD, distill the research into recommendations for practice, and provide examples of how practitioners use these practices in their programs.

FW Evidence-Based Resource Guide Series Overview

Introduction to the series.

1 Issue Brief

Overview of current approaches and challenges to preventing and treating HIV for people with mental illness and/or SUD.

2 What Research Tells Us

Current evidence on effectiveness of programs and strategies to prevent HIV among people with co-occurring mental illness and/or SUD and link them to HIV care: Practices to increase uptake of and improve adherence to Pre-Exposure Prophylaxis (PrEP), Syringe Services Programs, Contingency Management, Cognitive Behavioral Therapy, and Patient Navigation.

3 Guidance for Selecting and Implementing Evidence-based Practices

Practical information to consider when selecting and implementing programs and practices to improve health outcomes for people with mental illness and/or SUD with or at risk for HIV.

4 Examples of Effective Programs and Strategies

Descriptions of programs and practices to prevent HIV and link people with HIV and co-occurring mental illness and/or SUD to HIV care.

5 Resources for Evaluation and Quality Improvement

Guidance and resources for implementing best practices, monitoring outcomes, and improving quality.


A NOTE ON MEDICATIONS FOR OPIOID USE DISORDER

SAMHSA has an extensive online resource center with tools for use alongside this guide. For example, practitioners can use the current (2020) [Treatment Improvement Protocol \(TIP\) 63: Medications for Opioid Use Disorder](#) together with practices recommended in this guide to support improved health outcomes for people with or at risk for HIV who are experiencing opioid use disorder. To avoid duplication, this guide does not discuss medications for opioid use disorder.

FOCUS OF THE GUIDE

People with mental illness and/or SUD are disproportionately affected by HIV. They may participate in behaviors that increase risk for contracting and transmitting HIV, such as sharing injection drug equipment or engaging in sexual behaviors that increase HIV risk. This guide addresses the co-occurrence of HIV and mental illness and/or SUD. It reviews effective programs and practices to prevent HIV and, for those with HIV, to increase linkage and retention in care in order to improve health outcomes.

The framework below provides an overview of this guide. The guide addresses the prevention and treatment of HIV among people with mental illness and/or SUD, and focuses on prevention and treatment practices that have been evaluated with adults. The review of these programs and practices in Chapter 2 of the guide includes specific outcomes, practitioner types, and delivery settings.





Issue Brief

First detected in 1981,¹ human immunodeficiency virus (HIV) is a retrovirus that infects a type of white blood cells called CD4+ T-cells and puts people at increased risk for other infections. If left untreated, HIV can lead to acquired immunodeficiency syndrome (AIDS), which was once a fatal infection.

While there is no cure for HIV, it can be effectively managed as a chronic illness with antiretroviral therapy (ART), and prevented through harm reduction strategies (e.g., condoms and syringe services programs) and medical interventions (e.g., pre-exposure prophylaxis [PrEP] and post-exposure prophylaxis [PEP]).

Substantial progress has been made in preventing HIV and supporting people with HIV, however, there is still room for improvement in addressing linkage to treatment, ART initiation and adherence, and viral suppression, as well as engagement and retention along the HIV care continuum.

Challenges with client engagement across the HIV care continuum hinder the effectiveness of prevention and treatment efforts. These challenges increase the likelihood of HIV transmission and negative health outcomes for people with HIV.

Established in 2019, the federal initiative “Ending the HIV Epidemic: A Plan for America” (EHE)⁴ capitalizes on scientific discoveries and increased public awareness to prevent and treat HIV. As of 2020, there are 1 million people with HIV in the United States, and an estimated 38,000 new infections occur each year.⁵ The goal of the EHE initiative is to reduce new infections by 75 percent by 2025 and by 90 percent by 2030.⁶

The success of the EHE initiative relies on identifying pathways to increase access to HIV prevention and treatment for those with complex needs.⁷⁻⁸

Biomedical Interventions for HIV Prevention and Treatment

Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) are medications that can be taken to prevent HIV transmission. PrEP has been shown to reduce the risk of contracting HIV from sex by 99 percent, and contracting HIV from injection drug use by 74 percent.² PEP, when taken within three days of possible exposure to the virus, has been shown to lower chances of HIV transmission by more than 80 percent.³


ART is a combination of medications used to treat HIV. ART blocks HIV replication, decreasing the amount of HIV in blood and bodily fluids. By reducing the HIV viral load (amount of virus) in the body, ART improves the health outcomes of people with HIV; decreases mortality; and, when treatment results in an undetectable viral load, reduces the chance of transmitting the disease to others to zero. The availability of and adherence to ART has changed HIV from a terminal diagnosis to a manageable chronic disease.

HIV CARE CONTINUUM:

The series of steps a person with HIV takes from initial diagnosis through sustained treatment and viral suppression.



GOALS OF ENDING THE HIV EPIDEMIC (EHE) INITIATIVE



HIV Testing

In the United States, about 1 in 7 (14 percent) of the estimated 1 million people with HIV do not know they have the disease.⁹ Testing identifies a person's HIV status and helps to link those who are newly diagnosed with HIV to care. Testing also helps to prevent HIV transmission and new infections.¹⁰ Individuals who are undiagnosed or unaware of their HIV infection account for an estimated 30 to 40 percent of ongoing HIV transmissions.¹¹⁻¹² The U.S. Preventive Services Task Force recommends that clinicians conduct screening for

HIV infection among individuals aged 15 to 65, younger adolescents and older adults at increased risk, and all pregnant women, giving the recommendation an "A" rating, requiring HIV testing be provided free by health insurance companies.¹³⁻¹⁵

The EHE initiative recommends the following steps to increase the number of undiagnosed people with HIV who receive an HIV test, are diagnosed, and receive treatment: 1) make HIV testing simple, accessible, and routine in healthcare and non-healthcare settings using innovative technology, systems, and programs; and 2) conduct focused work to increase annual testing among people who are at substantial risk for HIV. HIV testing can be conducted in a range of clinical settings or at home (through rapid or mail-in self-tests).¹⁶⁻¹⁷

Behavioral health providers play an essential role in providing integrated HIV, viral hepatitis, mental health, and substance use screenings within the clinic setting. In a 2019 "Dear Colleague Letter," SAMHSA called on mental health and substance use providers to increase on-site, same-day oral fluid HIV testing efforts and include HIV testing as part of the standard of care.¹⁹ Oral fluid testing can be self-administered and provides results within 20 minutes.²⁰ Settings that provide screening for many common co-occurring illnesses often include testing for viral hepatitis to address both hepatitis prevention and potentially serious co-occurring HIV and viral hepatitis infections.²¹

People with any mental illness diagnoses or symptoms were more likely to report being tested for HIV than those without mental illness diagnoses or symptoms.²²



Hepatitis A

12,474 Acute Cases Reported in 2018

24,900 Acute Infections Estimated in 2018
(17,500 – 27,400)*



Hepatitis B

3,322 Acute Cases Reported in 2018

21,600 Acute Infections Estimated in 2018
(12,300 – 52,800)*



Hepatitis C

3,621 Acute Cases Reported in 2018


50,300 Acute Infections Estimated in 2018
(39,800 – 171,600)*

Source: Centers for Disease Control and Prevention. Viral Hepatitis Surveillance — United States, 2018. <https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm>. Published July 2020. Accessed August 6, 2020.

However, only 48.5 percent of people with a mental illness have had an HIV test.²³ Once diagnosed with HIV, persons with three or more psychosocial concerns were less likely to be adherent to HIV medications and persons with four or more problems were less likely to be virally suppressed.²⁴ People with mental illnesses were less likely to be prescribed ART and achieve viral suppression.²⁵

Aligning with the EHE key strategy of diagnosing all individuals with HIV, universal testing in behavioral health settings can support rapid linkage to preventive services and HIV care including supportive services to increase PrEP uptake and adherence, syringe services programs (SSPs), cognitive behavioral therapy (CBT), contingency management (CM), and patient navigation (further discussed in Chapter 2).²⁶ The flow diagram (on page 4) shows the role of mental health and substance use providers in caring for clients who are at risk for or have been diagnosed with HIV.

ROLE OF BEHAVIORAL HEALTH PROVIDERS IN PREVENTION AND TREATMENT OF HIV




Substance Use and HIV

SUD can increase the risk of getting HIV and negatively impact HIV care, treatment, and related health outcomes. The prevalence of substance use among people with HIV is also higher than among the general population (as shown in the chart below). People who inject drugs (PWID) are at increased risk for blood borne pathogens, such as HIV and hepatitis B and C.²⁷ In 2017, 9 percent (or 3,641) of the 38,739 new HIV diagnoses in the United States and its territories were among PWID.⁶ ²⁸ Of that population, 2,625 were male and 1,016 were female.²⁸ Six percent (or 2,389) of new HIV diagnoses in the United States were directly attributed to PWID.²⁹ New HIV diagnoses are most prevalent among Whites, Blacks/African Americans, and individuals between the ages of 25 and 44.²⁸

In addition, research suggests that substance use, including alcohol,³⁰⁻³² methamphetamine,³³⁻³⁴ cocaine,³⁵ opioids, and inhalants, increases sexual behaviors that are associated with increased likelihood of getting HIV (e.g., condomless sex).^{28, 36-38}

Mental Health and HIV

Mental illness can interfere with HIV prevention and adherence to treatment⁴⁸⁻⁴⁹ and is linked to behaviors that increase likelihood of getting HIV.





Substances and HIV-Related Outcomes	
Alcohol	Heavy alcohol consumption is linked to sexual behaviors that increase likelihood of getting HIV and associated with delays in HIV diagnosis and lower rates of ART receipt and adherence. ³⁹⁻⁴⁰
Opioids	Opioid use is associated with injection drug use equipment sharing and sexual behaviors that increase likelihood of getting HIV. ⁴¹⁻⁴² Injection drug use presents increased likelihood for HIV transmission, because the virus can survive in a used syringe for up to 42 days. A person without HIV has a 1 in 160 chance of getting HIV when using a syringe previously used by someone who has HIV. ³⁸ Emerging evidence suggests that individuals who misuse prescription opioids are engaging in sexual behaviors that increase likelihood of getting HIV (e.g., condomless sex, sex with multiple partners). ⁴²⁻⁴³
Methamphetamine	Methamphetamine use is associated with injection drug use equipment sharing and sexual behaviors that increase likelihood of getting HIV. People who actively use methamphetamines have lower rates of adherence to ART and medical follow-up (impacting both prevention and treatment). ⁴⁴⁻⁴⁵
“Club drugs” [e.g., 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Molly), Ketamine (Special K), Gamma Hydroxybutyric Acid (GHB, Liquid Ecstasy), alkyl nitrites (Poppers, TNT)] ⁴⁶	“Club drugs” have been linked to sexual behaviors that increase likelihood of getting HIV. However, studies on these drugs are complicated, as it can be difficult to determine the timing of drug use and sexual behavior. Poly-drug use is also common among users of club drugs, complicating analyses. ⁴⁷

The prevalence of mental illness among people with HIV is also higher than among the general population (as shown in the chart below). People with HIV may experience high rates of depression, mood disorders, and generalized anxiety disorder.⁵⁰⁻⁵⁵ An estimated 10 to 28 percent of people with HIV have co-occurring mental illness and/or SUD.⁵⁶ People with HIV who also experience depression report higher rates of other co-occurring mental health concerns such as anxiety disorders (78 percent) and SUD (61 percent), as well as increased viral loads.^{54, 57-58} Depression in people with HIV can also negatively affect

HIV treatment, as it is associated with discontinuation of and non-adherence to ART.⁵⁹⁻⁶⁰

In addition to depression and anxiety, trauma and post-traumatic stress disorder (PTSD) are strongly associated with HIV. Experiences of trauma among people with HIV can lead to behavior that increases likelihood of transmitting HIV, lower adherence to HIV care and ART, and higher likelihood of AIDS-related mortality.⁶¹ Among women in the United States with HIV, 30 percent have PTSD (five times the national rate for women).⁶²





Furthermore, women from low-income, high-HIV prevalence communities experience stressors that lead to the development of PTSD, such as high rates of child maltreatment and physical, emotional, and sexual abuse.⁶³

Interrelated Factors that Impact HIV Prevention and Treatment Efforts

Understanding the complex relationship between social determinants of health, unmet needs, and HIV-related risk factors is key to addressing HIV and mental illness and/or SUD.⁶⁴ For example, it is difficult to engage people in HIV prevention or treatment programs when their basic ancillary needs (e.g., housing, child care, transportation, food, employment, health insurance) are not met.⁶⁵⁻⁶⁸ In urban, high-poverty areas, higher HIV prevalence tends to be associated with socioeconomic status, including educational attainment, household income, employment status, structural racism, and housing status.⁶⁹⁻⁷⁰ There are six key interrelated factors (identified below) that impact HIV prevention and treatment efforts addressed through the practices highlighted in this guide.

Stigma, social marginalization, and discrimination

Stigma is a “perennial problem,”⁷¹ contributing to poor ART adherence, higher rates of depression,⁷² and challenges related to HIV prevention (e.g., fear of disclosure impacting negotiation of condom use).⁷³ Stigmatizing beliefs (e.g., that HIV can be transmitted through coughing or sneezing) contribute to a culture of social discomfort, prejudice, violence, and discriminatory actions (e.g., avoiding interactions with a person they know has HIV).⁷³ Stigma and mistrust of medical systems may deter individuals from seeking care and from sharing

with their healthcare providers details about behaviors that increase risk of getting HIV (e.g., injection drug use, condomless sex) and existing medical conditions (e.g., mental illness, SUD, HIV status, testing, and medication adherence).

Access to appropriate, tailored, and skilled care

Mental illness and SUD are conditions that present barriers to accessing and linking to HIV care, as well as initiating and adhering to medication (ART, PrEP, and PEP).^{60, 74-80} Access to treatment is key to reaching viral suppression.⁷⁹ Individuals may experience challenges in finding providers that have expertise in HIV, mental health, and SUD. Mental illness and SUD treatment providers are well positioned to address some of the social determinants of health and unmet needs, but they may need additional training to address co-occurring HIV.⁸¹

Care coordination

Untreated or undertreated mental illness and/or SUD can create obstacles to initiating and continuing PrEP and ART, increasing the potential for HIV transmission. Integrated testing (as previously described) and service delivery (e.g., multi-disciplinary teams and one-stop-shop models that provide co-located or coordinated substance use, mental health, medical, and social services, further discussed in Chapter 3) are successful strategies for engaging and retaining in care people with or at risk for HIV who may have multiple co-occurring health and ancillary service needs.⁸²⁻⁸⁵ Coordinated care, linkage to HIV care, and patient follow-up and monitoring within behavioral health settings (further discussed in Chapter 2) are also key to facilitating HIV prevention and treatment.

Medical co-morbidities

People with HIV have been shown to be at higher risk for cardiovascular disease, hepatic and renal disease, osteoporosis and fractures, metabolic disorders, skin and soft-tissue disorders, pulmonary disorders, central nervous system disorders, and various forms of cancer.⁸⁶⁻⁸⁷ Cognitive difficulties can be caused by the impact of HIV on the brain (i.e., HIV-associated neurocognitive disorder).⁸⁸⁻⁸⁹ Possible side effects and interactions from pharmacological therapy, including ART and medication for opioid use disorder, may further complicate health outcomes.^{86-87, 90}

Viral hepatitis

People with HIV are disproportionately affected by viral hepatitis (hepatitis A virus [HAV], hepatitis B virus [HBV], and hepatitis C virus [HCV]). Of those with co-occurring HIV and viral hepatitis, about one third have both HBV and HCV. HBV and HCV are bloodborne pathogens, which can be spread through needle sharing associated with injection-drug use.²¹ Nearly 75 percent of people with HIV who inject drugs also are infected with HCV.⁹¹ Both HBV and HCV are also associated with sexual behaviors that increase risk of HIV (e.g., condomless sex). About half of people who have HCV do not display symptoms, so it is important that regular testing is done.⁹² Co-occurring HIV and viral hepatitis present challenges in managing and treating HIV infection.^{91, 94-95} Hepatitis A, B, and C are all associated with liver inflammation and liver damage. When the liver is inflamed, it is less able to process medications including anti-retroviral medications, which can cause

worsened side effects of HIV medicine.⁹⁶ People with HIV who contract viral hepatitis are more likely to experience a faster progression of liver-related injury than people who do not have HIV.²¹ Medications to treat hepatitis are similar to HIV in that they are anti-retroviral. However, some medications that treat HIV and HCV are not safe to use together, so it is important that people with HIV and HCV regularly consult with a doctor.⁹⁴

Incarceration

While the extent of HIV transmission within jails and prisons is not fully understood,⁹⁷⁻⁹⁹ the risk of HIV is heightened for incarcerated populations compared to non-incarcerated populations, namely due to high rates of HIV in prisons, inconsistent screening for HIV upon entry and release, condomless sex, injection drug use equipment sharing, and the labeling of condoms as contraband within prisons.¹⁰⁰⁻¹⁰² Release from incarceration is widely considered an especially vulnerable period for both opioid overdose¹⁰¹⁻¹⁰³ and discontinuation of HIV care and ART treatment provided during incarceration. The interruption in care can lead to reductions in treatment adherence^{101, 104} and increases in viral loads.¹⁰¹⁻¹⁰²

¹ HIV.gov. (n.d.). *A timeline of HIV and AIDS*. <https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline>

² Centers for Disease Control and Prevention. (2019, October 17). *PrEP*. <https://www.cdc.gov/hiv/basics/prep.html>

Reference List

- ³ Centers for Disease Control and Prevention. (2019, August 6). *PEP*. <https://www.cdc.gov/hiv/basics/pep.html>
- ⁴ Fauci, A. S., Redfield, R. R., Sigounas, G., Weahkee, M. D., & Giroir, B. P. (2019). Ending the HIV Epidemic: A plan for the United States. *Journal of the American Medical Association (JAMA)*, 321(9), 844-845. <https://doi.org/10.1001/jama.2019.1343>
- ⁵ HIV.gov. (2020, January 16). *HIV basics - overview: Data & trends: U.S. statistics*. <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>
- ⁶ HIV.gov. (2019, September 3). *What is Ending the HIV Epidemic: A plan for America?* <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>
- ⁷ Remien, R. H. (2019, January). The impact of mental health across the HIV care continuum: Mental health treatment gaps are drivers of increased HIV acquisition and poor health outcomes. American Psychological Association Psychology and AIDS Exchange Newsletter. <https://www.apa.org/pi/aids/resources/exchange/2019/01/continuum>
- ⁸ Bavinton, B. R., Pinto, A. N., Phanuphak, N., Grinsztejn, B., Prestage, G. P., Zablotska-Manos, I. B., Jin, F., Fairley, C. K., Moore, R., Roth, N., Bloch, M., Pell, C., McNulty, A. M., Baker, D., Hoy, J., Tee, B. K., Templeton, D. J., Cooper, D. A., Emery, S.,... Grulich, A. E. (2018). Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. *The Lancet HIV*, 5(8), e438-e447. [https://doi.org/10.1016/s2352-3018\(18\)30132-2](https://doi.org/10.1016/s2352-3018(18)30132-2)
- ⁹ Centers for Disease Control and Prevention. (2020, July 30). 'Ending the HIV Epidemic': CDC Role - Diagnose. <https://www.cdc.gov/endhiv/diagnose.html>
- ¹⁰ Mayo Clinic. (2020, January 10). HIV testing. <https://www.mayoclinic.org/tests-procedures/hiv-testing/about/pac-20385018#:~:text=Why%20it's%20done,spreading%20the%20virus%20to%20others.>
- ¹¹ Centers for Disease Control and Prevention. (2020, January 21). HIV testing. <https://www.cdc.gov/hiv/guidelines/testing.html>
- ¹² Skarbinski, J., Rosenberg, E., Paz-Bailey, G., et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. *JAMA Intern Med.* 2015;175(4):588–596. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2130723>
- ¹³ Moyer, VA US Preventive Services Task Force . Screening for HIV: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159:51–60. <https://www.acpjournals.org/doi/10.7326/0003-4819-159-1-201307020-00645>
- ¹⁴ Background: The Affordable Care Act's new rules on preventive care. CMS.gov website. Published July 14, 2010. Accessed October 1, 2019. <https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/preventive-care-background.html>
- ¹⁵ Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., Kubik, M., Landefeld, C. S., Mangione, C. M., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B. (2019). Screening for HIV Infection. *JAMA*, 321(23), 2326. <https://doi.org/10.1001/jama.2019.6587>
- ¹⁶ Centers for Disease Control and Prevention. (2020, August 4). *HIV Testing: Let's Stop HIV Together*. <https://www.cdc.gov/stophivtogether/hiv-testing/index.html>
- ¹⁷ Centers for Disease Control and Prevention. GetTested: National HIV, STD, and hepatitis testing. <https://gettested.cdc.gov/>
- ¹⁸ Centers for Disease Control and Prevention. (2018). Quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens. <https://stacks.cdc.gov/view/cdc/50872>
- ¹⁹ Substance Abuse and Mental Health Services Administration, & McCance-Katz, Elinore. (2019, November 21). Dear colleague letter from Dr. McCance-Katz on oral fluids HIV testing. <https://www.samhsa.gov/sites/default/files/oral-fluids-dear-colleague-letter.pdf>
- ²⁰ Centers for Disease Control and Prevention. *Types of HIV Tests*. (2020, June 8). <https://www.cdc.gov/hiv/basics/hiv-testing/test-types.html>
- ²¹ Centers for Disease Control and Prevention. (2020, May 21). Viral hepatitis: People with coinfecting with HIV and viral hepatitis. <https://www.cdc.gov/>

[hepatitis/populations/hiv.htm](#)

- 22 Blank, M. B., Himelhoch, S. S., Balaji, A. B., Metzger, D. S., Dixon, L. B., Rose, C. E., Oraka, E., Davis-Vogel, A., Thompson, W. W., & Heffelfinger, J. D. (2014). A multisite study of the prevalence of HIV with rapid testing in mental health settings. *American Journal of Public Health*, 104(12), 2377–2384. <https://doi.org/10.2105/AJPH.2013.301633>
- 23 Yehia, B. R., Cui, W., Thompson, W. W., Zack, M. M., McKnight-Eily, L., DiNenno, E., Rose, C. E., & Blank, M. B. (2014). HIV testing among adults with mental illness in the United States. *AIDS Patient Care and STDs*, 28(12), 628–634. <https://doi.org/10.1089/apc.2014.0196>
- 24 Mizuno, Y., Purcell, D. W., Knowlton, A. R., Wilkinson, J. D., Gourevitch, M. N., & Knight, K. R. (2015). Syndemic vulnerability, sexual and injection risk behaviors, and HIV continuum of care outcomes in HIV-positive injection drug users. *AIDS and Behavior*, 19(4), 684–693. <https://doi.org/10.1007/s10461-014-0890-0>
- 25 Yehia, B. R., Stephens-Shield, A. J., Momplaisir, F., Taylor, L., Gross, R., Dubé, B., Glanz, K., & Brady, K. A. (2015). Health outcomes of HIV-infected people with mental illness. *AIDS and Behavior*, 19(8), 1491–1500. <https://doi.org/10.1007/s10461-015-1080-4>
- 26 HIV.gov. (2020, May 8). ‘Ending the HIV Epidemic’: Key strategies in the plan. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies>
- 27 Wejnert, C., Hess, K. L., Hall, H. I., Van Handel, M., Hayes, D., Fulton, P. J., An, Q., Koenig, L. J., Prejean, J., & Valleroy, L. A. (2016). Vital signs: Trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. *Morbidity and Mortality Weekly Report (MMWR)*, 65(47), 1336–1342. <https://doi.org/10.15585/mmwr.mm6547e1>
- 28 Centers for Disease Control and Prevention. (2019, August 21). *HIV and people who inject drugs*. <https://www.cdc.gov/hiv/group/hiv-idu.html>
- 29 Centers for Disease Control and Prevention. (2019, August 6). *Basic statistics*. <https://www.cdc.gov/hiv/basics/statistics.html>
- 30 Bryant, K. J., Nelson, S., Braithwaite, R. S., & Roach, D. (2010). Integrating HIV/AIDS and alcohol research. *Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism*, 33(3), 167–178. <https://www.ncbi.nlm.nih.gov/pubmed/23584058>
- 31 Woolf, S. E., & Maisto, S. A. (2009). Alcohol use and risk of HIV infection among men who have sex with men. *AIDS and Behavior*, 13(4), 757–782. <https://doi.org/10.1007/s10461-007-9354-0>
- 32 Kerr, D. C., Washburn, I. J., Morris, M. K., Lewis, K. A., & Tiberio, S. S. (2015). Event-level associations of marijuana and heavy alcohol use with intercourse and condom use. *Journal of Studies on Alcohol and Drugs*, 76(5), 733–737. <https://doi.org/10.15288/jsad.2015.76.733>
- 33 Hoenigl, M., Chaillon, A., Moore, D. J., Morris, S. R., Smith, D. M., & Little, S. J. (2016). Clear links between starting methamphetamine and increasing sexual risk behavior: A cohort study among men who have sex with men. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 71(5), 551–557. <https://doi.org/10.1097/qai.0000000000000888>
- 34 Freeman, P., Walker, B. C., Harris, D. R., Garofalo, R., Willard, N., Ellen, J. M., & Adolescent Trials Network for HIV/AIDS Interventions 016b Team. (2011). Methamphetamine use and risk for HIV among young men who have sex with men in 8 US cities. *Archives of Pediatrics & Adolescent Medicine*, 165(8), 736–740. <https://doi.org/10.1001/archpediatrics.2011.118>
- 35 Khan, M. R., Berger, A., Hemberg, J., O’Neill, A., Dyer, T. P., & Smyrk, K. (2013). Non-injection and injection drug use and STI/HIV risk in the United States: The degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users. *AIDS and Behavior*, 17(3), 1185–1194. <https://doi.org/10.1007/s10461-012-0276-0>
- 36 Woolf-King, S. E., Rice, T. M., Truong, H. M., Woods, W. J., Jerome, R. C., & Carrico, A. W. (2013). Substance use and HIV risk behavior among men who have sex with men: The role of sexual compulsivity. *Journal of Urban Health: Bulletin of the New York Academy of Medicine*, 90(5), 948–952. <https://doi.org/10.1007/s11524-013-9820-0>
- 37 Shoptaw, S., Montgomery, B., Williams, C. T., El-Bassel, N., Aramrattana, A., Metsch, L., Metzger, D. S., Kuo, I., Bastos, F. I., & Strathdee, S. A. (2013). Not just the needle: The state of HIV-prevention science among substance users and future directions. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 63, S174–S178. <https://doi.org/10.1097/QAI.0b013e3182987028>
- 38 Centers for Disease Control and Prevention. (2019, September 18). *Injection drug use and HIV risk*. <https://www.cdc.gov/hiv/risk/idu.html>
- 39 Vagenas, P., Azar, M. M., Copenhaver, M. M., Springer, S. A., Molina, P. E., & Altice, F. L. (2015). The impact of alcohol use and related disorders on

the HIV continuum of care: A systematic review. *Current HIV/AIDS Reports*, 12(4), 421-436. <https://doi.org/10.1007/s11904-015-0285-5>

- 40 Chichetto, N. E., Mannes, Z. L., Allen, M. K., Cook, R. L., & Ennis, N. (2019). HIV care provider perceptions and approaches to managing unhealthy alcohol use in primary HIV care settings: A qualitative study. *Addiction Science & Clinical Practice*, 14(1), 21. <https://doi.org/10.1186/s13722-019-0150-8>
- 41 Lerner, A. M., & Fauci, A. S. (2019). Opioid injection in rural areas of the United States: A potential obstacle to ending the HIV epidemic. *Journal of the American Medical Association (JAMA)*, 322(11), 1041-1042. <https://doi.org/10.1001/jama.2019.10657>
- 42 Buttram, M. E., & Kurtz, S. P. (2016). Alternate routes of administration among prescription opioid misusers and associations with sexual HIV transmission risk behaviors. *Journal of Psychoactive Drugs*, 48(3), 187-194. <https://doi.org/10.1080/02791072.2016.1187319>
- 43 Lemons, A., DeGroot, N., Perez, A., Craw, J., Nyaku, M., Broz, D., Mattson, C. L., & Beer, L. (2019). Opioid misuse among HIV-positive adults in medical care: Results from the medical monitoring project, 2009-2014. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 80(2), 127-134. <https://doi.org/10.1097/QAI.0000000000001889>
- 44 Yeon, P., & Albrecht, H. (2007). Crystal meth and HIV/AIDS: The perfect storm. *NEJM Journal Watch*. <https://www.jwatch.org/ac200712030000001/2007/12/03/crystal-meth-and-hiv-aids-perfect-storm>
- 45 Health Resources and Services Administration. (2009, June). *HRSA CARE Action: Methamphetamine and HIV*. <https://hab.hrsa.gov/sites/default/files/hab/Publications/careactionnewsletter/june2009.pdf>
- 46 Drug Enforcement Agency Houston Division. (2017). *DEA intelligence report: Drug slang code words*. <https://www.dea.gov/sites/default/files/2018-07/DIR-020-17%20Drug%20Slang%20Code%20Words.pdf>
- 47 Grov, C., Kelly, B. C., & Parsons, J. T. (2009). Polydrug use among club-going young adults recruited through time-space sampling. *Journal of Substance Use and Misuse*, 44(6), 848-864. <https://doi.org/10.1080/10826080802484702>
- 48 Mehrotra, M. L., Glidden, D. V., McMahan, V., Amico, K. R., Hosek, S., Defechereux, P., Mayer, K. H., Veloso, V. G., Bekker, L., Avelino-Silva, V. I., Schechter, M., & Grant, R. M. (2016). The effect of depressive symptoms on adherence to daily oral PrEP in men who have sex with men and transgender women: A marginal structural model analysis of the iPrEx OLE study. *AIDS and Behavior*, 20(7), 1527-1534. <https://doi.org/10.1007/s10461-016-1415-9>
- 49 Senn, T. E., & Carey, M. P. (2009). HIV testing among individuals with a severe mental illness: Review, suggestions for research, and clinical implications. *Psychological Medicine*, 39(3), 355-363. <https://doi.org/10.1017/S0033291708003930>
- 50 Yehia, B. R., Stewart, L., Momplaisir, F., Mody, A., Holtzman, C. W., Jacobs, L. M., Hines, J., Mounzer, K., Glanz, K., Metlay, J. P., & Shea, J. A. (2015). Barriers and facilitators to patient retention in HIV care. *BMC Infectious Diseases*, 15(1), 246. <https://doi.org/10.1186/s12879-015-0990-0>
- 51 Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S., Turner, B. J., Eggen, F., Beckman, R., & Vitiello, B. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Archives of General Psychiatry*, 58(8), 721-728. <https://doi.org/10.1001/archpsyc.58.8.721>
- 52 Machtinger, E. L., Wilson, T. C., Haber, J. E., & Weiss, D. S. (2012). Psychological trauma and PTSD in HIV-positive women: A meta-analysis. *AIDS and Behavior*, 16(8), 2091-2100. <https://doi.org/10.1007/s10461-011-0127-4>
- 53 Parhami, I., Fong, T. W., Siani, A., Carlotti, C., & Khanlou, H. (2013). Documentation of psychiatric disorders and related factors in a large sample population of HIV-positive patients in California. *AIDS and Behavior*, 17(8), 2792-2801. <https://doi.org/10.1007/s10461-012-0386-8>
- 54 Gaynes, B. N., Pence, B. W., Eron Jr, J. J., & Miller, W. C. (2008). Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosomatic Medicine*, 70(4), 505-511. <https://doi.org/10.1097/psy.0b013e31816aa0cc>
- 55 Do, A. N., Rosenberg, E. S., Sullivan, P. S., Beer, L., Strine, T. W., Schulden, J. D., Fagan, J. L., Freedman, M. S., & Skarbinski, J. (2014). Excess burden of depression among HIV-infected persons receiving medical care in the United States: Data from the Medical Monitoring Project and the Behavioral Risk Factor Surveillance System. *PloS One*, 9(3), e92842. <https://doi.org/10.1371/journal.pone.0092842>
- 56 Chander, G., Himelhoch, S., & Moore, R. D. (2006). Substance abuse and psychiatric disorders in HIV-positive patients. *Drugs*, 66(6), 769-789. <https://doi.org/10.2165/00003495-200666060-00004>
- 57 Schumacher, J. E., McCullumsmith, C., Mugavero, J. E., & Carey, M. P. (2010). HIV testing among individuals with a severe mental illness: Review, suggestions for research, and clinical implications. *Psychological Medicine*, 39(3), 355-363. <https://doi.org/10.1017/S0033291708003930>

- M. J., Ingle-Pang, P. E., Raper, J. L., Willig, J. H., You, Z., Batey, D. S., Crane, H., Lawrence, S. T., Wright, C., Treisman, G., & Saag, M. S. (2013). Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. *AIDS and Behavior*, *17*(8), 2781-2791. <https://doi.org/10.1007/s10461-012-0342-7>
- 58 Substance Abuse and Mental Health Services Administration, & Health Resources and Services Administration. (2016). *The case for behavioral health screening in HIV care settings*. U.S. Department of Health and Human Services. <https://store.samhsa.gov/product/The-Case-for-Behavioral-Health-Screening-in-HIV-Care-Settings/SMA16-4999>
- 59 Safren, S. A., O'Cleirigh, C., Tan, J. Y., Raminani, S. R., Reilly, L. C., Otto, M. W., & Mayer, K. H. (2009). A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-ad) in HIV-infected individuals. *Health Psychology*, *28*(1), 1-10. <https://doi.org/10.1037/a0012715>
- 60 Leserman, J. (2008). Role of depression, stress, and trauma in HIV disease progression. *Psychosomatic Medicine*, *70*(5), 539-545. <https://doi.org/10.1097/psy.0b013e3181777a5f>
- 61 Sales, J. M., Swartzendruber, A., & Phillips, A. L. (2016). Trauma-informed HIV prevention and treatment. *Current HIV/AIDS Reports*, *13*(6), 374-382. <https://doi.org/10.1007/s11904-016-0337-5>
- 62 Machtiger, Wilson, T., E., Haberer, J., & Weiss, D. (2012). Psychological trauma and PTSD in HIV-positive women: A meta-analysis. *AIDS and Behavior*, *16*, 2091-2100. <https://doi.org/10.1007/s10461-011-0127-4>
- 63 Golin, C. E., Haley, D. F., Wang, J., Hughes, J. P., Kuo, I., Justman, J., Adimora, A. A., Soto-Torres, L., O'Leary, A., & Hodder, S. (2016). Post-traumatic stress disorder symptoms and mental health over time among low-income women at increased risk of HIV in the U.S. *Journal of Health Care for the Poor and Underserved*, *27*(2), 891-910. <https://doi.org/10.1353/hpu.2016.0093>
- 64 Singer, M. (1994). AIDS and the health crisis of the U.S. urban poor; the perspective of critical medical anthropology. *Social Science & Medicine*, *39*(7), 931-948. [https://doi.org/10.1016/0277-9536\(94\)90205-4](https://doi.org/10.1016/0277-9536(94)90205-4)
- 65 Aidala, A. A., Wilson, M. G., Shubert, V., Gogolishvili, D., Globerman, J., Rueda, S., Bozack, A. K., Caban, M., & Rourke, S. B. (2016). Housing status, medical care, and health outcomes among people living with HIV/AIDS: A systematic review. *American Journal of Public Health*, *106*(1), e1-e23. <https://doi.org/10.2105/ajph.2015.302905>
- 66 Feller, D. J., & Agins, B. D. (2017). Understanding determinants of racial and ethnic disparities in viral load suppression: A data mining approach. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*, *16*(1), 23-29. <https://doi.org/10.1177/2325957416667488>
- 67 Gupta, G. R., Parkhurst, J. O., Ogden, J. A., Aggleton, P., & Mahal, A. (2008). Structural approaches to HIV prevention. *The Lancet*, *372*(9640), 764-775. [https://doi.org/10.1016/s0140-6736\(08\)60887-9](https://doi.org/10.1016/s0140-6736(08)60887-9)
- 68 Kamarulzaman, A., & Altice, F. L. (2015). Challenges in managing HIV in people who use drugs. *Current Opinion in Infectious Disease*, *28*(1), 10-16. <https://doi.org/10.1097/QCO.0000000000000125>
- 69 Denning, P., & DiNenno, E. (2019, December 11). *Communities in crisis: Is there a generalized HIV epidemic in impoverished urban areas of the United States?* Centers for Disease Control and Prevention. <https://www.cdc.gov/hiv/group/poverty.html>
- 70 Buot, M. G., Docena, J. P., Ratemo, B. K., Bittner, M. J., Burlew, J. T., Nuritdinov, A. R., & Robbins, J. R. (2014). Beyond race and place: Distal sociological determinants of HIV disparities. *PLoS One*, *9*(4). <https://doi.org/10.1371/journal.pone.0091711>
- 71 National Academies of Sciences, Engineering, and Medicine. (2020). *Opportunities to improve opioid use disorder and infectious disease services: Integrating responses to a dual epidemic*. The National Academies Press. <https://doi.org/10.17226/25626>
- 72 Turan, B., Budhwani, H., Fazeli, P. L., Browning, W. R., Raper, J. L., Mugavero, M. J., & Turan, J. M. (2017). How does stigma affect people living with HIV? The mediating roles of internalized and anticipated HIV stigma in the effects of perceived community stigma on health and psychosocial outcomes. *AIDS and Behavior*, *21*(1), 283-291. <https://doi.org/10.1007/s10461-016-1451-5>
- 73 Vanable, P. A., Carey, M. P., Blair, D. C., & Littlewood, R. A. (2006). Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. *AIDS and Behavior*, *10*(5), 473-482. <https://doi.org/10.1007/s10461-006-9099-1>
- 74 Antelman, G., Kaaya, S., Wei, R., Mbwambo, J., Msamanga, G. I., Fawzi, W. W., & Fawzi, M. C. S. (2007). Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. *Journal of Acquired Immune Deficiency*

- Syndromes (JAIDS)*, 44(4), 470-477. <https://doi.org/10.1097/QAI.0b013e31802f1318>
- 75 Bemelmans, M., Baert, S., Negussie, E., Bygrave, H., Biot, M., Jamet, C., Ellman, T., Banda, A., van den Akker, T., & Ford, N. (2016). Sustaining the future of HIV counselling to reach 90-90-90: A regional country analysis. *Journal of the International AIDS Society*, 19(1), 20751. <http://dx.doi.org/10.7448/IAS.19.1.20751>
- 76 Gonzalez, J. S., Batchelder, A. W., Psaros, C., & Safren, S. A. (2011). Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 58(2), 181-187. <https://doi.org/10.1097/QAI.0b013e31822d490a>
- 77 Krumme, A. A., Kaigamba, F., Binagwaho, A., Murray, M. B., Rich, M. L., & Franke, M. F. (2015). Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy. *Journal of Epidemiology & Community Health*, 69(3), 284-289. <https://doi.org/10.1136/jech-2014-204494>
- 78 Uthman, O. A., Magidson, J. F., Safren, S. A., & Nachega, J. B. (2014). Depression and adherence to antiretroviral therapy in low-, middle-and high-income countries: A systematic review and meta-analysis. *Current HIV/AIDS Reports*, 11(3), 291-307. <https://doi.org/10.1007/s11904-014-0220-1>
- 79 Hartzler, B., Dombrowski, J. C., Crane, H. M., Eron, J. J., Geng, E. H., Mathews, W. C., Mayer, K. H., Moore, R. D., Mugavero, M. J., Napravnik, S., Rodriguez, B., & Donovan, D. M. (2017). Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS and Behavior*, 21(4), 1138-1148. <https://doi.org/10.1007/s10461-016-1584-6>
- 80 Korthuis, P. T., Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., & McCarty, D. (2017). Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: A pilot/feasibility randomized trial. *Addiction*, 112(6), 1036-1044. <https://doi.org/10.1111/add.13753>
- 81 Seeman, M. V. (2015). The role of mental health services in addressing HIV infection among women with serious mental illness. *Psychiatric Services*, 66(9), 966-974. <https://doi.org/10.1176/appi.ps.201400411>
- 82 Substance Abuse and Mental Health Services Administration, & National Council for Behavioral Health. *What is integrated care?* Center of Excellence for Integrated Health Solutions. <https://www.thenationalcouncil.org/integration-primary-care-behavioral-health/integrated-care/>
- 83 Backus, L., Czarnogorski, M., Yip, G., Thomas, B. P., Torres, M., Bell, T., & Ross, D. (2015). HIV care continuum applied to the US Department of Veterans Affairs: HIV virologic outcomes in an integrated health care system. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 69(4), 474-480. <https://doi.org/10.1097/qai.0000000000000615>
- 84 Health Resources and Services Administration. (2018, February). *HRSA CARE Action: The role of behavioral health services in the Ryan White HIV/AIDS program*. <https://hab.hrsa.gov/sites/default/files/hab/Publications/careactionnewsletter/BehavioralHealth.pdf>
- 85 Ojikutu, B., Holman, J., Kunches, L., Landers, S., Perlmutter, D., Ward, M., Fant, G., & Hirschhorn, L. (2014). Interdisciplinary HIV care in a changing healthcare environment in the USA. *AIDS Care*, 26(6), 731-735. <https://doi.org/10.1080/09540121.2013.855299>
- 86 Gallant, J., Hsue, P. Y., Shreay, S., & Meyer, N. (2017). Comorbidities among US patients with prevalent HIV infection—a trend analysis. *Journal of Infectious Diseases*, 216(12), 1525-1533. <https://doi.org/10.1093/infdis/jix518>
- 87 Altice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. (2010). Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. *The Lancet*, 376(9738), 367-387. [https://doi.org/10.1016/s0140-6736\(10\)60829-x](https://doi.org/10.1016/s0140-6736(10)60829-x)
- 88 National Institute on Drug Abuse. (2020, April 10). *Common comorbidities with substance use disorders research report*. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-3-connection-between-substance-use-disorders-hiv>
- 89 Krel, R., & Thomas, F. P. (2018, April 12). *How is HIV-associated neurocognitive disorder (HAND) diagnosed and treated?* Medscape. <https://www.medscape.com/answers/1167008-171239/how-is-hiv-associated-neurocognitive-disorder-hand-diagnosed-and-treated>
- 90 Grov, C., Golub, S. A., Parsons, J. T., Brennan, M., & Karpiak, S. E. (2010). Loneliness and HIV-related stigma explain depression among older HIV-positive adults. *AIDS Care*, 22(5), 630-639. <https://doi.org/10.1080/09540120903280901>
- 91 Centers for Disease Control and Prevention. (2017, June). HIV and viral hepatitis. <https://www.cdc.gov/hepatitis/populations/hiv.htm>
- 92 Mayo Clinic. (2020, March 20). Hepatitis C: Symptoms & causes. <https://www.mayoclinic.org/>

[diseases-conditions/hepatitis-c/symptoms-causes/syc-20354278](https://www.cdc.gov/diseases-conditions/hepatitis-c/symptoms-causes/syc-20354278)

- ⁹³ Panel on Opportunistic Infections in Adults and Adolescents with HIV. (2020, January 10). Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. U.S. Department of Health and Human Services. <https://aidsetc.org/resource/guidelines-prevention-and-treatment-opportunistic-infections-hiv-infected-adults-and>
- ⁹⁴ National Library of Medicine. (2019, June 13). HIV and hepatitis C. U.S. Department of Health and Human Services, National Institutes of Health. <https://aidsinfo.nih.gov/understanding-hiv-aids/factsheets/26/88/hiv-and-hepatitis-c>
- ⁹⁵ American Association for the Study of Liver Disease, & Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org/>
- ⁹⁶ Jones, Amelia. (2019, May). Liver disease, hepatitis, and HIV. NAM. <https://www.aidsmap.com/about-hiv/liver-disease-hepatitis-and-hiv>
- ⁹⁷ Centers for Disease Control and Prevention. (2019, October 25). *HIV by group*. <https://www.cdc.gov/hiv/group/index.html>
- ⁹⁸ Ojikutu, B. O., Srinivasan, S., Bogart, L. M., Subramanian, S., & Mayer, K. H. (2018). Mass incarceration and the impact of prison release on HIV diagnoses in the US south. *PloS One*, *13*(6), e0198258-e0198258. <https://doi.org/10.1371/journal.pone.0198258>
- ⁹⁹ National Center for Innovation in HIV Care, The Fenway Institute, & Fenway Health. (2017). *Models for improving linkage to care for people living with HIV released from jail or prison*. U.S. Department of Health and Human Services. <https://targethiv.org/sites/default/files/file-upload/resources/HIV%20and%20Incarceration%20Brief.pdf>
- ¹⁰⁰ Avert. (2019, October 10). *Prisoners, HIV and AIDS*. https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/prisoners#footnote1_pbx20my
- ¹⁰¹ Sawyer, W., & Widra, E. (2017). *Unpacking the connections between race, incarceration, and women's HIV rates*. Prison Policy Initiative. <https://www.prisonpolicy.org/blog/2017/05/08/hiv/>
- ¹⁰² Wohl, D. A. (2016). HIV and mass incarceration where infectious diseases and social justice meet. *North Carolina Medical Journal*, *77*(5), 359-364. <https://doi.org/10.18043/ncm.77.5.359>
- ¹⁰³ Boston University Center for Innovation in Social Work & Health. (n.d.) *Transitional care coordination: From jail intake to community HIV primary care*. TargetHIV. <https://targethiv.org/deii/deii-transitional-care>
- ¹⁰⁴ Beckwith, C., Castonguay, B. U., Trezza, C., Bazerman, L., Patrick, R., Cates, A., Olsen, H., Kurth, A., Liu, T., Peterson, J., & Kuo, I. (2017). Gender differences in HIV care among criminal justice-involved persons: Baseline data from the Care+ Corrections Study. *PloS One*, *12*(1), e0169078. <https://doi.org/10.1371/journal.pone.0169078>

What Research Tells Us

This chapter presents five practices that healthcare practitioners can use to prevent and treat human immunodeficiency virus (HIV) among people living with mental illness and/or substance use disorders (SUD).

- Practices to increase uptake of and improve adherence to Pre-Exposure Prophylaxis (PrEP)
- Syringe Services Programs (SSPs)
- Contingency Management (CM)
- Cognitive Behavioral Therapy (CBT)
- Patient Navigation

Although selected practices are non-pharmacological, some are focused on improving uptake and adherence to medications. Each practice is described and given a rating to assist practitioners, clinic administrators, and policy makers in identifying ones that might serve their population of focus. This chapter also provides an overview of each practice, including a discussion of the typical implementation settings, populations that benefit from the practices, intensity of services, and practice outcomes.

Practice Selection

To be considered for inclusion in this guide, eligible practices had to meet the following criteria:

- Must be clearly defined and replicable
- Impact HIV prevention and treatment–related health outcomes among people with mental illness and/or SUD
- Are currently in use



- Have accessible technical assistance and support for implementation

Evidence Review and Rating

Authors completed a comprehensive review of published research for each selected practice to determine its strength as an evidence-based practice. Eligible research studies had to be published after the year 2000 and:

- Employ a randomized or quasi-experimental design, or
- Be a single sample pre-post design or an epidemiological study with a strong counterfactual (i.e., a study that analyzes what would have happened in the absence of the intervention).

Descriptive and implementation studies and meta-analyses were not included in the review, but were documented to provide context and identify implementation supports for the practices. Authors included systematic reviews when assessing SSPs, as an evidence base for SSPs was established pre-2000.*

Each eligible study was reviewed for evidence of measurable change in HIV and mental illness and/or SUD-related health outcomes. In addition, trained reviewers checked each study to ensure rigorous methodology, asking questions such as:

- Are experimental and comparison groups demographically equivalent, with the only difference being that participants in the experimental group received the intervention and those in the comparison group received treatment as usual or no/minimal intervention?
- Was baseline equivalence established between the treatment and comparison groups on outcome measures?
- Were missing data addressed appropriately?
- Were outcome measures reliable, valid, and collected consistently from all participants?


Using these criteria, each study's causal impact was assessed and given a rating of low, moderate, or high. Only randomized controlled trials, quasi-experimental designs, and epidemiological studies with a strong comparison were

eligible to receive a high or moderate rating (see Appendix 2 for more information about the evidence review process).

Causal Impact: Evidence demonstrating that an intervention causes, or is responsible for, the outcome measured in the study's sample population.

After all studies for a practice were assessed and rated, each practice was placed into one of three categories based on its causal evidence:

- SSPs, CM, CBT, and Patient Navigation have strong evidence.
- Practices to Increase Uptake and Improve Adherence to PrEP have an emerging evidence base.



* Due to concerns raised in the mid-1990s about the ethics of experimental design in SSP research,¹⁻³ researchers have had to rely on longitudinal and epidemiological approaches to understand the impact of regular use of an SSP on injection drug use behaviors, substance use frequency, substance use treatment enrollment, and HIV incidence, among people who inject drugs. Systematic reviews support strong evidence of effectiveness.⁴⁻⁵

Identification of Practices Associated with HIV Prevention and Treatment

In the discussion of selected practices, the following icons will be used to indicate ways in which the practice has been implemented to improve HIV prevention and treatment outcomes:



Practices to Increase Uptake of and Improve Adherence to PrEP



Emerging Evidence

Goal

PrEP is a biomedical intervention in which people at risk of getting HIV adhere to a regimen of daily oral antiretroviral medications. The Food and Drug Administration has approved two forms of PrEP medication⁶ that prevent HIV from multiplying within the body. Long-acting injectable forms of PrEP are currently being tested.⁷

Efficacy of PrEP as a biomedical intervention is **established**.

However, evidence for interventions that aim to increase PrEP uptake and adherence among people at risk of HIV who have mental illness and/or SUD is **emerging**.

The U.S. Preventive Services Task Force gave PrEP a Grade A recommendation.⁸ It is an effective tool for reducing HIV transmission, including among populations behaviorally vulnerable to HIV, such as people who inject drugs (PWID)⁹ and people who may be exposed to HIV through sexual contact.¹⁰ PrEP is approximately 99 percent effective at preventing HIV when taken consistently and adhering to prescription guidelines.⁹ PrEP is recommended for people who have had an increased risk of getting HIV in the past 6 months, and the risks/benefits of uptake and continuing should be an ongoing discussion between the client and provider.

While the efficacy of PrEP as a biomedical intervention is clear, people may face significant barriers to starting and adhering to PrEP, posing obstacles to reaching the goals of the Ending the HIV Epidemic (EHE) initiative. Barriers include, but are not limited to, the following:


- Stigma (both of HIV and of taking PrEP)
- Low awareness of the existence of PrEP among eligible PrEP users
- Low perception of risk of getting HIV
- Concern about possible side effects
- Lack of social support
- Perceived and actual cost
- Difficulty following the daily regimen¹⁰
- Health insurance coverage, or health insurance that does not cover laboratory and clinical visits¹¹⁻¹³
- Limited access to care (e.g., transportation, hours of services)

Mental illness and/or SUD may compound these barriers.

Since the effectiveness of PrEP as a biomedical intervention has been established, this evidence review examines psychosocial supports to increase uptake and adherence to PrEP. These psychosocial interventions include the following:

- *PrEP Mate*: A bidirectional text-messaging program, grounded in the information, motivation, and behavioral (IMB) theory of behavior change, involving daily text reminders to take PrEP and weekly text check-ins.¹⁸
- *Bio-Behavioral Community Health Recovery Program (CHRP-BB)*: A weekly group therapy and text-message reminder intervention encouraging PrEP adherence and teaching health management skills for people who are vulnerable to HIV (through injection drug use or condomless sex).¹⁹
- *Pharmacy-led PrEP (P-PrEP)*: An integrated care intervention in which an in-clinic pharmacist consults with the client and prescribes PrEP the same day that the client tests negative for HIV.¹⁵

Outcomes Associated with Practices to Increase Uptake and Improve Adherence to PrEP



- Increased PrEP uptake, sustained for up to 9 months.¹⁵⁻¹⁷
- Increased PrEP adherence, sustained for up to 12 months.¹⁵⁻¹⁹

Typical Settings

Practitioners can implement practices designed to increase PrEP uptake and adherence in diverse mental illness, SUD, and HIV treatment settings, including the following:

- Safety net health clinics focused on HIV prevention and treatment¹⁸
- Mobile application that extends the reach of PrEP support¹⁸
- Methadone maintenance clinics¹⁹
- Non-clinical testing centers; pharmacies; community health centers¹⁵⁻¹⁷

Safety-net clinics provide care to individuals who have limited or no access to health care (as a result of financial circumstances, insurance status, or health conditions).²⁰

Demographic Groups

Several categories of people can benefit from practices designed to increase PrEP uptake and adherence, including:

- Young men (mean age of 24) who have sex with men (MSM)¹⁹
- Individuals who reported recreational drug use¹⁹

- Individuals who reported binge drinking over the past 3 months¹⁹
- PWID¹⁹
- People who test negative for HIV¹⁷

PrEP should not be prescribed to people with HIV (as it is an inappropriate medical intervention for HIV) and/or people with severe renal insufficiency.¹⁰

Practitioner Types

A diverse range of behavioral health practitioners and clinical providers can implement practices to increase PrEP uptake and adherence, including:

- Clinic and research staff¹⁸
- Graduate-level trained facilitators¹⁹
- Pharmacists¹⁵⁻¹⁷

Intensity and Duration

While PrEP can be taken indefinitely, intensity and duration of individual practices to support PrEP uptake and adherence vary depending on the intervention.

- PrEPMate includes daily text reminders to take PrEP and weekly check-in texts about PrEP adherence, side effects, and attitudes around PrEP sent from clinicians¹⁸⁻¹⁹
- CHRP-BB includes four 50-minute weekly group meetings that address behaviors related to increased risk of getting HIV and increased PrEP adherence and daily text reminders to take PrEP¹⁹
- P-PrEP includes same-day PrEP referral by a pharmacist and follow-up appointment with a clinician within 6 weeks¹⁷

Syringe Services Programs (SSPs)



Goal

SSPs reduce the risk of infectious disease associated with injection drug use through preventive services, including provision of sterile syringes, injection drug equipment, and harm reduction education, as well as linkage to HIV and mental illness and/or SUD treatment.²¹⁻²³


Decades of research demonstrate the efficacy and importance of SSPs in reducing the transmission of

infectious diseases, including HIV and hepatitis C virus (HCV).²⁴ Due to concerns raised in the mid-1990s about the ethics of experimental design in SSP research,¹⁻³ researchers have had to rely on longitudinal and epidemiological approaches to understand the impact of regular use of an SSP on reductions in harm associated with injection drug use, substance use frequency and treatment enrollment, and HIV incidence among PWID.

SSPs have been shown to reduce HIV and HCV incidence by approximately 50 percent and are a key practice identified in the EHE initiative.²⁵⁻²⁶ Additionally, SSPs have been effective in engaging hard to reach populations, as SSPs reduce typical barriers to entry

(e.g., clients do not need insurance coverage, pre-scheduled appointments, referrals)⁷ and can adjust delivery venues to meet community needs (e.g., fixed-site or mobile exchange vans).²⁸ SSPs are also a prime setting for implementing combined interventions, including medication for opioid use disorder.²⁹

Outcomes Associated with SSPs

	<ul style="list-style-type: none">• Reduction in self-reported receptive syringe sharing (i.e., using a previously used syringe)³⁰⁻³³• Increase in frequency of injecting with a sterile syringe, as opposed to a non-sterile syringe^{31, 34}• Reduction in self-reported sharing of injection equipment and/or paraphernalia³¹⁻³³• Reduction in HIV incidence³⁰• Reduction in self-reported substance use frequency³⁵
---	---

Typical Settings

SSPs are community-based interventions that vary significantly based on implementation setting, geographic location, scope, and services to meet local community needs.^{26, 36} The eight studies in this evidence review showed that SSPs have been effective in both urban and rural settings and have operated successfully as both long-standing programs and temporary emergency public health responses to HIV outbreaks. SSPs have also been effective in both fixed-site and mobile settings.³⁰⁻³¹

Demographic Groups

PWID, regardless of gender, age, education, marital status, income, or housing status, can benefit from consistent availability of sterile syringes provided through SSPs.³⁴ Access to sterile injection drug equipment, harm reduction education, and linkage to treatment through SSPs²² can lead to reductions in harm associated with injection drug use, substance use frequency, and overall HIV incidence.³⁰⁻³⁵

Geographic proximity may also impact an individual's ability to access an SSP, suggesting that populations living near SSPs benefit most from their services.³²

In this practice, individuals can acquire large numbers of syringes to distribute to their networks of others

who also inject. As a result, SSPs can facilitate a larger number of sterile syringes available within a community.^{33, 37}

Practitioner Types

SSP activities can be conducted by:

- Pharmacists, pharmacy managers, clerks, and technicians dispensing over-the-counter syringes^{34, 38}
- Care service coordinators³¹ and outreach workers³⁹
- Professional staff and volunteers (including trained healthcare professionals)

These personnel are best equipped to take on these roles when provided with overdose prevention and response training and appropriate education about sterile syringe distribution and needle-stick injuries.⁴⁰⁻⁴¹

Intensity and Duration

SSPs are structural interventions designed to impact population health.³⁸ Implementing an SSP is less about a specific number of interactions with PWID, and more about providing consistent, stable access to sterile syringes to increase the volume of sterile syringes available in a given community (benefiting both direct participants of SSPs and their networks).

However, the higher the number of interactions with SSPs, the more opportunities a provider has to offer additional harm reduction education materials (e.g., naloxone kits, PrEP, PEP) and SUD treatment.

Studies in this evidence review identified the following factors as affecting the success of service provision:

- **Operating hours:** Due to limited funding, SSPs may restrict their hours, potentially reducing interactions with clients and the number of syringes provided (at the individual and community levels).³⁴
- **Location of the SSP:** The distance between an individual's home and the SSP has been identified as a barrier to accessing SSPs.^{32, 34, 39}
- **Number of syringes provided:** SSPs can provide sterile syringes (not purchased using federal funding) in single or multiple day supplies, based on the number of syringes returned and reported injection frequency.³¹

Contingency Management (CM)



Strong Evidence

Goal

CM is a behavioral therapy that uses motivational incentives and tangible reinforcers to increase desirable behavior.⁴²⁻⁴³ People in CM programs are given reinforcers—often vouchers that can be exchanged for money or goods, or chances to win prizes—when they consistently demonstrate positive behavior (e.g., negative urine drug screens, showing up for an appointment).⁴⁴

Many state Medicaid, Medicare, and private insurance entities may not reimburse for CM reinforcers. Additionally, the Department of Health and Human Services' (HHS) Office of the Inspector General (OIG) has ruled that the Centers for Medicare and Medicaid Services (CMS) may not provide more than \$75 annually (or \$15 per individual appointment) in goods to beneficiaries, limiting CM enforcers to that amount.⁴⁵⁻⁴⁷ Medicaid, Medicare, and private insurance agencies may reimburse for CM as a service, but any value of payment for the reinforcers is prohibited. Therefore, CM implementation requires careful coordination with HHS, the state health department, and other insurance providers. Providers wishing to implement CM may identify other funding for reinforcers (up to \$75 per beneficiary annually), including federal, state, and private grants, as well as contributions from or opportunities to share costs with community partners.

Practitioners can implement CM along with individual or group counseling or in conjunction with scheduled medical visits, including urine drug screens, daily methadone dosing, or HIV-related appointments.⁴⁸⁻⁴⁹

Outcomes Associated with CM

CM is an effective psychosocial intervention for reducing substance use and maintaining substance use abstinence for periods of up to 1 year.⁵⁰ In 2006, researchers began testing CM principles in the prevention and treatment of HIV.⁵¹ Behavior change takes time, and while CM has been shown to be effective for periods up to one year, it is important to note that these may be temporary changes for life-long disorders. HIV prevention and treatment outcomes attributed to CM are outlined below:

	<ul style="list-style-type: none"> Reduction in self-reported sexual behaviors that increase risk for HIV over the previous month (i.e., number of sexual partners, condomless sex, sex for money or nonmonetary items, and anal sex) sustained for up to 12 months.^{42, 44, 48} Reduction in self-reported drug-use behaviors that increase likelihood for getting HIV over the previous month, (i.e., injection drug use, receptive syringe sharing, syringe lending, and using injection drug use equipment that has not been cleaned or sterilized) sustained for up to 12 months.^{42, 48-49}
	<ul style="list-style-type: none"> Reduction in viral load, sustained for up to 6 months.^{44, 52} Increase in adherence to antiretroviral therapy (ART), sustained for up to 4 months.⁵³

Typical Settings

Practitioners can use CM across a variety of outpatient and inpatient settings and across urban, suburban, and rural settings, including:

- Outpatient treatment clinics^{42, 44, 48-49, 52}
- SUD treatment settings (e.g., methadone clinics)⁴⁹
- Counseling centers^{42, 25}
- HIV-focused drop-in centers⁴⁴

Demographic Groups

	<ul style="list-style-type: none"> CM has been effective in preventing HIV among adults aged 18 to 65, living in urban and suburban areas, who use cocaine and opioids and who are taking methadone. It has also been effective among adults who engage in sexual and drug use behaviors that increase likelihood of getting HIV.^{42, 44, 48-49}
	<ul style="list-style-type: none"> CM is effective in increasing linkage to and retention in HIV care among people with co-occurring HIV and SUD including adults aged 18 to 65, living in urban and suburban settings, with HIV, and who use cocaine and opioids. It has also shown efficacy among PWID and adults who take methadone.^{42, 44, 48-49, 52}

Practitioner Types

CM can be implemented by a variety of practitioners, including:

- Counselors^{42, 53}
- Post-doctoral fellows in psychology (who are provided with supervision from licensed psychologists)⁴⁴
- Clinic staff with education levels ranging from no bachelor's degree to master's degree in social work⁴⁸⁻⁴⁹

Formal CM-specific training is not required, but training or coursework in behavioral analysis is available to support implementation of this practice.

Intensity and Duration

CM does not require a prescribed number of sessions or specified length of individual sessions, and has

demonstrated efficacy when implemented in the following settings for the following durations:

- An intensive outpatient setting with daily counseling over 6 weeks⁴⁸
- A methadone clinic with daily methadone dosing and weekly individual and group counseling over 12 weeks^{42, 49}
- A counseling center with individual counseling over 16 weeks⁵²
- A counseling center with weekly group counseling sessions over 24 weeks⁴⁴

CM can also act as a “buy-in” for other behavioral interventions associated with longer-term benefits. For example, when combined with counseling, it may increase attendance at sessions, which in turn can have long-term therapeutic benefits.⁴⁸



Cognitive Behavioral Therapy (CBT)





Strong Evidence

Goal



Providers in mental health settings are uniquely positioned to prevent HIV and support linkage and retention in HIV care and ART adherence for people with HIV. Through individual and group counseling such as CBT, providers can build “reciprocal, robust, and trusting relationships” by having consistent and confidential interactions with clients over time.⁵⁴

CBT is a form of psychotherapy that seeks to modify problematic thinking, beliefs, or behavior through skill-building. CBT programs share three core principles. They are 1) goal-oriented; 2) time-limited; and 3) structured.⁵⁵ CBT helps individuals identify specific problems and gain the skills to manage and solve them.⁵⁶ All studies included in this evidence review employed the core components of CBT (basing individual and group work on thoughts, feelings, emotions, and skill-building).

This evidence review includes specific applications of CBT for mental health clinicians to use with clients living with mental illness and/or SUD with and at risk for HIV, detailed below:

	<p align="center">Cognitive Behavioral Skill Building Intervention (E-CB)</p> <p>E-CB facilitates HIV prevention through structured sessions on the following topics:</p> <ul style="list-style-type: none"> • HIV education, including personalizing risk of getting HIV, condom use and negotiation skills and identifying situations with increased risk of getting HIV • developing and practicing problem solving, assertiveness, and communication training approaches.⁵⁷
	<p align="center">Cognitive Behavioral Therapy for Trauma and Self Care (Project Thrive)</p> <p>Project Thrive addresses posttraumatic stress responses in MSM with histories of childhood sexual abuse who are at increased risk for HIV. This individual therapy model integrates counseling for sexual health with cognitive and behavioral strategies as a feasible and acceptable treatment among MSM to effectively reduce sexual risk for HIV and decrease post-traumatic stress disorder (PTSD) symptom severity.⁵⁸⁻⁵⁹</p>
	<p align="center">Behavioral Activation for Methamphetamine Dependence (Project IMPACT)</p> <p>Project IMPACT is an individual therapy intervention that aims to reduce crystal methamphetamine use and condomless sex among MSM. This integrated treatment consists of behavioral activation, an evidence-based approach for depression that involves identifying and participating in pleasurable, goal-directed activities, and CBT with HIV sexual risk counseling.⁶⁰</p>
	<p align="center">Cognitive Behavioral Therapy for Social Anxiety and Sexual Health (Sexual Confidence)</p> <p>Sexual Confidence adapts the CBT framework for social anxiety to include substance use management in interpersonal situations and reducing sexual behaviors that increase likelihood of getting HIV through sessions on the following:</p> <ul style="list-style-type: none"> • setting goals related to reducing risk of getting HIV and reducing social anxiety • the role of social anxiety and substance use in increasing risk of getting HIV • discussing and practicing coping skills for anxiety reduction⁶¹⁻⁶²
	<p align="center">Cognitive Behavioral Therapy for HIV Medication Adherence and Depression (CBT-AD)</p> <p>CBT-AD integrates continued adherence counseling with traditional CBT techniques for the treatment of depression. CBT-AD uses proactive problem solving, action planning, and motivational interviewing to:</p> <ul style="list-style-type: none"> • facilitate behavior change⁶³ • address the cognitive and behavioral patterns commonly experienced by adults with co-occurring depression and HIV⁶⁴ • improve ART adherence⁶³

Outcomes Associated with CBT

	<ul style="list-style-type: none"> • Reduced sexual behaviors that increase likelihood of getting HIV, including improved attitudes towards condom use and greater condom use skills, sustained for up to 6 months^{57,62, 65-66} • Reduced PTSD and depression symptom severity for up to 9 months^{58, 60} • Reduction in crystal methamphetamine use for up to 6 months⁶⁶ • Increased perceived susceptibility to getting HIV, defined as perceptions of personal vulnerability to HIV disease, sustained for up to 6 months⁵⁷
	<ul style="list-style-type: none"> • Reduction in viral load, sustained for up to 12 months⁶⁷ • Increase in adherence to ART, sustained for up to 15 months^{63, 68-70}



Typical Settings

Practitioners can incorporate CBT in mental illness and/or SUD and social service settings including:

- Academic medical centers⁶⁵
- Outpatient treatment centers⁵⁷
- Methadone clinics⁶³
- Homeless shelters⁷¹
- Community health clinics⁶⁹

Demographic Groups

CBT is a well-established, effective treatment for people with mental illness and/or SUD who have or at risk for HIV. It is appropriate for anyone who can relate to the CBT core components, problem-solving approach, and structure, including:

	<ul style="list-style-type: none"> • Men who have sex with men (MSM) who are at risk for HIV^{61, 71} • People with severe mental illness at risk for HIV⁵⁷ • People with at least one HIV-related risk behavior, including self-reported injection drug use, two or more sex partners in the past 90 days, or having a partner with HIV⁶⁵ • People with a history of child sexual abuse and at risk for getting HIV⁵⁸
	<ul style="list-style-type: none"> • People with co-occurring HIV and depression⁶⁸⁻⁶⁹ • People with co-occurring HIV and depression who inject drugs⁶³

Practitioner Types






CBT can be implemented effectively by a variety of professionals including:

- Clinical psychologists⁶³
- Master's level psychologists,⁶⁸ social workers, and counselors
- Case managers⁷²
- Facilitators with an average of 10 years of experience leading group-based HIV prevention interventions with people who use drugs⁶⁵

Practitioners do not need to be certified to practice CBT, but certifications are available.⁷³

Intensity and Duration

CBT generally provides the tools for behavior change in 8 to 12 individual or group sessions, meeting once or twice weekly, with each session lasting between 60 and 90 minutes.⁷⁴ The length of treatment also varies depending on the individual's symptoms, resources, and preference. As highlighted below, studies included in this evidence review varied by time and number of sessions.

	<p>The E-CB intervention consists of six 90-minute sessions over the course of 6 weeks. Weekly sessions gave participants time to practice lessons between sessions, reinforcing content discussed during the sessions.⁵⁷</p>
	<p>Project Thrive consists of approximately 10 individual therapy sessions on integrated cognitive therapy strategies, behavioral techniques, and sexual risk reduction counseling.⁵⁸</p>
	<p>Project IMPACT consists of 10 weekly, 50-minute, in-person sessions that include HIV risk reduction sessions, sessions of cognitive behavioral therapy for reducing substance use, behavioral activation sessions, and preventing re-starting substance use.⁶⁰</p>
	<p>Sexual Confidence consists of 10 weekly 1 hour sessions using an integrated CBT model focusing on conversations between the client and facilitator (instead of a didactic learning session).⁶²</p>
	<p>CBT-AD consists of between nine and 12 50- to 60-minute sessions, with three "open sessions" (which allow for the individual and therapist to revisit the modules that are most relevant to the client's specific needs).^{63, 64, 67, 69}</p>

Patient Navigation



Strong Evidence

Goal

Patient navigation is a client-centered approach aimed at improving care engagement by addressing client and system barriers, and helps clients access medical and support services in an often complex healthcare system.⁷⁵ Originally developed as a strategy to improve timely access to cancer screening, diagnosis, and treatment,⁷⁶ patient navigation has been used to improve the health outcomes of multiple medical conditions, including HIV. During individual sessions, navigators work with participants to facilitate access to care, review health information, overcome personal or logistical challenges, and provide psychosocial support by promoting self-efficacy and problem-solving behaviors. In addition to the sessions, navigators accompany participants to HIV care and SUD treatment appointments.

In the context of the HIV-care continuum, patient navigation services typically focus on linkage to and retention in care, improving HIV treatment outcomes, client satisfaction, and client self-management.⁷⁷

Outcomes Associated with Patient Navigation



- Viral suppression, sustained up to 12 months⁷⁸
- Linkage to HIV care, with the greatest probability of linkage occurring within 6 months^{53, 78}
- Retention in HIV care, sustained up to 12 months⁷⁸
- Adherence to ART medications, sustained up to 12 months⁵³

Typical Settings

Practitioners can provide patient navigation services in a wide range of treatment settings including:

- Correctional and criminal justice settings⁷⁸
- Mental illness and/or SUD treatment programs⁷⁹
- Primary health and HIV-specific care clinics⁵³
- Hospitals⁵³

PATIENT NAVIGATION:

Supporting transition between jail and community

While incarcerated, people with HIV often achieve viral suppression due to the highly structured environment and consistent access to care. Post-release delays in linkage to and retention in care can cause declines in viral suppression.⁷⁴

Peer patient navigators with shared lived experiences can play a key part in facilitating linkage to care by acting as role models. In the study included in this review, peer patient navigators established relationships with participants before they left jail, met them at the time of release, provided referrals for post-release housing and SUD treatment, and counseled them on retention and adherence behaviors in HIV care.

Demographic Groups

Patient navigation can be used with a variety of populations, but is often targeted for those at highest likelihood of not linking to or continuing in care⁸⁰ including:

- People with HIV, aged 18 or older, who report recent use of substances (i.e., opioids, stimulants, alcohol)⁵³
- People with HIV (specifically men and transgender women) transitioning from jail to the community⁷⁸

Practitioner Types

Patient navigation can be implemented effectively by a variety of professionals including:

- Medical professionals or clinical staff, community members, social workers, and other diverse professionals (e.g., case management, discharge planning, criminal justice system)⁷⁷
- Peer patient navigators⁷⁸

Patient navigators often share qualifications and skills with other support service providers in clinical settings, such as advocates, health educators, or case managers.⁷⁴ Matching peer patient navigators with individuals who have similar experiences is a successful approach for linking and retaining clients in HIV care⁸¹ and can play a key role in building social networks and establishing trust, especially among stigmatized populations.⁸²

Intensity and Duration

Patient navigation services are customized to the specific needs of clients, so there is no standard model for the intensity and duration of the program.⁸⁰ Typically, navigators meet regularly with clients for 11 to 12 individual sessions over 6 months, and their work continues through a predetermined endpoint (determined by the clinic model). In the case of HIV care, this endpoint is often linkage to care.⁷⁷



Summary of Evidence-based Review

Practice	Practices to Increase Uptake of and Improve Adherence to PrEP	Syringe Services Programs (SSPs)	Contingency Management (CM)	Cognitive Behavioral Therapy (CBT)	Patient Navigation
Review Rating	Emerging Evidence	Strong Evidence	Strong Evidence	Strong Evidence	Strong Evidence
Focus of the practice	Practices designed to overcome barriers to initiating and sustaining PrEP use.	A harm reduction method for reducing the likelihood of HIV and HCV associated with injection drug use.	Focus on positively rewarding desired behaviors.	Focus on helping clients improve their quality of life not by changing their circumstances, but by altering their perceptions of those circumstances.	A client-centered approach aimed at improving engagement in HIV care by addressing client and system barriers.
Can be used in out-patient healthcare settings	✓	✓	✓	✓	✓
Can be used in in-patient healthcare settings	✓	-	✓	✓	✓
Specific training available	✓	✓	-	✓	✓
Can be practiced by peers	-	✓	-	-	✓
Special populations with whom the practice has been successfully implemented	Young MSM; PWID or recreationally use drugs	PWID	Individuals with co-occurring HIV and SUD; individuals who engage in sexual or drug use behaviors that increase likelihood of getting HIV	MSM; individuals with severe mental illness; individuals with co-occurring HIV, mental illness and/or SUD	Individuals with SUD; men and transgender women transitioning from jail to community
Intensity and duration	Indefinite	Indefinite	No prescribed intensity or duration; shown to be effective for between 6 to 24 weeks	Varies depending on specific CBT intervention implemented, ranges from 1 to 2 weekly sessions over the course of 8 to 12 weeks	No prescribed intensity or duration; typical range of 11 to 12 sessions over 6 months

Reference List

- ¹ Leary, W. E. (1996, October 18). Questions on ethics lead to review of needle-exchange study. *The New York Times*. <https://www.nytimes.com/1996/10/18/us/questions-on-ethics-lead-to-review-of-needle-exchange-study.html>
- ² Benowitz, S. (1997, February 2). Politics polarizing issues in needle-exchange study. *The Scientist*. <https://www.the-scientist.com/news/politics-polarizing-issues-in-needle-exchange-study-57635>
- ³ Fisher, D. G., Fenaughty, A. M., Cagle, H. H., & Wells, R. S. (2003). Needle exchange and injection drug use frequency: A randomized clinical trial. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, 33(2), 199-205. <https://doi.org/10.1097/00126334-20030610-00014>
- ⁴ Abdul-Quader, A. S., Feelemyer, J., Modi, S., Stein, E. S., Briceno, A., Semaan, S., Horvath, T., Kennedy, G. E., & Des Jarlais, D. C. (2013). Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. *AIDS and Behavior Addiction*, 17(9), 2878-2892. <https://doi.org/10.1007/s10461-013-0593-y>
- ⁵ Aspinall, E. J., Nambiar, D., Goldberg, D. J., Hickman, M., Weir, A., Van Velzen, E., Palmateer, N., Doyle, J. S., Hellard, M. E., & Hutchinson, S. J. (2014). Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: A systematic review and meta-analysis. *International Journal of Epidemiology*, 43(1), 235-248. <https://doi.org/doi:10.1093/ije/dyt243>
- ⁶ Centers for Disease Control and Prevention. (2020, May 18). *Pre-exposure prophylaxis (PrEP)*. <https://www.cdc.gov/hiv/clinicians/prevention/prep.html>
- ⁷ Cohen, J. (2020). Long-acting injectable drug prevents HIV infections. *Science*. <https://doi.org/10.1126/science.abc8634>
- ⁸ U.S. Preventive Services Task Force. (2019). Preexposure prophylaxis for the prevention of HIV infection: U.S. Preventive Services Task Force recommendation statement. *Journal of the American Medical Association (JAMA)*, 321(22), 2203-2213. <https://doi.org/10.1001/jama.2019.6390>
- ⁹ Centers for Disease Control and Prevention. (2019, October 17). *PrEP*. <https://www.cdc.gov/hiv/basics/prep.html>
- ¹⁰ Centers for Disease Control and Prevention. (2020, May 18). *Pre-exposure prophylaxis (PrEP)*. <https://www.cdc.gov/hiv/clinicians/prevention/prep.html>
- ¹¹ Sidebottom, D., Ekström, A. M., & Strömdahl, S. (2018). A systematic review of adherence to oral pre-exposure prophylaxis for HIV - How can we improve uptake and adherence? *BMC Infectious Diseases*, 18(1), 581-581. <https://doi.org/10.1186/s12879-018-3463-4>
- ¹² Otto, M. A. (2019, April 4). *PrEP adherence lowest among Medicaid patients, others*. MDedge. <https://www.mdedge.com/infectiousdisease/article/198180/hiv/prep-adherence-lowest-among-medicaid-patients-others>
- ¹³ Huang, Y. A., Tao, G., Smith, D. K., & Hoover, K. W. (2020). Persistence with HIV preexposure prophylaxis in the United States, 2012-2017. *Clinical Infectious Diseases*. Advance online publication. <https://doi.org/10.1093/cid/ciaa037>
- ¹⁴ Kay, E. S., & Pinto, R. M. (2020). Is insurance a barrier to HIV preexposure prophylaxis? Clarifying the issue. *American Journal of Public Health*, 110(1), 61-64. <https://doi.org/10.2105/AJPH.2019.305389>
- ¹⁵ Havens, J. P., Scarsi, K. K., Sayles, H., Klepser, D. G., Swindells, S., & Bares, S. H. (2019). Acceptability and feasibility of a pharmacist-led human immunodeficiency virus pre-exposure prophylaxis program in the midwestern United States. *Open Forum Infectious Diseases*, 6(10), ofz365. <https://doi.org/10.1093/ofid/ofz365>
- ¹⁶ Khosropour, C. M., Backus, K. V., Means, A. R., Beauchamps, L., Johnson, K., Golden, M. R., & Mena, L. (2020). A pharmacist-led, same-day, HIV pre-exposure prophylaxis initiation program to increase PrEP uptake and decrease time to PrEP initiation. *AIDS Patient Care & STDs*, 34(1), 1-6. <https://doi.org/10.1089/apc.2019.0235>
- ¹⁷ Smith, B. L., Hester, A. M., Cantos, V. D., James, T. R., & Lora, M. H. (2019). 1280. A pharmacist-led PrEP program at the epicenter of the HIV epidemic in Atlanta; our experience. *Open Forum Infectious Diseases*, 6(Suppl 2), S461. <https://doi.org/10.1093/ofid/ofz360.1143>

- 18 Liu, A. Y., Vittinghoff, E., von Felten, P., Amico, K. R., Anderson, P. L., Lester, R., Andrew, E., Estes, I., Serrano, P., Brothers, J., Buchbinder, S., Hosek, S., & Fuchs, J. D. (2019). Randomized controlled trial of a mobile health intervention to promote retention and adherence to preexposure prophylaxis among young people at risk for human immunodeficiency virus: The epic study. *Clinical Infectious Diseases*, 68(12), 2010-2017. <https://doi.org/10.1093/cid/ciy810>
- 19 Shrestha, R., Altice, F. L., Karki, P., & Copenhaver, M. M. (2018). Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: A pilot feasibility study. *AIDS and Behavior*, 22(8), 2640-2649. <https://doi.org/10.1007/s10461-018-2099-0>
- 20 National Association of Public Hospitals and Health Systems. (n.d.). *What is a Safety Net Hospital?* http://www.literacynet.org/hls/hls_conf_materials/WhatIsASafetyNetHospital.pdf
- 21 Dawson, L., & Kates, J. (2018). *HIV and the opioid epidemic: 5 key points*. Kaiser Family Foundation. <https://www.kff.org/hivaids/issue-brief/hiv-and-the-opioid-epidemic-5-key-points/>
- 22 Centers for Disease Control and Prevention (2020, June 4). *Summary of information on the safety and effectiveness of syringe services programs (SSPs)*. <https://www.cdc.gov/ssp/syringe-services-programs-summary.html>
- 23 HIV.gov. (2020, January 31). *Syringe services programs - Opioid crisis is raising risks of HIV & other infectious diseases*. <https://www.hiv.gov/federal-response/policies-issues/syringe-services-programs>
- 24 HIV.gov. (2020, July 2). *What is Ending the HIV Epidemic: A plan for America?* <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>
- 25 Ojikutu, B., Holman, J., Kunches, L., Landers, S., Perlmutter, D., Ward, M., Fant, G., & Hirschhorn, L. (2014). Interdisciplinary HIV care in a changing healthcare environment in the USA. *AIDS Care*, 26(6), 731-735. <https://doi.org/10.1080/09540121.2013.855299>
- 26 Centers for Disease Control and Prevention (2019, May 23). *Syringe services programs (SSPs) fact sheet*. <https://www.cdc.gov/ssp/syringe-services-programs-factsheet.html>
- 27 Clarke, K., Harris, D., Zweifler, J. A., Lasher, M., Mortimer, R. B., & Hughes, S. (2016). The significance of harm reduction as a social and health care intervention for injecting drug users: An exploratory study of a needle exchange program in Fresno, California. *Social Work In Public Health*, 31(5), 398-407. <https://doi.org/10.1080/19371918.2015.1137522>
- 28 Miller, C. L., Tyndall, M., Spittal, P., Li, K., Palepu, A., & Schechter, M. T. (2002). Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges. *Journal of Urban Health*, 79(2), 257-265. <https://doi.org/10.1093/jurban/79.2.257>
- 29 Hood, J. E., Banta-Green, C. J., Duchin, J. S., Breuner, J., Dell, W., Finegood, B., Glick, S. N., Hamblin, M., Holcomb, S., Mosse, D., Oliphant-Wells, T., & Shim, M. M. (2019). Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. *Substance Abuse*, 1-9. <https://doi.org/10.1080/08897077.2019.1635557>
- 30 Kerr, T., Small, W., Buchner, C., Zhang, R., Li, K., Montaner, J., & Wood, E. (2010). Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. *American Journal of Public Health*, 100(8), 1449-1453. <https://doi.org/10.2105/AJPH.2009.178467>
- 31 Dasgupta, S., Broz, D., Tanner, M., Patel, M., Halleck, B., Peters, P. J., Weidle, P. J., O'Donnell, J., Amlung, J., McAlister, C., Chapman, E., Bailey, A., Burnett, J., & Duwve, J. (2019). Changes in reported injection behaviors following the public health response to an HIV outbreak among people who inject drugs: Indiana, 2016. *AIDS and Behavior*, 23(12), 3257-3266. <https://doi.org/10.1007/s10461-019-02600-x>
- 32 Williams, C. T., & Metzger, D. S. (2010). Race and distance effects on regular syringe exchange program use and injection risks: A geobehavioral analysis. *American Journal of Public Health*, 100(6), 1068-1074. <https://doi.org/10.2105/AJPH.2008.158337>
- 33 Behrends, C. N., Li, C., & Gibson, D. R. (2017). Decreased odds of injection risk behavior associated with direct versus indirect use of syringe exchange: Evidence from two California cities. *Substance Use & Misuse*, 52(9), 1151-1159. <https://doi.org/10.1080/10826084.2017.1299182>

- 34 Rudolph, A. E., Crawford, N. D., Ompad, D. C., Benjamin, E. O., Stern, R. J., & Fuller, C. M. (2010). Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies. *Journal of the American Pharmacists Association*, 50(2), 140-147. <https://doi.org/10.1331/japha.2010.09193>
- 35 Huo, D., Bailey, S. L., & Ouellet, L. J. (2006). Cessation of injection drug use and change in injection frequency: The Chicago needle exchange evaluation study. *Addiction*, 101(11), 1606-1613. <https://doi.org/10.1111/j.1360-0443.2006.01577.x>
- 36 North American Syringe Exchange Network. (n.d.). *SEP locations*. Retrieved July 17, 2020, from <https://nasen.org/map/>
- 37 Benyo, A. (2006). *Promoting secondary exchange: Opportunities to advance public health*. The Harm Reduction Coalition. <http://harmreduction.org/hrc/wp-content/uploads/2012/01/promotingsecondaryexchange.pdf>
- 38 Cooper, H., Des Jarlais, D., Ross, Z., Tempalski, B., Bossak, B. H., & Friedman, S. R. (2012). Spatial access to sterile syringes and the odds of injecting with an unsterile syringe among injectors: A longitudinal multilevel study. *Journal of Urban Health: Bulletin of the New York Academy of Medicine*, 89(4), 678-696. <https://doi.org/10.1007/s11524-012-9673-y>
- 39 Welch-Lazoritz, M., Habecker, P., Dombrowski, K., Villegas, A. R., Davila, C. A., Colón, Y. R., & De León, S. M. (2017). Differential access to syringe exchange and other prevention activities among people who inject drugs in rural and urban areas of Puerto Rico. *International Journal of Drug Policy*, 43, 16-22. <https://doi.org/10.1016/j.drugpo.2016.12.011>
- 40 AIDS Projects Management Group. (2007). *Guide to starting and managing needle and syringe programmes*. World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/43816/9789241596275_eng.pdf?sequence=1
- 41 New York State Department of Health AIDS Institute. (2009, January). *Policies and procedures: Syringe exchange programs*. Harm Reduction Coalition. <https://harmreduction.org/hrc/wp-content/uploads/2012/01/NYSDOHAI-pp.pdf>
- 42 Ghitza, U. E., Epstein, D. H., & Preston, K. L. (2008). Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. *Addictive Behaviors*, 33(4), 593-604. <https://doi.org/10.1016/j.addbeh.2007.11.009>
- 43 Shoptaw, S., Reback, C. J., Peck, J. A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R. C., Freese, T. E., & Hucks-Ortiz, C. (2005). Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. *Drug and Alcohol Dependence*, 78(2), 125-134. <https://doi.org/10.1016/j.drugalcdep.2004.10.004>
- 44 Petry, N. M., Weinstock, J., Alessi, S. M., Lewis, M. W., & Dieckhaus, K. (2010). Group-based randomized trial of contingencies for health and abstinence in HIV patients. *Journal of Consulting and Clinical Psychology*, 78(1), 89-97. <https://doi.org/10.1037/a0016778>
- 45 Special advisory bulletin: Offering gifts and other inducements to beneficiaries. (2002). Office of the Inspector General. <https://oig.hhs.gov/fraud/docs/alertsandbulletins/SABGiftsandInducements.pdf>
- 46 Health Care Programs: Fraud and abuse; Revised OIG civil money penalties resulting from public law 104-191. (2000). Office of the Inspector General. <https://oig.hhs.gov/authorities/docs/cmpfinal.pdf>
- 47 Office of Inspector General policy statement regarding gifts of nominal value to medicare and medicaid beneficiaries. (2016). Office of the Inspector General. <https://oig.hhs.gov/fraud/docs/alertsandbulletins/OIG-Policy-Statement-Gifts-of-Nominal-Value.pdf>
- 48 Petry, N. M., Weinstock, J., & Alessi, S. M. (2011). A randomized trial of contingency management delivered in the context of group counseling. *Journal of Consulting and Clinical Psychology*, 79(5), 686-696. <https://doi.org/10.1037/a0024813>
- 49 Hanson, T., Alessi, S. M., & Petry, N. M. (2008). Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients. *Addiction*, 103(7), 1187-1197. <https://doi.org/10.1111/j.1360-0443.2008.02216.x>
- 50 Haug, N. A., & Sorensen, J. L. (2006). Contingency management interventions for HIV-related behaviors. *Current HIV/AIDS Reports*, 3(4), 154-159. <https://doi.org/10.1007/s11904-006-0010-5>
- 51 Schroeder, J. R., Epstein, D. H., Umbricht, A., & Preston, K. L. (2006). Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. *Addictive Behaviors*, 31(5), 868-879. <https://doi.org/10.1016/j.addbeh.2005.07.009>

- 52 Rosen, M. I., Dieckhaus, K., McMahon, T. J., Valdes, B., Petry, N. M., Cramer, J., & Rounsaville, B. (2007). Improved adherence with contingency management. *AIDS Patient Care & STDs*, *21*(1), 30-40. <https://doi.org/10.1089/apc.2006.0028>
- 53 Metsch, L. R., Feaster, D. J., Gooden, L., Matheson, T., Stitzer, M., Das, M., Jain, M. K., Rodriguez, A. E., Armstrong, W. S., Lucas, G. M., Nijhawan, A. E., Drainoni, M., Herrera, P., Vergara-Rodriguez, P., Jacobson, J. M., Mugavero, M. J., Sullivan, M., Daar, E. S., McMahon, D. K.,... Del Rio, C. (2016). Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: A randomized clinical trial. *Journal of the American Medical Association (JAMA)*, *316*(2), 156-170. <https://doi.org/10.1001/jama.2016.8914>
- 54 Seeman, M. V. (2015). The role of mental health services in addressing HIV infection among women with serious mental illness. *Psychiatric Services*, *66*(9), 966-974. <https://ps.psychiatryonline.org/doi/10.1176/appi.ps.201400411>
- 55 Beck, J. S. (2011). *Cognitive behavior therapy: Basics and beyond* (2nd ed.). Guilford Press.
- 56 Fenn, K., & Byrne, M. (2013). The key principles of cognitive behavioural therapy. *InnovAiT*, *6*(9), 579-585. <https://doi.org/10.1177/1755738012471029>
- 57 Malow, R. M., McMahon, R. C., Dévieux, J., Rosenberg, R., Frankel, A., Bryant, V., Lerner, B., & Miguez, M. J. (2012). Cognitive behavioral HIV risk reduction in those receiving psychiatric treatment: A clinical trial. *AIDS and Behavior*, *16*(5), 1192-1202. <https://doi.org/10.1007/s10461-011-0104-y>
- 58 O'Cleirigh, C., Safren, S. A., Taylor, S. W., Goshe, B. M., Bedoya, C. A., Marquez, S. M., Boroughs, M. S., & Shipherd, J. C. (2019). Cognitive behavioral therapy for trauma and self-care (CBT-tsc) in men who have sex with men with a history of childhood sexual abuse: A randomized controlled trial. *AIDS and Behavior*, *23*(9), 2421-2431. <https://doi.org/10.1007/s10461-019-02482-z>
- 59 Taylor, S. W., Goshe, B. M., Marquez, S. M., Safren, S. A., & O'Cleirigh, C. (2018). Evaluating a novel intervention to reduce trauma symptoms and sexual risk taking: Qualitative exit interviews with sexual minority men with childhood sexual abuse. *Psychology, Health & Medicine*, *23*(4), 454-464. <https://doi.org/10.1080/13548506.2017.1348609>
- 60 Mimiaga, M. J., Pantalone, D. W., Biello, K. B., Hughto, J. M. W., Frank, J., O'Cleirigh, C., Reisner, S. L., Restar, A., Mayer, K. H., & Safren, S. A. (2019). An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men. *AIDS Care*, *31*(9), 1083-1095. <https://doi.org/10.1080/09540121.2019.1595518>
- 61 Hart, T. A., Tulloch, T. G., & O'Cleirigh, C. (2014). Integrated cognitive behavioral therapy for social anxiety and HIV prevention for gay and bisexual men. *Cognitive and Behavioral Practice*, *21*(2), 149-160. <https://doi.org/10.1016/j.cbpra.2013.07.001>
- 62 Hart, T. A., Noor, S. W., Vernon, J. R., Antony, M. M., Gardner, S., & O'Cleirigh, C. (2020). Integrated cognitive-behavioral therapy for social anxiety and HIV/STI prevention for gay and bisexual men: A pilot intervention trial. *Behavior Therapy*, *51*(3), 503-517. <https://doi.org/10.1016/j.beth.2019.09.001>
- 63 Safren, S. A., O'Cleirigh, C. M., Bullis, J. R., Otto, M. W., Stein, M. D., & Pollack, M. H. (2012). Cognitive behavioral therapy for adherence and depression (CBT-ad) in HIV-infected injection drug users: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*, *80*(3), 404-415. <https://doi.org/10.1037/a0028208>
- 64 Newcomb, M. E., Bedoya, C. A., Blashill, A. J., Lerner, J. A., O'Cleirigh, C., Pinkston, M. M., & Safren, S. A. (2015). Description and demonstration of cognitive behavioral therapy to enhance antiretroviral therapy adherence and treat depression in HIV-infected adults. *Cognitive and Behavioral Practice*, *22*(4), 430-438. <https://doi.org/10.1016/j.cbpra.2014.02.001>
- 65 Tobin, K., Davey-Rothwell, M. A., Nonyane, B. A. S., Knowlton, A., Wissow, L., & Latkin, C. A. (2017). RCT of an integrated CBT-HIV intervention on depressive symptoms and HIV risk. *PloS One*, *12*(12), e0187180-e0187180. <https://doi.org/10.1371/journal.pone.0187180>
- 66 Mimiaga, M. J., Reisner, S. L., Pantalone, D. W., O'Cleirigh, C., Mayer, K. H., & Safren, S. A. (2012). A pilot trial of integrated behavioral activation and sexual risk reduction counseling for HIV-uninfected men who have sex with men abusing crystal methamphetamine. *AIDS Patient Care and STDs*, *26*(11), 681-693. <https://doi.org/https://dx.doi.org/10.1089%2Fapc.2012.0216>

- 67 Safren, S. A., O’Cleirigh, C., Tan, J. Y., Raminani, S. R., Reilly, L. C., Otto, M. W., & Mayer, K. H. (2009). A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-ad) in HIV-infected individuals. *Health Psychology, 28*(1), 1-10. <https://doi.org/10.1037/a0012715>
- 68 Safren, S. A., Bedoya, C. A., O’Cleirigh, C., Biello, K. B., Pinkston, M. M., Stein, M. D., Traeger, L., Kojic, E., Robbins, G. K., Lerner, J. A., Herman, D. S., Mimiaga, M. J., & Mayer, K. H. (2016). Cognitive behavioural therapy for adherence and depression in patients with HIV: A three-arm randomised controlled trial. *The Lancet HIV, 3*(11), e529-e538. [https://doi.org/10.1016/S2352-3018\(16\)30053-4](https://doi.org/10.1016/S2352-3018(16)30053-4)
- 69 Simoni, J. M., Wiebe, J. S., Saucedo, J. A., Huh, D., Sanchez, G., Longoria, V., Andres Bedoya, C., & Safren, S. A. (2013). A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: The Nuevo Día study. *AIDS and Behavior, 17*(8), 2816-2829. <https://doi.org/10.1007/s10461-013-0538-5>
- 70 Johnson, M. O., Charlebois, E., Morin, S. F., Remien, R. H., Chesney, M. A., & National Institute of Mental Health Healthy Living Project Team. (2007). Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: The healthy living project randomized controlled study. *Journal of Acquired Immune Deficiency Syndromes (JAIDS), 46*(5), 574-580. <https://doi.org/10.1097/qai.0b013e318158a474>
- 71 Mayer, K. H., Safren, S. A., Elsesser, S. A., Psaros, C., Tinsley, J. P., Marzinke, M., Clarke, W., Hendrix, C., Taylor, S. W., Haberer, J., & Mimiaga, M. J. (2017). Optimizing pre-exposure antiretroviral prophylaxis adherence in men who have sex with men: Results of a pilot randomized controlled trial of “Life-Steps for PrEP”. *AIDS and Behavior, 21*(5), 1350-1360. <https://doi.org/10.1007/s10461-016-1606-4>
- 72 Linn, J., Neff, J. A., Theriot, R., Harris, J., Interrante, J., & Graham, M. (2003). Reaching impaired populations with HIV prevention programs: A clinical trial for homeless mentally ill African-American men. *Cellular and Molecular Biology (Noisy-le-Grand, France), 49*(7), 1167-1175. <https://pubmed.ncbi.nlm.nih.gov/14682400/>
- 73 Beck Institute. (2019). *Beck CBT certification*. <https://beckinstitute.org/certification/>
- 74 Foa, E. B., Keane, T. M., Friedman, M. J., & Cohen, J. A. (2009). Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies (2nd ed.). Guilford Press.
- 75 Boston University Center for Innovation in Social Work & Health (2016). *Enhanced patient navigation for HIV-positive women of color. TargetHIV*. <https://targethiv.org/deii/deii-enhanced-patient-navigation>
- 76 Harold P. Freeman Patient Navigation Institute. (2020). *Our model: The gold standard*. <http://www.hpfreemanpni.org/our-model/>
- 77 Farrisi, D., & Dietz, N. (2013). Patient navigation is a client-centered approach that helps to engage people in HIV care. *HIV Clinician, 25*(1), 1-3. <https://pubmed.ncbi.nlm.nih.gov/23476957>
- 78 Cunningham, W. E., Weiss, R. E., Nakazono, T., Malek, M. A., Shoptaw, S. J., Ettner, S. L., & Harawa, N. T. (2018). Effectiveness of a peer navigation intervention to sustain viral suppression among HIV-positive men and transgender women released from jail: The link la randomized clinical trial. *JAMA Internal Medicine, 178*(4), 542-553. <https://doi.org/10.1001/jamainternmed.2018.0150>
- 79 Center for Health Policy and Inequalities Research. (n.d.). Including peers as part of a substance use treatment program for individuals living with HIV: The peer assisted treatment of HIV and substance (PATHS) model. http://chpir.org/wp-content/uploads/paths_model.pdf
- 80 Broeckaert, L., & Challacombe, L. (2014, August 11). *Health navigation: A review of the evidence*. Remedy Health Media. <https://www.thebodypro.com/article/health-navigation-a-review-of-the-evidence>
- 81 Cabral, H. J., Davis-Plourde, K., Sarango, M., Fox, J., Palmisano, J., & Rajabiun, S. (2018). Peer support and the HIV continuum of care: Results from a multi-site randomized clinical trial in three urban clinics in the United States. *AIDS and Behavior, 22*(8), 2627-2639. <https://doi.org/10.1007/s10461-017-1999-8>
- 82 AIDS United. (2015). *Best practices for integrating peer navigators into HIV models of care*. https://www.aidsunited.org/data/files/Site_18/PeerNav_v8.pdf

Guidance for Selecting and Implementing Evidence-based Practices

This chapter discusses key implementation considerations to address the challenges of implementing programs for human immunodeficiency virus (HIV) prevention and treatment among people with mental illness and/or substance use disorders (SUD). It covers steps from practice selection and program funding through engaging and retaining people in care.

Prior to implementing practices identified in Chapter 2, each program or clinic should conduct a needs assessment to understand the following factors:

- Client population (e.g., the population of focus, their unique HIV-related risk factors,¹ cultures, challenges, and assets)
- Existing protocols and procedures that could facilitate or become barriers to implementation (e.g., intake procedures)
- Local factors that could impact service delivery (e.g., partnerships with community-based organizations and service providers, geography, transportation, and socio-political climate)²
- Program or organizational strengths, resources, and areas for development (e.g., organizational leaders and program champions, budget, available health insurance reimbursement to support planned activities, staffing and infrastructure, and information management support)³
- Training opportunities (program-specific and ongoing professional development)



Based on the needs assessment, practitioners can work with their clinical teams, administrators, leaders, and community members and partners to take the following steps to identify practices that are appropriate and feasible given available resources and local characteristics:

- Identify prevention and treatment priorities
- Identify desired short- and long-term outcomes
- Map resources (e.g., housing, employment, transportation, legal services) available within the local area to effectively connect clients with needed services
- Develop a [logic model](#) (a graphic depiction of the relationship between a program’s activities and their intended outcomes)⁴

Implementation Challenges and Strategies

This chapter includes strategies to promote implementation and appropriate adaptation of practices to the population of focus, as well as specific implementation tools for the programs and practices described in Chapters 2 and 4. Key considerations described in this chapter include:

- Adapting and tailoring the practice to meet the needs of the client population
- Care coordination
- Workforce capacity and development
- Access to services
- Financing



Challenge

Practices implemented without adaptation may not be relevant to or acceptable for the client population.⁵ Practices should be culturally relevant, available in the appropriate language, and produced at the appropriate reading level.⁶⁻⁷

Core components are defined by SAMHSA in the Strategic Prevention Framework as “those parts of a program or practice that are responsible for producing positive outcomes, and thus most essential and indispensable.”⁸

Strategies

Program administrators and clinic leadership can:

- Identify and consistently implement key characteristics (or core components) of each practice to generate anticipated outcomes.^{1,9} Outside of the core components, organizations can use their needs assessment to identify local-level adaptations that will improve service delivery to their client population.¹⁰
- When adapting a program, organizations should strive to preserve the setting (e.g., outpatient clinic, mobile health unit), maintain the prescribed dosage, and, if necessary, add rather than remove content.¹¹
- Use a systematic process, such as the ADAPT-ITT model, to balance local program adaptation needs and adherence to the instructions provided in the original model.⁵
- Engage existing and potential clients in project planning, practice selection, and materials development. Members of the client community will have insight into ways to make programs culturally appropriate, reflecting a community’s preferred language, attitudes, beliefs, values, and experiences.
- Assess and address staff and client health literacy,¹²⁻¹³ and ensure materials meet federal plain language and National Standards for Culturally and Linguistically Appropriate Services guidelines.¹⁴⁻¹⁵
- Adapt and tailor client care plans and individualize case management approaches to meet the unique needs of the client. Effective case management is a client-driven process where the case manager and client collaborate on a care plan, including specific goals for prevention or treatment, and then continue to communicate to ensure the client is able to reach their goals.

THE EIGHT STEPS OF THE ADAPT-ITT MODEL

- A** **Assessment:** conduct an assessment to understand the population of interest and organization-level capacity to implement the intervention
- D** **Decision:** select the intervention
- A** **Adaptation:** pre-test the intervention with the population of interest
- P** **Production:** produce a revised draft of the intervention guide maintaining fidelity to the core elements, behavioral theory, and internal logic of the initial intervention
- T** **Topical Experts:** engage subject matter experts in a review of the intervention guide produced in Production step
- I** **Integration:** integrate feedback from the Topical Experts and Production steps, and produce a second draft
- T** **Train:** train facilitators, recruiters and retention staff, interviewers, and data management staff to ensure consistent implementation and data collection efforts
- T** **Test:** pilot test the intervention and integrate findings into a third draft. Conduct a second pilot test to determine if the intervention will be effective in the organization's service delivery area and with the population of interest



COORDINATING CARE

Challenge

People at risk for or with HIV who also have co-occurring mental illness and/or SUD experience complex medical comorbidities. Fragmented behavioral health and HIV primary care services make it difficult for practitioners to communicate with each other and their clients, potentially leading to poor HIV and mental illness and/or SUD outcomes.¹⁶

Moreover, fragmented care systems place a burden on the clients as they become the ones responsible for communicating sometimes complex health information among practitioners. Ancillary needs (e.g., housing, childcare, transportation, food insecurity, employment), which are critical to clients seeking or engaging in care, may also be difficult to address in a fragmented system.¹⁷⁻²⁰

Strategies

Effectively addressing these interrelated conditions takes a coordinated approach²¹ between mental illness and/or SUD and HIV care providers, and other agencies and stakeholders that are well-positioned to address the social determinants of health. Coordinated models may feature screening for mental illness and/or SUD using validated tools; team-based care, including both physician and non-physician staff; shared IT and electronic medical record systems to facilitate communication within care teams; and systematic measurement and review of patient outcomes.

When HIV clinics screen for mental illness and SUD and are able to provide coordinated care to address mental illness, SUD, and HIV, clients are more likely to reach viral suppression than their counterparts visiting HIV primary care services without coordinated mental health and substance use services.³² Coordinated services help practitioners streamline service delivery to address unmet needs.

Collaborative Care involves increased collaboration between behavioral healthcare management, mental health, and primary care providers. This model includes taking a team-based, client-centered, collaborative approach to elements of client care, such as client registries, client education, screening or assessment tools, adherence monitoring, and evidence-based treatment guidelines.²²⁻²³

Integrated Care involves merging primary health care, mental illness and/or SUD screening and treatment, additional medical services (e.g., hepatology, dermatology), and social services (e.g., housing, employment) into one treatment plan. These linkages improve client outcomes by combining efforts such as referrals, case planning, and resources.²³⁻²⁶

The two terms are not interchangeable, and exist on a continuum.²⁷ For example, a system can collaborate while having separate EHR, billing, and scheduling systems. A system can also have integrated care with co-located services where practitioners collaborate and case-conference to discuss client care.

Examples of coordinated care models include patient centered medical homes,²⁸ primary care case management arrangements,²⁹ co-located or limited capacity primary care in behavioral health organizations,²⁹ SAMHSA's Primary Care and Behavioral Health Integration model,³⁰ and Certified Community Behavioral Health Clinic models.³¹

Practitioners can use the following strategies to determine the level of integration feasible and appropriate within their organization:

- Identify leaders within clinical networks and health systems who can champion integration and advocate for coordination, co-location, and integration over time.²¹ Integration takes administrative, political, and financial investments, as well as cultural change and different ways of communicating among care teams and clinics.
- Modify funding structures, billing codes, and procedures to account for new coordinated models and consultation between practitioners.²¹
- Permit data sharing across AIDS-Service Organizations, social and health service practitioners, behavioral health specialists, and the department of corrections to increase service coordination.³³ When sharing data across organizations, review updated laws, policies, and regulations on confidentiality to maintain compliance and protect client information³⁴ and obtain consent from clients for data sharing during client assessment and intake.



Challenge

Behavioral health treatment practitioners and their clinical teams (e.g., case managers, clinical coordinators) are well positioned to address unmet needs (e.g., transportation, housing, employment, childcare), but may need additional training to address co-occurring infectious diseases.³⁵

Practitioners who deliver services aimed at preventing and treating HIV among people experiencing co-occurring mental illness and/or SUD may need training and capacity building in the following areas:

- Practice-specific training to facilitate consistent implementation
- Working with clients who have co-occurring HIV and mental illness and/or SUD
- Creating a culturally appropriate, non-judgmental, and non-stigmatizing clinical environment supportive of both clients and staff³⁶⁻³⁹

Strategies

Provide intervention-specific training to implement the practices.

- Receiving customized, site-specific training can be resource intensive, and the provision of program-specific training and technical assistance may be dependent on grant awards. In recent years, federal funders have emphasized the need for replicable practice models that are easy to adapt, scale up, and implement in the absence of technical assistance, leading to an increase in robust training resources available online. These models include:
 - [CDC’s Effective Behavioral Intervention \(EBIs\) models](#)
 - [HRSA’s Dissemination of Evidence Informed Interventions \(DEII\) model](#)
 - [HRSA’s Evidence-Informed Interventions \(E2i\) models](#)
- Program managers and practitioners should select implementation trainings that are not overly cumbersome or time consuming.⁴⁰

Provide cross-disciplinary training and institutional support to practitioners to facilitate better understanding of different disciplines and ways to promote coordinated client care.

- Promote cross-training provided by the AIDS Education and Training Centers ([AETCs](#)) on HIV-related programs, policies, and practices to both Ryan White HIV/AIDS Program (RWHAP) and behavioral health practitioners. Similarly, promote training offered by [SAMHSA’s Prevention, Mental Health and Addiction Technology Transfer Centers](#) for practitioners and volunteers providing care for persons with and at risk of HIV.
- Create mechanisms for staff to work and train across HIV and behavioral health service programs.⁴¹
- Identify in-house trainings (e.g., grand-rounds, in-service trainings), local trainings, online webinars, opportunities to attend conferences, and continuing education unit training opportunities to support cross-disciplinary learning.⁹
- Prevent vicarious trauma (i.e., work-related trauma due to continuous exposure to victims of trauma and violence),⁴² burnout, and turnover by

supporting manageable caseloads for staff and providing consistent clinical supervision. For example, peers and patient navigators may not have the formal clinical training their licensed mental health, substance use, and social work colleagues do, and may benefit from ongoing, structured clinical supervision.⁴³

Provide ongoing trainings on ways to create welcoming, supportive environments for people with or at risk for HIV.

- Conduct and support staff training to enhance [cultural competence](#) and create a safe, supportive environment that improves client-staff relationships and reduces the risk of a client discontinuing treatment.³³
- Include sessions on non-stigmatizing language⁴⁴ and trauma-informed practices⁴⁵⁻⁴⁶ to improve client interactions with all staff (from the front desk, to their nurse, to the billing department).



Challenge

Linkage to and retention in care requires connection between the client and the provider. However, transportation and geographic barriers can make in-person, face-to-face connections challenging.

- Transportation-related challenges⁴⁵ can include having to travel long distances to clinics,³⁹ inability to afford gas or fares for public transportation, and unreliable or lack of access to a personal vehicle or public transportation for travel to appointments.³⁸
- People with HIV in rural areas are less likely to receive HIV care or be engaged in ART as a result of limited availability of HIV-specific practitioners, provider discrimination, confidentiality concerns, and lack of financial resources.⁴⁷ Geographic barriers can be compounded by HIV-related stigma where individuals may be reluctant to seek HIV prevention or treatment services in a small town or community for fear they may be “outed.”⁴⁸

Strategies

Program administrators and practitioners can overcome these challenges by employing the following strategies:

- *Telehealth* - Telehealth can connect clients with specialty practitioners and provide access to services without having to travel.⁴⁹ Telephone-based Cognitive Behavioral Therapy (CBT), as an example, has been shown to reduce depressive symptoms and improve ART adherence among people with HIV.⁵⁰
- *Transportation assistance* - Vouchers for gas or public transportation can help eliminate worry about missing appointments due to transportation cost-related barriers.⁵¹ In one model, peer navigators provided transportation to appointments for the first month to give clients sufficient time to establish a long-term transportation plan.⁵² Ride share companies may also provide travel assistance. For example, Uber Health has partnered with an IT vendor, Cerner, in six states to get clients to and from their medical appointments. Lyft is also designated as a covered option for providing rides for eligible Medicaid beneficiaries.⁵³
- *Combined healthcare visits* - Combining HIV care and other healthcare needs (e.g., routine check-up, behavioral health services) in one visit can limit the number of times a client needs to visit their healthcare provider, especially in settings where significant travel may be needed to attend appointments.⁵⁴ Practitioners should clarify if adequate reimbursement for these visits is available by confirming whether third party payers have the capacity to reimburse for same-day services.
- *Mobile health programs* - Mobile health programs have been used successfully to increase HIV screening among high-incidence populations in underserved areas.⁵⁵ Many syringe services programs (SSPs) utilize mobile sites due to their flexibility to respond to changing client needs and ability to provide a more informal, easily accessible location for clients who are unable to travel to a fixed site.⁵⁶
- *Outreach* - Outreach activities, commonly used to link and retain people with HIV in care, can reduce barriers to accessing care. Patient navigation models specifically emphasize outreach, with navigation sessions often taking

place in community settings where clients may feel more comfortable than in a clinic environment.⁵⁷ SSPs also expand their reach through secondary or peer-delivery models. SSPs provide people who inject drugs (PWID) with sterile injection drug use equipment to distribute to their networks and to inform them of disposal options.⁵⁶



Challenge

Funding (including financing trainings, reimbursing staff, furnishing programs with needed materials) is essential to implementing and sustaining public health practices. Specific financing challenges for the recommended programs include:

- Insurance reimbursements for services
- Sustainable federal and state funding for service delivery not covered by insurance
- Restrictions on the use of federal funding for SSPs
- Lack of funding for reinforcers and vouchers necessary for Contingency Management (CM)
- Lack of funding for highly experienced clinicians to implement and facilitate programming

Strategies

Clinic administrators and leadership need to consider strategies for how to:

- Fund a practice
- Diversify funding streams across federal, state, local, and private initiatives⁵⁸
- Counteract cost-prohibitive challenges to program implementation

When doing so, they should pay particular attention to:

- The specific resources available and needed to implement HIV and mental illness and/or SUD services, including number of staff, additional costs related to program materials, and anticipated duration of funding.⁵⁸
- Potential collaborators that may have access to alternative funding sources. Community-based organizations, correctional facilities, community health centers, or mental illness and/or SUD

treatment settings can act as partners when applying for grants that may only be accessible to specific types of organizations. Partnerships can also be a way to offset the cost of program-related materials.

- CM costs pose a unique challenge, as many state Medicaid, Medicare, and private insurance entities may not reimburse the reinforcers that are used in this practice, and programs are prohibited from reimbursing for more than \$75 annually or \$15 per individual appointment, regardless of the source of the funds. Additional funding sources, such as federal, state, and private grants, as well as contributions from or opportunities to share costs with partners, can help overcome barriers to funding CM reinforcers. SAMHSA suggests soliciting donations (which might prove particularly effective at providing CM reinforcers) and making use of volunteers or internships to cut costs.⁶⁰

RYAN WHITE HIV/AIDS PROGRAM (RWHAP)

- RWHAP, a federal initiative started in 1990, can act as the “payer of last resort” for people with HIV, and be used to complete care for uninsured and underinsured individuals (for out of pocket costs, including medication copays or co-insurance for office visits). RWHAP complements and supplements other health programs such as Medicaid and commercial health insurance.
- RWHAP plays a critical role in improving health outcomes for people with HIV across the care continuum.
- This funding is only available for people with HIV, leaving a gap in coverage for preventive services.
- Each year over half a million people receive at least one service under the program.
- RWHAP is the third largest source of federal funding for HIV care in the United States, following Medicare and Medicaid, and was funded at \$2.3 billion in FY 2019.⁵⁹

- How the practice aligns with federal-level priorities and funding opportunities.
- The “Ending the HIV Epidemic: A Plan for America” initiative allocated \$716 million in fiscal year (FY) 2021 to preventing, diagnosing, treating, and responding to HIV.⁶¹
- Potential insurance reimbursement strategies.
 - PrEP is included in Grade A preventive interventions by the U.S. Preventive Services Task Force. Therefore, most insurance plans are required to cover prescriptions for PrEP at no cost to the client. However, the task force recommendation does not extend to lab tests or other clinical services.⁶²
 - The Centers for Medicare & Medicaid Services offer grant funding to reimburse patient navigators.⁶³
- Opportunities to expand the types of trained facilitators leading behavioral health interventions, such as CBT and CM. Tapping graduate students and psychology or social work interns to facilitate these programs under clinical supervision can offset program costs as these practitioners are generally not paid.⁶⁴⁻⁶⁵

Special Funding Considerations for SSPs

The Consolidated Appropriations Act of 2016 allows the U.S. Department of Health and Human Services to fund SSP education and program evaluation.⁶⁶ Importantly, this legislation, as well as subsequent congressional appropriations acts, states that federal funds cannot be used to purchase needles or syringes.⁶⁷⁻⁶⁸

Practice Resources

Practices to Increase Uptake of and Improve Adherence to PrEP

- The AETC’s [“Prescribing PrEP for HIV Prevention: A Guide for Medical Providers”](#) is a “pocket-guide” for practitioners considering prescribing PrEP. It includes an ideal timeline for screenings and visits, billing codes, and information about potential side effects.⁶⁹
- The [Harford County Health Department PrEP Resource Binder](#)⁷⁰ and [Michigan Department of Health & Human Services PrEP Provider Toolkit](#)⁷¹ are resources for providers (e.g., CDC consultation, prescribing guidelines, and summaries of PrEP efficacy trials) and clients considering PrEP (e.g., FAQs).
- The Fenway Institute’s [Implementing PrEP for HIV Prevention: State-wide Initiative and Provider Experiences presentation](#) focuses on state-wide implementations of PrEP, provider feedback and experiences, and health communication materials to promote PrEP uptake.⁷²

Syringe Services Programs (SSPs)

- The Harm Reduction Coalition [Capacity Building Services](#) provides free mentoring, training, and technical assistance, including the HIV Harm Reduction Navigator Core Competency Training and Skills-Building Training, to health departments, community-based organizations, and other community stakeholders seeking to establish, expand, or improve the effectiveness of their SSPs.⁷³
- The CDC’s [Capacity Building Assistance Provider Network](#) provides free training and technical assistance, continuous quality improvement, and marketing and administrative support for health departments, community-based organizations, and community partners looking to implement or improve HIV prevention programs and services.⁷⁴
- The Harm Reduction Coalition’s [Guide to Developing and Managing Syringe Access Programs](#) provides an overview of harm reduction principles and guidance on how to develop, implement, and manage a SSP.⁷⁵
- The National Alliance of State and Territorial AIDS Directors (NASTAD) and Urban Coalition for HIV/AIDS Prevention Services (UCHAPS)



[Syringe Services Programs \(SSP\) Development and Implementation Guidelines for State and Local Health Departments](#) provides guidance on several aspects of SSP implementation, including how to conduct a community needs assessment, select a service delivery model, monitor outcomes, and build capacity of program staff.⁵⁶

- Comer Family Foundation’s [Guide to Establishing Syringe Services Programs in Rural, At-Risk Areas](#) provides an overview of the importance of SSPs in fighting the opioid epidemic. This resource offers guidance on considerations for SSP implementation and case studies of rural SSPs.⁷⁶
- Oregon Health Authority [Harm Reduction and SSP Planning Manual and Resource Library](#) offers a manual and several resources on SSP planning and implementation.⁷⁷

Contingency Management

- [Contingency Management: Using Motivational Incentives to Improve Drug Abuse Treatment](#) provides an overview of CM principles, a case study of a program using CM, and guidance regarding how to implement and supervise CM procedures.⁷⁸
- The UCLA Integrated Substance Abuse Program’s [A Treatment Manual for Implementing Contingency Management: Using Incentives to Improve Parolee Enrollment and Attendance in Community Treatment](#) is a guide for implementing CM for SUD treatment among parolees.⁷⁹
- The Behavioral Health Recovery Management project [A Clinician’s Guide for Implementing Contingency Management Programs](#) provides step-by-step guidance on CM implementation.⁸⁰

Cognitive Behavioral Therapy

- National Association of Cognitive Behavioral Therapists [CBT Onsite Training](#) provides multiple resources for both administrators and clients, training, and certification for CBT administrators (i.e., professionals, educators, graduate students).⁸¹
- Beck Academy [CBT training and certification](#) offers training and certification for CBT administrators (i.e., professionals, educators, graduate students), online and in-person training

courses, newsletters, assistance with program implementation, and information on utilizing supervisors and consultants.⁸²

- The Evidence-Based Practice Institute’s [Intersecting Epidemics: Evidenced Based Approaches for Treating Depression and HIV/AIDS](#) is an on-demand course (paid access), including a video recording, slides, and handouts.⁸³
- Massachusetts General Hospital offers an [online CBT program](#) led by clinical experts (through paid access) for practitioners, including live chats with faculty and interactive discussion boards.⁸⁴

Patient Navigation

- Texas Institute for Excellence in Mental Health [Peer Specialist Training and Certification Programs: A National Overview](#) is a compilation of information on existing peer specialist training and certification programs in the United States.⁸⁵
- [Best Practices for Integrating Peer Navigators into HIV Models of Care](#) is an AIDS United publication that provides findings and lessons learned from diverse peer navigation models and grantee types.⁸⁶
- As part of the National Minority AIDS Council’s Organizational Effectiveness Series: Building Healthy Organizations, [HIV Navigation Services: A Guide to Peer and Patient Navigation Programs](#) provides information and tools to use in planning and implementing patient navigation programs.⁸⁷
- [The Peer Assisted Treatment of HIV and Substance \(PATHS\) Model guide](#) describes the development, implementation, and evaluation of a navigation program that incorporates peers into a substance use treatment program for people with HIV.⁸⁸
- Rural Health Information Hub’s [Rural HIV/AIDS Prevention and Treatment Toolkit](#) contains resources and information focused on developing, implementing, evaluating, and sustaining rural HIV/AIDS programs, including a patient navigation model.⁸⁹

Reference List

- ¹ Veniegas, R. C., Kao, U. H., & Rosales, R. (2009). Adapting HIV prevention evidence-based interventions in practice settings: An interview study. *Implementation Science*, *4*(1), 76. <https://doi.org/10.1186/1748-5908-4-76>
- ² Kegeles, S. M., Rebchook, G., Tebbetts, S., Arnold, E., & TRIP Team. (2015). Facilitators and barriers to effective scale-up of an evidence-based multilevel HIV prevention intervention. *Implementation Science*, *10*(1), 50. <https://doi.org/10.1186/s13012-015-0216-2>
- ³ Ramsey, A., Lord, S., Torrey, J., Marsch, L., & Lardiere, M. (2016). Paving the way to successful implementation: Identifying key barriers to use of technology-based therapeutic tools for behavioral health care. *Journal of Behavioral Health Services Research*, *43*(1), 54-70. <https://doi.org/10.1007/s11414-014-9436-5>
- ⁴ Centers for Disease Control and Prevention. (2018, December 18). *Logic models*. <https://www.cdc.gov/eval/logicmodels/index.htm>
- ⁵ Wingood, G. M., & DiClemente, R. J. (2008). The ADAPT-ITT model: A novel method of adapting evidence-based HIV interventions. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*, *47*, S40-S46. <https://doi.org/10.1097/QAI.0b013e3181605df1>
- ⁶ Amodeo, M., Lundgren, L., Cohen, A., Rose, D., Chassler, D., Beltrame, C., & D'ippolito, M. (2011). Barriers to implementation of evidence-based practices in community-based addiction treatment: Comparing staff reports on motivational interviewing, adolescent community reinforcement approach, assertive community treatment, and cognitive-behavioral therapy. *Evaluation Program Planning*, *34*(4), 382-389. <https://doi.org/10.1016/j.evalprogplan.2011.02.005>
- ⁷ Cohen, A., Lundgren, L., Amodeo, M., Chassler, D., & Rose, D. (n.d.). Barriers to implementation of evidence-based practices in community-based addiction treatment: Comparing staff reports of barriers from a nationwide sample [PowerPoint Slides]. Centers for Addictions Research and Services, Boston University School of Social Work. <https://apha.confex.com/apha/138am/recordingredirect.cgi/id/39706>
- ⁸ Substance Abuse and Mental Health Services Administration. (2019). *A guide to SAMHSA's strategic prevention framework*. <https://www.samhsa.gov/sites/default/files/20190620-samhsa-strategic-prevention-framework-guide.pdf>
- ⁹ Collins Jr., C. B., & Sapiano, T. N. (2016). Lessons learned from dissemination of evidence-based interventions for HIV prevention. *American Journal of Preventive Medicine*, *51*(4), S140-S147. <https://doi.org/10.1016/j.amepre.2016.05.017>
- ¹⁰ Galbraith, J. S., Herbst, J. H., Whittier, D. K., Jones, P. L., Smith, B. D., Uhl, G., & Fisher, H. H. (2011). Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention. *Health Education Research*, *26*(5), 872-885. <https://doi.org/10.1093/her/cyr030>
- ¹¹ Substance Abuse and Mental Health Services Administration. (2018). *Selecting best-fit programs and practices: Guidance for substance misuse prevention practitioners*. https://www.samhsa.gov/sites/default/files/ebp_prevention_guidance_document_241.pdf
- ¹² Network of the National Library of Medicine. (n.d.). *Health literacy*. National Institutes of Health. <https://nnlm.gov/initiatives/topics/health-literacy>
- ¹³ Centers for Disease Control and Prevention. (2019, October 17). *Assess health literacy in your organization*. <https://www.cdc.gov/healthliteracy/researchevaluate/organization-assessment-tools.html>
- ¹⁴ Agency for Healthcare Research and Quality. (2015, January). *Guide to implementing the health literacy universal precautions toolkit*. <https://www.ahrq.gov/health-literacy/quality-resources/tools/literacy-toolkit/impguide/index.html>
- ¹⁵ Office of Minority Health Resource Center. (2018, October 2). *The National CLAS Standards*. U.S. Department of Health and Human Services. <https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53>

- ¹⁶ Substance Abuse and Mental Health Services Administration, Health Resources and Services Administration, & National Council for Behavioral Health. (2016, September 14). *Strategies for success in integrating HIV care into behavioral health care*. Center of Excellence for Integrated Health Solutions. https://www.thenationalcouncil.org/coe_resource/strategies-for-success-in-integrating-hiv-care-into-behavioral-health-care/strategies-for-success-in-integrating-hiv-care-into-behavioral-health-care-9-14-16/
- ¹⁷ Aidala, A. A., Wilson, M. G., Shubert, V., Gogolishvili, D., Gliberman, J., Rueda, S., Bozack, A. K., Caban, M., & Rourke, S. B. (2016). Housing status, medical care, and health outcomes among people living with HIV/AIDS: A systematic review. *American Journal of Public Health, 106*(1), e1-e23. <https://doi.org/10.2105/ajph.2015.302905>
- ¹⁸ Feller, D. J., & Agins, B. D. (2017). Understanding determinants of racial and ethnic disparities in viral load suppression: A data mining approach. *Journal of the International Association of Providers of AIDS Care (JIAPAC), 16*(1), 23-29. <https://doi.org/10.1177/2325957416667488>
- ¹⁹ Gupta, G. R., Parkhurst, J. O., Ogden, J. A., Aggleton, P., & Mahal, A. (2008). Structural approaches to HIV prevention. *The Lancet, 372*(9640), 764-775. [https://doi.org/10.1016/s0140-6736\(08\)60887-9](https://doi.org/10.1016/s0140-6736(08)60887-9)
- ²⁰ Kamarulzaman, A., & Altice, F. L. (2015). Challenges in managing HIV in people who use drugs. *Current Opinion in Infectious Disease, 28*(1), 10-16. <https://doi.org/10.1097/QCO.0000000000000125>
- ²¹ Heath Jr., B., Reynolds, K., & Romero, P. W. (2013). *A standard framework for levels of integrated healthcare*. Substance Abuse and Mental Health Services Administration – Health Services and Resources Administration Center for Integrated Health Solutions <https://www.pcpcc.org/resource/standard-framework-levels-integrated-healthcare>
- ²² Ivbijaro, G. O., Enum, Y., Khan, A. A., Lam, S. S., & Gabzdyl, A. (2014). Collaborative care: Models for treatment of patients with complex medical-psychiatric conditions. *Current Psychiatry Reports, 16*(11), 506. <https://doi.org/10.1007/s11920-014-0506-4>
- ²³ National Institute of Mental Health. (2017, February). *Integrated care*. U.S. Department of Health and Human Services. <https://www.nimh.nih.gov/health/topics/integrated-care/index.shtml>
- ²⁴ Chuah, F. L. H., Haldane, V. E., Cervero-Liceras, F., Ong, S. E., Sigfrid, L. A., Murphy, G., Watt, N., Balabanova, D., Hogarth, S., Maimaris, W., Otero, L., Buse, K., McKee, M., Piot, P., Perel, P., & Legido-Quigley, H. (2017). Interventions and approaches to integrating HIV and mental health services: A systematic review. *Health Policy and Planning, 32*(Suppl. 4), iv27-iv47. <https://doi.org/10.1093/heapol/czw169>
- ²⁵ Kinman, C. R., Gilchrist, E. C., Payne-Murphy, J. C., & Miller, B. F. (2015). *Provider- and practice-level competencies for integrated behavioral health in primary care: A literature review*. Agency for Healthcare Research and Quality (AHRQ). https://integrationacademy.ahrq.gov/sites/default/files/AHRQ_AcadLitReview.pdf
- ²⁶ Hoge M.A., Morris J.A., Laraia M., Pomerantz A., & Farley, T. (2014). *Core competencies for integrated behavioral health and primary care*. Substance Abuse and Mental Health Services Administration – Health Services and Resources Administration Center for Integrated Health Solutions <http://womenshealthcouncil.org/wp-content/uploads/2016/11/WF-Core-Competencies-for-Integrated-Behavioral-Health-and-Primary-Care.pdf>
- ²⁷ Substance Abuse and Mental Health Services Administration – Health Services and Resources Administration Center for Integrated Health Solutions. (2020, January). *Standard framework for levels of integrated care*. National Council for Behavioral Health. https://www.thenationalcouncil.org/wp-content/uploads/2020/01/CIHS_Framework_Final_charts.pdf?dof=375ateTbd56
- ²⁸ Keuroghlian, A. (2017). *Expanding access to behavioral health care for people living with HIV/AIDS*. National Center for Innovation in HIV Care. <https://targethiv.org/library/expanding-access-behavioral-health-care-people-living-hiv/AIDS>
- ²⁹ Shah, V. (2018). *Behavioral health integration within the HIV continuum of care*. National Alliance of State and Territorial AIDS Directors. https://www.nastad.org/sites/default/files/resources/docs/issue_brief_final.pdf
- ³⁰ Scharf, D. M., Eberhart, N. K., Hackbarth, N. S., Horvitz-Lennon, M., Beckman, R., Han, B., Lovejoy, S. L., Pincus, H. A., & Burnam, M. A. (2014). Evaluation of the SAMHSA Primary and Behavioral Health Care Integration (PBHCI) grant program: Final report. *Rand Health Quarterly, 4*(3), 6. Retrieved July 17, 2020, from <https://www.rand.org/pubs/periodicals/health-quarterly/issues/v4/n3/06.html>

- 31 Substance Abuse and Mental Health Services Administration. (2018, October 11). *Section 223 demonstration program for certified community behavioral health clinics*. <https://www.samhsa.gov/section-223>
- 32 Hoang, T., Goetz, M. B., Yano, E. M., Rossman, B., Anaya, H. D., Knapp, H., Korthuis, P. T., Henry, R., Bowman, C., & Gifford, A. (2009). The impact of integrated HIV care on patient health outcomes. *Medical care*, 47(5), 560-567. <https://doi.org/10.1097/MLR.0b013e31819432a0>
- 33 Grau, L. E., Griffiths-Kundishora, A., Heimer, R., Hutcheson, M., Nunn, A., Towey, C., & Stopka, T. J. (2017). Barriers and facilitators of the HIV care continuum in southern new england for people with drug or alcohol use and living with HIV/AIDS: Perspectives of HIV surveillance experts and service providers. *Addiction Science & Clinical Practice*, 12(1), 24. <https://doi.org/10.1186/s13722-017-0088-7>
- 34 Integrated Behavioral Health Partners. (n.d.). *Confidentiality*. Integrated Behavioral Health Partners. <http://www.ibhpartners.org/get-started/procedures/confidentiality/>
- 35 Seeman, M. V. (2015). The role of mental health services in addressing HIV infection among women with serious mental illness. *Psychiatric Services*, 66(9), 966-974. <https://doi.org/10.1176/appi.ps.201400411>
- 36 Geter, A., Herron, A. R., & Sutton, M. Y. (2018). HIV-related stigma by healthcare providers in the United States: A systematic review. *AIDS Patient Care and STDs*, 32(10), 418-424. <https://doi.org/10.1089/apc.2018.0114>
- 37 Stringer, K. L., Turan, B., McCormick, L., Durojaiye, M., Nyblade, L., Kempf, M., Lichtenstein, B., & Turan, J. M. (2016). HIV-related stigma among healthcare providers in the deep south. *AIDS and Behavior*, 20(1), 115-125. <https://doi.org/10.1007/s10461-015-1256-y>
- 38 Yehia, B. R., Stewart, L., Momplaisir, F., Mody, A., Holtzman, C. W., Jacobs, L. M., Hines, J., Mounzer, K., Glanz, K., & Metlay, J. P. (2015). Barriers and facilitators to patient retention in HIV care. *BMC Infectious Diseases*, 15(1), 246. <https://doi.org/10.1186/s12879-015-0990-0>
- 39 Kempf, M., McLeod, J., Boehme, A. K., Walcott, M. W., Wright, L., Seal, P., Norton, W. E., Schumacher, J. E., Mugavero, M., & Moneyham, L. (2010). A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: Implications for targeted interventions. *AIDS Patient Care and STDs*, 24(8), 515-520. <https://doi.org/10.1089/apc.2010.0065>
- 40 D'Ippolito, M., Lundgren, L., Amodeo, M., Beltrame, C., Lim, L., & Chassler, D. (2015). Addiction treatment staff perceptions of training as a facilitator or barrier to implementing evidence-based practices: A national qualitative research study. *Substance Abuse*, 36(1), 42-50. <https://doi.org/10.1080/08897077.2013.849646>
- 41 Hoge, M. A., Morris, J. A., Laraia, M., Pomerantz, A., & Farelly, T. (2014). *Core competencies for integrated behavioral health and primary care*. Substance Abuse and Mental Health Services Administration, & Health Resources and Services Administration Center of Excellence for Integrated Health Solutions. <https://www.hrsa.gov/behavioral-health/core-competencies-integrated-behavioral-health-and-primary-care>
- 42 Office for Victims of Crime. *The vicarious trauma toolkit*. Office of Justice Programs, U.S. Department of Justice. <https://ovc.ojp.gov/program/vtt/introduction>
- 43 Georgia Mental Health Consumer Network, Tucker, S., Tiegreen, W., Toole, J., Banathy, J., Mulloy, D., & Swarbrick, M. (2013). *Supervisor guide: Peer support whole health and wellness*. Health Resources and Services Administration. <https://bhta.hrsa.gov/resources/supervisor-guide-peer-support-whole-health-and-wellness>
- 44 Recovery Research Institute. *Addictionary®*. Massachusetts General Hospital, Harvard Medical School. <https://www.recoveryanswers.org/addiction-ary/>
- 45 Substance Abuse and Mental Health Services Administration, & Health Resources and Services Administration Center for Integrated Health Solutions. (2015). *Improving health through trauma-informed care*. <https://bhta.hrsa.gov/resources/improving-health-through-trauma-informed-care>
- 46 Substance Abuse and Mental Health Services Administration. (2014). *Trauma-informed care in behavioral health services. Treatment Improvement Protocol (TIP) series 57*. U.S. Department of Health and Human Services. <https://store.samhsa.gov/product/TIP-57-Trauma-Informed-Care-in-Behavioral-Health-Services/SMA14-4816>
- 47 Pellowski, J. A. (2013). Barriers to care for rural people living with HIV: A review of domestic research and health care models. *Journal of the Association of Nurses in AIDS Care*, 24(5), 422-437. <https://doi.org/10.1016/j.jana.2012.08.007>

- 49 Dandachi, D., Lee, C., Morgan, R. O., Tavakoli-Tabasi, S., Giordano, T. P., & Rodriguez-Barradas, M. C. (2019). Integration of telehealth services in the healthcare system: With emphasis on the experience of patients living with HIV. *Journal of Investigative Medicine*, 67(5), 815-820. <https://doi.org/10.1136/jim-2018-000872>
- 50 Himelhoch, S., Medoff, D., Maxfield, J., Dihmes, S., Dixon, L., Robinson, C., Potts, W., & Mohr, D. C. (2013). Telephone based cognitive behavioral therapy targeting major depression among urban dwelling, low income people living with HIV/AIDS: Results of a randomized controlled trial. *AIDS and Behavior*, 17(8), 2756-2764. <https://doi.org/10.1007/s10461-013-0465-5>
- 51 Yehia, B. R., Stewart, L., Momplaisir, F., Mody, A., Holtzman, C. W., Jacobs, L. M., Hines, J., Mounzer, K., Glanz, K., Metlay, J. P., & Shea, J. A. (2015). Barriers and facilitators to patient retention in HIV care. *BMC Infectious Diseases*, 15(1), 246. <https://doi.org/10.1186/s12879-015-0990-0>
- 52 Center for Health Policy and Inequalities Research. Including peers as part of a substance use treatment program for individuals living with HIV: The peer assisted treatment of HIV and substance (PATHS) model. http://chpir.org/wp-content/uploads/paths_model.pdf
- 53 Cohen, J. K. (2019, October 28). *Lyft, uber expand reach into healthcare*. Modern Healthcare. <https://www.modernhealthcare.com/patients/lyft-uber-expand-reach-healthcare>
- 54 Kempf, M. C., McLeod, J., Boehme, A. K., Walcott, M. W., Wright, L., Seal, P., Norton, W. E., Schumacher, J. E., Mugavero, M., & Moneyham, L. (2010). A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: Implications for targeted interventions. *AIDS Patient Care and STDs*, 24(8), 515-520. <https://doi.org/10.1089/apc.2010.0065>
- 55 Yu, S. W. Y., Hill, C., Ricks, M. L., Bennet, J., & Oriol, N. E. (2017). The scope and impact of mobile health clinics in the United States: A literature review. *International Journal for Equity in Health*, 16(1), 178. <https://doi.org/10.1186/s12939-017-0671-2>
- 56 National Alliance of State & Territorial Aids Directors, & Urban Coalition for HIV/AIDS Prevention Services. (2012). *Syringe services program (SSP) development and implementation guidelines for state and local health departments*. https://www.nastad.org/sites/default/files/resources/docs/055419_NASTAD-SSP-Guidelines-August-2012.pdf
- 57 AIDS United. (2015). *Best practices for integrating peer navigators into HIV models of care*. https://www.aidsunited.org/data/files/Site_18/PeerNav_v8.pdf
- 58 Center for Substance Abuse Treatment. (2000). Chapter 10—Funding and policy considerations. In *Substance abuse treatment for persons with HIV/AIDS. Treatment Improvement Protocol (TIP) series, no. 37*. Substance Abuse and Mental Health Services Administration. <https://www.ncbi.nlm.nih.gov/books/NBK64925/>
- 59 Kaiser Family Foundation. (2019, February 4). *The Ryan White HIV/AIDS program: The basics*. <https://www.kff.org/hiv/aids/fact-sheet/the-ryan-white-hiv-aids-program-the-basics/>
- 60 Center for Substance Abuse Treatment. (2009). *Implementing change in substance abuse treatment programs*. Technical Assistance Publication Series 31. HHS Publication No. (SMA) 09-4377. Substance Abuse and Mental Health Services Administration. <https://www.ctcertboard.org/files/pdfs/TAP31.pdf>
- 61 HIV.gov. (2019, September 3). *What is 'Ending the HIV Epidemic: A plan for America'?* <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>
- 62 Andrews, M. (2019, July 15). *Even when HIV prevention drug is covered, other costs block treatment*. Kaiser Health News. <https://khn.org/news/even-when-hiv-prevention-drug-is-covered-other-costs-block-treatment/>
- 63 Keith, K. (2019, September 1). *Centers for Medicare and Medicaid Services (CMS) announces new navigator grantees for 2020, 2021*. Health Affairs. <https://www.healthaffairs.org/doi/10.1377/hblog20190831.204373/full#:~:text=For%202020%20and%202021%2C%20CMS,based%20marketplace%20using%20HealthCare.gov>
- 64 Safren, S. A., O'Cleirigh, C. M., Bullis, J. R., Otto, M. W., Stein, M. D., & Pollack, M. H. (2012). Cognitive behavioral therapy for adherence and depression (CBT-ad) in HIV-infected injection drug users: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*, 80(3), 404-415. <https://doi.org/10.1037/a0028208>
- 65 Petry, N. M., Weinstock, J., & Alessi, S. M. (2011). A randomized trial of contingency management delivered in the context of group counseling. *Journal of Consulting and Clinical Psychology*, 79(5), 686-696. <http://dx.doi.org/10.1037/a0024813>

- ⁶⁶ HIV.gov. (2020, January 31). *Syringe services programs - Opioid crisis is raising risks of HIV & other infectious diseases*. <https://www.hiv.gov/federal-response/policies-issues/syringe-services-programs>
- ⁶⁷ Centers for Disease Control and Prevention (2019, May 23). *Federal funding for syringe services programs*. <https://www.cdc.gov/ssp/ssp-funding.html>
- ⁶⁸ National Academies of Sciences, Engineering, and Medicine. (2020). *Opportunities to improve opioid use disorder and infectious disease services: Integrating responses to a dual epidemic*. The National Academies Press. <https://doi.org/10.17226/25626>
- ⁶⁹ AETC National Coordinating Resource Center, & Oregon AETC. (2019, February 25). *Prescribing PrEP for HIV prevention: A guide for medical providers*. <https://aidsetc.org/resource/prescribing-prep-hiv-prevention-guide-medical-providers>
- ⁷⁰ Kosinski, Z., & Harford County Health Department PrEP Program. (2018). *PrEP program resource binder*. https://harfordcountyhealth.com/wp-content/uploads/2018/10/PrEP-Provider-Toolkit_optimized.pdf
- ⁷¹ Michigan Department of Health & Human Services. (2019). *PrEP provider toolkit*. https://www.michigan.gov/documents/mdhhs/PrEP_Provider_Toolkit_MDHHS_547647_7.pdf
- ⁷² Calabrese, S. K., St. George, D., Callis, B., & Buchelli, M. (2015, June 4). *Implementing PrEP for HIV prevention: State-wide initiatives and provider experiences* [PowerPoint slides]. National LGBT Health Education Center, Fenway Institute. https://www.lgbthealtheducation.org/wp-content/uploads/Implementing-PrEP-for-HIV-Prevention_Final.pdf
- ⁷³ Harm Reduction Coalition. (n.d.). *Syringe access implementation*. <https://harmreduction.org/our-work/syringe-access-implementation/>
- ⁷⁴ Centers for Disease Control and Prevention. (2020, March 19). *Capacity building assistance*. U.S. Department of Health and Human Services. <https://www.cdc.gov/hiv/capacity-building-assistance/index.html>
- ⁷⁵ Winkelstein, E. (2010). *Guide to developing and managing syringe access programs*. Harm Reduction Coalition. <https://harmreduction.org/issues/syringe-access/guide-to-managing-programs/>
- ⁷⁶ La Belle, R. (2017). *A guide to establishing syringe services programs in rural, at-risk areas*. Comer Family Foundation. <https://www.comerfamilyfoundation.org/img/A-Guide-to-Establishing-Syringe-Services-Programs-in-Rural-At-Risk-Areas.pdf>
- ⁷⁷ Oregon Public Health Division.(2019) *Harm reduction and SSP planning and resource manual*. Oregon Health Authority. <https://www.oregon.gov/oha/PH/PreventionWellness/SubstanceUse/Pages/harm-reduction-library.aspx>
- ⁷⁸ Petry, N.M. & Stitzer, M.L. (2002). *Contingency Management: Using Motivational Incentives to Improve Drug Abuse Treatment*. Yale University Psychotherapy Development Center. https://medicine.yale.edu/psychiatry/research/programs/clinical_people/pdc/ContingencyManagement_176454_284_46619_v1.pdf
- ⁷⁹ Prendergast, M., Hall, E., & Rokke, A. (2011). *A treatment manual for implementing contingency management*. UCLA Integrated Substance Abuse Programs. http://www.uclaisap.org/assets/documents/Manual%20for%20Implementing%20Contingency%20Management_11-8-2011%20clean.pdf
- ⁸⁰ Petry, N. (2001). *A clinician's guide for implementing contingency management programs*. Department of Psychiatry, University of Connecticut School of Medicine. https://www.drugsandalcohol.ie/13618/1/NTA_Contingency_management_Petry.pdf
- ⁸¹ National Association of Cognitive-Behavioral Therapists. (n.d.). *CBT: Cognitive-behavioral therapy onsite training*. <https://www.nacbt.org/cbt-cognitive-behavioral-therapy-onsite-training/>
- ⁸² Beck Institute. (2019). *Beck cognitive behavior therapy: Get training*. <https://beckinstitute.org/get-training/>
- ⁸³ Safren, S. (2020). *Intersecting epidemics: Evidenced based approaches for treating depression and HIV/AIDS*. PracticeGround. <https://www.practiceground.org/abct-2018-safren>
- ⁸⁴ Massachusetts General Hospital Psychiatry Academy. (2020). *Cognitive behavioral therapy*. Massachusetts General Hospital. <https://www.massgeneral.org/psychiatry/treatments-and-services/cognitive-behavioral-therapy-program>
- ⁸⁵ Kaufman, L., Kuhn, W., Stevens Manser, S., & Texas Institute for Excellence in Mental Health. (2016). *Peer specialist training and certification programs: A national overview*. Health Resources and Services Administration. <https://bhta.hrsa.gov/resources/peer-specialist-training-and-certification-programs-national-overview>
- ⁸⁶ AIDS United. (2015). *Best practices for integrating peer navigators into HIV models of care*. https://www.aidsunited.org/data/files/Site_18/PeerNav_v8.pdf

⁸⁷ National Minority AIDS Council, & Linking and Integrating Networks for Collaboration. (2015). *HIV navigation services: A guide to peer & patient navigation programs*. Organizational Effectiveness Series: Building Healthy Organizations. http://nmac.org/wp-content/uploads/2012/08/OES-HNS_FINAL_9-3-2015.pdf

⁸⁸ Centers for Health Policy & Inequalities Research. (n.d.). Including peers as part of a substance use treatment program for individuals living with HIV: The peer assisted treatment of HIV and substance (PATHS) model. Duke University. http://chpir.org/wp-content/uploads/paths_model.pdf

⁸⁹ Rural Health Information Hub, Health Resources and Services Administration, & U.S. Department of Health and Human Services. (2020). *Rural HIV/AIDS prevention and treatment toolkit*. <https://www.ruralhealthinfo.org/toolkits/hiv-aids>

Examples of Effective Programs and Strategies

The chapter describes how practitioners have implemented three prevention and treatment programs as part of a comprehensive strategy to prevent and treat HIV among people living with mental illness and/or substance use disorders (SUD):

- **Faster Paths to Treatment:** a SUD bridge clinic program implementing practices to Increase Uptake and Improve Adherence to Pre-Exposure Prophylaxis (PrEP)
- **Louisville Metro Syringe Exchange Program (LMSEP):** a Syringe Services Program (SSP)
- **The Alexis Project:** a HIV linkage and retention program implementing both Contingency Management (CM) and Patient Navigation

The three examples highlighted in this chapter were identified through an environmental scan and in consultation with experts. While there are additional programs that could have been featured in this chapter, those highlighted below were included to provide diverse examples of settings in which HIV and mental illness and/or SUD can be addressed.

To be included, the interventions had to:

- Include one or more of the practices identified in Chapter 2
- Be replicable (well-defined with guidance materials or a manual)
- Have research to support their impact on HIV and mental illness and/or SUD, or be identified as a promising practice



- Provide appropriate and effective interventions for varied geographic areas, practice settings, and diverse populations

Programs should implement practices with fidelity to evaluated models. Fidelity is the degree to which a program delivers a practice as intended and must be maintained for desired therapy outcomes. However, many programs adapt chosen practices to better serve their clients. As practitioners modify practices to address the needs and constraints of their population, budget, setting, and other local factors, they should strive to adhere to the practice's foundational principles.

Faster Paths to Treatment

Boston Medical Center (Boston, MA)

Faster Paths to Treatment is a low-barrier SUD bridge clinic that opened in 2016 to address the opioid use disorder (OUD) epidemic and overdose crisis. It is part of a network of SUD treatment programs at Boston Medical Center, and it uses a flexible, client-centered, harm-reduction model to provide rapid access to medications for OUD, outpatient medically-managed withdrawal, overdose and HIV prevention services, sexually transmitted infection testing and treatment, and linkage to long-term SUD treatment and primary/psychiatric care after stabilization. Faster Paths serves a population with high rates of prior drug overdose, polysubstance use, and homelessness. It is funded by the Massachusetts Department of Public Health Bureau of Substance Addiction Services.

Model Features and Elements

Recognizing the need for on-demand services, Faster Paths offers both scheduled and walk-in appointments and aims to provide same day access to buprenorphine (a form of medication for opioid use disorder) and HIV prevention services including testing, PrEP, and post-exposure prophylaxis (PEP). Same day services mitigate the chance of loss to follow-up and support client engagement.



Evidence-Based Practice Implemented by the Program

Practices to increase uptake of and improve adherence to PrEP

Population of Focus

People who use substances; 66 percent of clinic clients report injection drug behavior. Many clients have co-occurring psychiatric disorders and face significant psychosocial barriers to care, including housing instability.

Approximate Time Period (Duration)

Clients are typically followed in Faster Paths for weeks to months

Related Resources

[Program Website](#)

[Taylor, J. L., Walley, A. Y., & Bazzi, A. R. \(2019\). Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs. Substance Abuse, 40\(4\), 441-443. <https://pubmed.ncbi.nlm.nih.gov/31644387/>](#)

[eReview of PrEP in PWID](#)

Findings and Outcomes

- Because Faster Paths clients often report recent potential HIV exposures, “PEP-to-PrEP” (starting on PEP and transitioning to PrEP) has been the safest, most efficient, and effective way to start PrEP for this population.¹ If a client reports being exposed to HIV within the last 72 hours, Faster Paths emphasizes PEP as a bridge to PrEP, which can be started immediately at the end of a 28-day PEP course in clients who remain HIV negative. In April 2020, 22 percent of provider visit notes (including initial visits and follow up visits) addressed PEP or PrEP.

- To support practitioners in consistently evaluating HIV prevention needs, Faster Paths has a standardized intake laboratory panel and electronic medical record note templates to assess risk of getting HIV and PrEP eligibility.



Lessons Learned

- Many clients seen in Faster Paths have limited awareness about PrEP and its potential benefits as a result of not having had the opportunity to discuss PrEP with a provider in the past, limited information about PrEP within their social network, and marketing that has not been inclusive of people who inject drugs (PWID).
- The way a provider discusses PrEP can be crucial for uptake. For example, it can be important to emphasize that PrEP is recommended for preventing HIV for a wide range of populations (e.g., PWID, men who have sex with men, and heterosexual people) to reduce stigma related to PrEP.
- Faster Paths aims to educate clients about PrEP in a manner that is not overwhelming (e.g., at initial or follow-up visits, depending on client preference), highlighting the ways PrEP can benefit both the client and their networks (i.e., sexual and injection drug use equipment-sharing partners), and emphasizing that PrEP will not necessarily be a life-long medication.
- Faster Paths clients have an increased likelihood of acute HIV disease due to a current outbreak among PWID in Boston, MA. In April, 2020, 13 percent of HIV screening tests in Faster Paths resulted in a new diagnosis of HIV transmission associated with injection drug use. Providers have expressed concern about starting same-day PrEP while awaiting HIV test results due to potential barriers to reaching the client to stop PrEP if the test returns positive. However, providers realized when they asked the client to return to the clinic to begin PrEP at a later date, opportunities were missed due to loss to follow-up. Therefore, if a client has a reliable method of contact, providers consider starting PrEP while HIV test results are pending.
- Many SUD providers were not educated about PEP/PrEP during their clinical training, and the PEP/PrEP cases seen in Faster Paths are complex. To increase provider confidence prescribing PEP/PrEP in PWID, Faster Paths conducts didactic sessions with faculty, nurses, fellows, licensed drug and alcohol counselors, and administrative staff and provides real-time clinical support when PEP/PrEP questions arise.



Louisville Metro Syringe Exchange Program (LMSEP)

Louisville Metro Department of Public Health and Wellness (Louisville, KY)

The Louisville Metro Syringe Exchange Program (LMSEP) is a SSP that started in 2015. Established through the Louisville Department of Public Health and Wellness, LMSEP has two main goals:

- Prevent the spread of blood-borne infectious diseases transmitted through syringe sharing
- Link PWID to treatment

As a harm reduction program, LMSEP works with numerous community organizations and stakeholders to provide the following to PWID in the Louisville Metro area:

- Access to free and sterile syringes
- Safe syringe disposal (on site and at two mailbox disposals in the community)
- Fentanyl test strips
- Safe injection supplies
- HIV and hepatitis C virus (HCV) testing and referrals
- Referrals for mental illness and/or SUD treatment
- Counseling
- Harm reduction education on HCV, HIV, sexually transmitted infections, wound care, and overdose prevention (including providing naloxone)

LMSEP offers syringe exchange services at their main site inside the Louisville Metro Department of Public Health and Wellness. In addition, they offer mobile van exchange services at seven satellite locations during the week.

Model Features and Elements

- The primary pillar of LMSEP is trust. Through its outreach work, LMSEP emphasizes accepting participants where they are and not judging them or stigmatizing them further. Staff and volunteers also tell participants that pursuing SUD treatment is voluntary and not a requirement of the program.
- Underscoring the importance of mutual respect between participants and staff, LMSEP created

Evidence-based Practice Implemented by the Program

Syringe Services Program (SSP)

[LMSEP](#) is an outpatient SSP organized by the Louisville Department of Public Health and Wellness. LMSEP offers social and health services to PWID through fixed-site and mobile van settings.

Population of Focus

PWID, specifically adults aged 18 to 25.

Approximate Time Period (Duration)

Indefinite

Related Resources

- [Program Website](#)
- [LMSEP Overview \(slides\)](#)
- [LMSEP Brochure of Services](#)
- [LMSEP Guidelines](#)
- [LMSEP Research Brief](#)

a Participant Bill of Rights and Responsibilities to ensure the rights and expectations of participants, staff, and volunteers are clear to all individuals involved with the program.

- During their first visit, participants are asked to complete a voluntary intake form. Using the Program Staff Check List and this intake form, staff discuss LMSEP's numerous harm reduction and treatment services with participants.
- Within LMSEP's harm reduction model, certified alcohol and SUD counselors and HIV prevention specialists provide onsite support, testing, and linkage. LMSEP staff link participants who test positive for HIV to a Kentucky Care Coordination program case manager at the University of Louisville to facilitate HIV-specific care and treatment.

Findings and Outcomes

- Since its establishment in 2015, LMSEP has served more than 20,000 unique participants, has had about 115,000 visits, and has distributed more than five million sterile syringes. LMSEP has also:
 - Tested more than 35,000 people for HIV and referred 29 for treatment
 - Tested more than 4,800 people for HCV and referred approximately 700 for treatment
 - Referred 719 people for SUD treatment
 - Connected more than 300 people to other community services
- Since LMSEP staff began distributing naloxone, 890 participants have reported almost 2,000 overdose reversals.
- Louisville has prevented a substantial rise in new HIV diagnoses, reporting a stable transmission rate while neighboring states have experienced increases. Before LMSEP opened, the rate of new HIV diagnoses in the Louisville metropolitan region was 15.3 per 100,000 in 2014. In 2017, the rate of new HIV diagnoses was 13.9 per 100,000.²



Lessons Learned

- Less restrictive dispensation policies (e.g., providing the number of supplies a client reports needing instead of offering one set of sterile supplies for every one set of used supplies) reduce syringe re-use and may benefit people who use injection drugs and may not directly attend a SSP.
- Build community collaboration and support to counter the stigma attached to the SSP practice. Engage partners from the start of program development throughout implementation. When assessing community readiness to start an SSP, LMSEP worked to build support with various partners and stakeholders, including political and social leaders, healthcare and social services providers, law enforcement, neighborhood associations, business owners, fire and rescue departments, the local media, and district and county attorneys.
- Building trust with program participants is often difficult but especially important. In LMSEP, this trust facilitated an increase of immunizations and treatment during a hepatitis A outbreak and the ability to educate participants on COVID-19 health and safety issues.



The Alexis Project

Friends Community Center, a Division of Friends Research Institute (Los Angeles County, CA)

The Alexis Project was developed under the Enhancing Engagement and Retention in Quality HIV Care for Transgender Women of Color Initiative funded by the Health Resources and Services Administration's (HRSA) Special Programs of National Significance (SPNS). The project utilizes a multi-tiered approach to identify, engage, and retain in care transgender women of color with HIV.

The Alexis Project is named after Alexis Rivera who died on March 28, 2012, at the age of 34, from complications related to HIV. She was a proud Latina transgender woman, community activist, and peer advocate.

Model Features and Elements

The Alexis Project incorporates social network recruitment and engagement, peer health navigation, and contingency management to promote achievement of health outcomes along the HIV care continuum. Through social network recruitment, the Alexis Project recruits transgender women of color, who know they have HIV but are not in care, to the combined peer health navigation and contingency management intervention.

Peer Health Navigation (PHN):

- Peer health navigators work with participants to develop a client-centered treatment plan and link them to HIV care and/or other needed services (e.g., hormone therapy, mental health counseling, substance use treatment, legal services, transportation assistance).
- Participants receive unlimited PHN sessions and can contact peer health navigators any time.
- Participants complete a needs and barriers assessment at each session.
- The goals of sessions are to:
 - Identify barriers to care,
 - Identify and link participants to needed services, and
 - Increase participants' self-efficacy in working with HIV care providers and other treatment facilities.

Evidence-based Practice Implemented by the Program

Contingency Management (CM), Peer Health Navigation (PHN)

Friends Community Center is a non-clinical community research center that collaborates with two medical clinics that provide HIV primary care.

Population of Focus

Transgender women of color with HIV

Approximate Time Period (Duration)

18 months

Resources on the Program

- [Program Website](#)
- [Alexis Project Implementation Manual](#)
- [SPNS Initiative: Enhancing Engagement and Retention in Quality HIV Care for Transgender Women of Color, 2012-2017 background](#)
- [Reback, C.J., Kisler, K.A., & Fletcher, J.B. \(2019\). A novel adaptation of peer health navigation and contingency management for advancement along the HIV care continuum among transgender women of color. AIDS and Behavior. <https://doi.org/10.1007/s10461-019-02554-0>](#)
- Participants receive increasingly valuable reinforcers in the form of CM reward points, which are redeemable for goods or services that promote a healthy, prosocial lifestyle (e.g., gift cards, bus tickets, payment of a utility bill, clothing).
- Increasingly valuable reinforcers serve as motivators for HIV care-seeking behavior and are specifically awarded to participants for attending HIV care visits and reaching and maintaining HIV milestones.

Findings and Outcomes

- Combined PHN and CM intervention was found to be effective in linking and retaining transgender women of color in HIV care.
- Average time from enrollment to linkage with HIV care was 67 days.
- 88 percent of participants attended at least two PHN sessions.
- 85 percent of participants attended a first HIV care visit, and 57 percent returned for a second HIV care visit.
- 14 percent of participants escalated through the entire CM schedule to achieve undetectable status.
- At intervention completion, 85 percent of participants were linked to care, and 44 percent had achieved and/or maintained viral load suppression.
- Increased attendance at PHN sessions was associated with increased probability of achieving behavioral and biomedical CM targets.



Lessons Learned

- Program administrators should support patient health navigators in setting boundaries to prevent burnout and vicarious trauma. Patient health navigators should receive ongoing training and support.
- Implementation teams will need to train HIV clinics on providing culturally competent health care to transgender women of color.
- Programs can promote retention in HIV care by providing unlimited PHN sessions, linking participants to other needed services, and providing an increasingly valuable reward schedule based on advancement through the HIV care continuum.
- PHN can be time consuming; for some participants, it may take multiple PHN sessions to feel ready to make a behavioral change. PHN should adopt a client-centered approach and build relationships first to develop a trusting partnership that facilitates lasting change for the client.



Coordination of Mental Health and HIV Care in a Mental Health Setting

Each of the case examples in this chapter illustrates how organizations have implemented one or more evidence-based practices in a clinical or community setting. While none of these examples highlights a program that is primarily focused on mental health, it is critical that programs primarily serving people with mental illness assess their clients for HIV risk, conduct HIV testing, and provide appropriate and integrated HIV prevention and treatment services and mental health treatment to address their client's complex needs.³

When first working with a potential client, mental health providers can conduct an intake and/or mental health assessment using screening tools such as the brief measure for assessing generalized anxiety disorder (GAD-7)⁴ or the major depressive disorder module of the Patient Health Questionnaire (PHQ-9).⁵ During this intake and screening, a mental health provider has an opportunity to discuss a client's overall health and wellbeing, including co-occurring medical conditions such as HIV.

- If a client has not had a recent HIV test, mental health providers can supply a self-administered oral fluids test which can provide results within 20 minutes.
 - If a client does not have HIV, a mental health provider can provide PrEP education, and support PrEP uptake and adherence (as described in Chapter 2); PrEP is highly effective in preventing HIV transmission from condomless sex and injection drug use.
 - If a client has HIV, a mental health provider can link a client to HIV primary care treatment, and provide the counseling necessary to support client mental health and ART uptake and adherence (including Cognitive Behavioral Therapy, as described in Chapter 2).
- For clients at risk for or with HIV, mental health providers can also connect the client to case management to address a client's unmet ancillary needs (e.g., housing, employment, transportation), which will help reduce barriers to PrEP and ART adherence.

Integrated behavioral health and infectious disease care can facilitate rapid screening, testing, and treatment, and improve health outcomes for people experiencing mental disorders and HIV. One example of effective mental health and HIV service integration is an infectious disease psychiatric consultation service embedded within the infectious disease outpatient department in a Boston hospital. Participants were offered a comprehensive approach to depression care that included pharmacologic and ancillary psychological therapies. When psychiatric consultation services were offered and linked to primary care, participants experienced benefits to both their mental health and HIV-related health outcomes. Participants had a statistically significant reduction in depression and viral load, and statistically significant increase in CD4 count. Additionally, a greater number of participants were prescribed anti-depressants and stimulants to treat their depression.⁶

Reference List

- ¹ Taylor, J. L., Walley, A. Y., & Bazzi, A. R. (2019). Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs. *Substance Abuse*, 40(4), 441-443. <https://doi.org/10.1080/08897077.2019.1675118>
- ² Moyer, S. (2019, December 12). *Louisville's syringe exchange - preventing HIV transmission while pointing to recovery*. Kentuckiana Health Collaborative. <https://www.khcollaborative.org/2019/12/louisvilles-syringe-exchange-2/>
- ³ Chuah, F., Haldane, V. E., Cervero-Liceras, F., Ong, S. E., Sigfrid, L. A., Murphy, G., Watt, N., Balabanova, D., Hogarth, S., Maimaris, W., Otero, L., Buse, K., McKee, M., Piot, P., Perel, P., & Legido-Quigley, H. (2017). Interventions and approaches to integrating HIV and mental health services: a systematic review. *Health policy and planning*, 32(suppl_4), iv27–iv47. <https://doi.org/10.1093/heapol/czw169>
- ⁴ Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). The brief measure for assessing generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, 166(10), 1092-1097. <https://doi.org/10.1001/archinte.166.10.1092>
- ⁵ Patient Health Questionnaire (PHQ-9). <https://www.med.umich.edu/1info/FHP/practiceguides/depress/phq-9.pdf>
- ⁶ Coleman, S. M., Blashill, A. J., Gandhi, R. T., Safren, S. A., & Freudenreich, O. (2012). Impact of integrated and measurement-based depression care: clinical experience in an HIV clinic. *Psychosomatics*, 53(1), 51–57. <https://doi.org/10.1016/j.psych.2011.07.004>




Resources for Evaluation and Quality Improvement

Evaluating a practice or program answers critical questions about how well a practice has been implemented, and what is and is not working. Evaluation can also show how clients benefit from a program. This information can be helpful in making program adjustments, if necessary, and demonstrating the value of a program or practice to justify its continuation and secure additional funding. In addition, stakeholders can use information gathered through evaluation to encourage implementation of that practice in other programs or communities.

This chapter provides an overview of approaches to evaluate implementation of and results from practices to prevent and treat human immunodeficiency virus (HIV) among people with mental illness and/or substance use disorders (SUD).

This chapter also includes information on implementing a continuous quality improvement (CQI) process. Finally, the chapter concludes with specific evaluation resources, including potential outcomes to track.



Types of Evaluations

Evaluation is typically conducted before a practice is implemented to determine its feasibility (*formative evaluation*), during implementation (*process evaluation* and *CQI*), and after the intervention has been delivered to at least one client (*outcome and impact evaluations*). Each type of evaluation is necessary to assess an intervention's effectiveness. The graphic below illustrates these evaluation types in greater detail.

CONTINUOUS QUALITY IMPROVEMENT (CQI)

What is CQI?

CQI involves a systematic process of assessing program or practice implementation and short-term outcomes and then involving program staff in identifying and implementing improvements in service delivery and organizational systems to achieve better treatment outcomes. CQI helps assess practice fidelity, the degree to which a program delivers a practice as intended. There are many potential CQI models and approaches (see e.g., <https://www.healthit.gov/faq/what-are-leading-continuous-quality-improvement-strategies-health-care-settings>).

CQI differs from process evaluation in that it involves quick assessments of program performance, timely identification of problems and potential solutions, and implementation of small improvements to enhance treatment quality. CQI is usually conducted by internal staff. Process evaluation involves longer-term assessments and is best conducted by an external evaluator.

The [Network for Improvement of Addiction Treatment \(NIATx\)](#), a project originally funded by SAMHSA's Center for Substance Abuse Treatment, offers tools to conduct CQI and improve services in substance use disorder treatment settings. NIATx is based on the principle of program improvement through a series of small changes, tested and implemented one at a time, that in the end have a cumulative effect.

The [Institute for Healthcare Improvement's PDSA Model for Improvement](#) identifies a scientific method for testing small-scale changes in an action-oriented, cyclical manner. The stages are: planning it (Plan), trying it (Do), observing the results (Study), and acting on what is learned (Act).


Why use CQI?

CQI takes a broader look at the systems in which programs or practices operate. Because of the pivotal role it plays in performance management, organizations preventing and treating HIV among people with mental illness and/or substance use disorders are encouraged to implement CQI procedures.

What are the steps involved in CQI?

Although steps in the CQI process may vary based on objectives, typical CQI steps are:

- Identify a program or practice issue needing improvement and a target improvement goal
- Analyze the issue and its root causes
- Develop an action plan to correct the root causes of the problem, including specific actions to be taken
- Implement the actions in the action plan
- Review the results to confirm that the issue and its root causes have been addressed and short-term and long-term treatment outcomes have improved
- Repeat these steps to identify and address other issues as they arise



Institute for Healthcare Improvement. (n.d.). *Science of improvement: Testing changes*. <http://www.ihl.org/resources/Pages/HowtoImprove/ScienceofImprovementTestingChanges.aspx>

New Jersey Department of Children and Families. (n.d.). *Five Stages of Continuous Quality Improvement*. <https://www.nj.gov/dcf/about/divisions/opma/CQI%20framework.pdf>

University of Wisconsin-Madison, NIATx National Program Office. (n.d.). *What is NIATx?* <https://www.niatx.net/what-is-niatx/>

U.S. Department of Health & Human Services Office of Adolescent Health. (n.d.). *Continuous Quality Improvement, Part 1: Basics for Pregnancy Assistance Fund Programs*. <https://www.hhs.gov/ash/oah/sites/default/files/cqi-intro.pdf>

Preparing to Collect Data

The following steps can help clinics and practitioners prepare to collect and analyze data:

1. Determine if the purpose of the data collection is evaluation or research.

Qualitative and quantitative evaluation and research enables managers and clinicians to learn from clients and obtain the perspective of those with lived experiences. Both evaluation and research can also involve collecting data from staff who deliver the new treatment to obtain their perspectives on facilitators and challenges to practice implementation.

Program evaluation supports program improvement. Research contributes to generalizable knowledge by implementing study protocols and procedures approved by Institutional Review Boards (IRB) that adhere to human subject research protections. When designing program evaluations, researchers should consult with their institutions to ensure they are following appropriate data collection procedures.

2. Identify team members to conduct evaluation activities.

Regardless of the type of evaluation conducted, collecting and analyzing data takes time. Programs need to identify team members who can conduct evaluation activities and secure funding to protect their time for evaluation trainings, data collection, and data analysis.

3. Determine outcomes of interest.

A challenging step in the process of implementing new practices is to determine whether the practice

Qualitative and quantitative data are complementary. Each provides critical insight into if and how the intervention is operating and achieving the intended objectives.

Qualitative data include any non-numeric, text-based information, such as verbal, visual, or written data. Qualitative data collection methods include interviews, focus groups, clinical observations, gathering data from documents and images, and open-ended survey questions and polling responses.

Quantitative data are any numeric data that can be processed by mathematical or statistical analysis. Quantitative data collection includes close-ended survey questions and polling responses, services and utilization data, and claims and encounter data.

has yielded desired outcomes. An outcome is the change a program hopes to accomplish through the implementation of a practice.

Outcomes

The table below provides a list of potential outcomes, example outcome indicators, and qualitative and quantitative data sources that program managers, clinicians, and others may use to evaluate practices identified in Chapter 2. Some of the short- and intermediate-term outcomes may be tracked at baseline and throughout the practice or program duration through an electronic health record, or through interviews with staff and clients. Longer-term outcomes may be obtained from administrative and survey data.



Outcome	Practice	Illustrative Indicators	Illustrative Data Sources
Short-term and intermediate outcomes			
Engagement in services	SSPs	<ul style="list-style-type: none"> Access to SSP (number of sites, hours open) Clients accessing SSP (visit numbers and dates) Syringes distributed and returned for disposal 	<ul style="list-style-type: none"> Qualitative interviews (staff and clients) Administrative data Intake/enrollment data
	PrEP	<ul style="list-style-type: none"> Sessions and contacts scheduled and completed 	<ul style="list-style-type: none"> Administrative data
	CBT		
	CM		
	PN		
HIV education	CBT	<ul style="list-style-type: none"> Change in knowledge, motivation, and skills to engage in HIV preventive acts (e.g., condom attitudes and use), Perceptions of personal vulnerability to HIV 	<ul style="list-style-type: none"> Qualitative interviews (staff and clients) Structured scales and assessments (e.g., Sexual Risk Behavior Assessment Schedule)
	CM		
	PN		
Knowledge of HIV and SUD harm reduction strategies	SSPs	<ul style="list-style-type: none"> Knowledge of safe injection practices Knowledge about HIV transmission Knowledge of overdose prevention strategies (e.g., naloxone access and trainings) 	<ul style="list-style-type: none"> Qualitative interviews (staff and clients) Structured scales and assessments Attendance/administrative data Number of naloxone trainings and naloxone kits distributed
	CBT		
PrEP uptake	PrEP	<ul style="list-style-type: none"> Number of PrEP prescriptions provided and filled 	<ul style="list-style-type: none"> Medical records Pharmacy records
Linkage or re-linkage to HIV care	SSPs	<ul style="list-style-type: none"> Number of HIV linkage-to-care visits scheduled and completed 	<ul style="list-style-type: none"> Administrative records Medical records
	CM		
	PN		
Injection drug use behaviors	SSPs	<ul style="list-style-type: none"> Injecting with a sterile syringe Sharing injection equipment 	<ul style="list-style-type: none"> Qualitative interviews (clients) Staff logbooks National Institute on Drug Abuse (NIDA) Risk Behavior Assessment
	CBT		
	CM		
Ancillary service delivery	SSPs	<ul style="list-style-type: none"> Referrals made and visits completed for specialty care and ancillary services (e.g., HIV/HCV/STI testing, medication-assisted treatment) 	<ul style="list-style-type: none"> Qualitative interviews (staff and client) Administrative data Medical records
	PN		
Retention in HIV care	CM	<ul style="list-style-type: none"> Number of medical visits that were at least 90 days apart (in the past year) 	<ul style="list-style-type: none"> Qualitative interviews (clients) Medical records
	PN		
Medication Adherence	PrEP	<ul style="list-style-type: none"> Ongoing PrEP prescriptions provided and filled 	<ul style="list-style-type: none"> Medical records Pharmacy records
	CBT	<ul style="list-style-type: none"> ART prescriptions provided and filled 	<ul style="list-style-type: none"> Qualitative interviews (client) Medical records Medication Event Monitoring Systems (MEMS)
	CM		
	PN		

Outcome	Practice	Illustrative Indicators	Illustrative Data Sources
Short-term and intermediate outcomes			
Substance Use	PN	<ul style="list-style-type: none"> SUD Days of substance use in the prior 30 days 	<ul style="list-style-type: none"> Qualitative interviews (client) Urine drug screen Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) Alcohol Use Disorders Identification Test (AUDIT) Drug Abuse Screening Test (DAST-10)
Individual-level mental health	CBT	<ul style="list-style-type: none"> Mental health score 	<ul style="list-style-type: none"> Structured scales and assessments (e.g., PHQ-9 for depression, Beck Depression Inventory, Hamilton Depression Scale, Montgomery-Asberg Depression Rating Scale, Generalized Anxiety Disorder (GAD-7) Scale)
	PN		<ul style="list-style-type: none"> 12-item short form health survey (SF-12)
Changes in HIV risk associated with SUD	SSPs	<ul style="list-style-type: none"> Frequency of substance use Cessation of injection drug use 	<ul style="list-style-type: none"> Qualitative interviews (staff and clients) NIDA Risk Behavior Assessment
Long-term and population-level outcomes and impacts			
Individual-level HIV outcomes	CBT	<ul style="list-style-type: none"> CD4 cell count 	<ul style="list-style-type: none"> Medical records Lab test/blood sample
	CM	<ul style="list-style-type: none"> Viral load 	
	PN		
Population-level HIV outcomes	SSPs	<ul style="list-style-type: none"> Rate of new HIV diagnoses 	<ul style="list-style-type: none"> Administrative data Medical records
	PrEP	<ul style="list-style-type: none"> Prevalence of HIV 	
	CBT		
	CM		
	PN		
<p> ■ SSPs ■ PrEP ■ CBT ■ CM ■ PN </p>			

Evaluation Resources

Evaluating Program Implementation

- [A Framework for Program Evaluation](#), from the Program Performance and Evaluation Office at the Centers for Disease Control and Prevention, summarizes essential elements of program evaluation.
- [The Community Toolbox](#), from the Center for Community Health and Development at the University of Kansas, includes a step-by-step guide to developing an evaluation of a community program, specific tools, and examples.

Quality Improvement and Continuous Performance Monitoring

- Institute for Healthcare Improvement's [Quality Improvement Essentials Toolkit](#) includes the tools and templates to launch a quality improvement project and manage performance improvement.

Evaluating Practices Specifically Addressing HIV and Mental Illness and/or SUD

- The Center for Innovation in Social Work and Health [Community Health Worker toolkit](#) includes best practices for evaluating peer programs.
- Rural Health Information Hub (RHIfhub) has created [HIV](#), [Mental Health](#), [SUD](#), and [Telehealth](#) specific Evidence-Based Toolkits for Rural Community Health (that can be broadly applied to both rural and urban health).
- The National Minority AIDS Council created a [guide to program evaluation](#) as part of their Organizational Effectiveness Series, defining types of evaluation, ways to assemble an evaluation team and design an evaluation plan, and steps to conducting an evaluation.

Appendix 1: Acknowledgments

This publication was developed with a significant contribution from Alexis Marbach, MPH, SAMHSA staff, a technical expert panel, and Abt Associates staff. The guidance is based on the thoughtful input of SAMHSA staff and the Expert Panel on the prevention and treatment of HIV among individuals experiencing co-occurring mental illness and/or substance use disorders (SUD) from October 2019 through August 2020. A series of guide development meetings was held virtually over a period of several months. Three expert panel meetings were convened during this time.

SAMHSA Staff

Fred Bamfo, DNP, MPH Center for Substance Abuse Treatment*

Christine Cichetti, National Mental Health and Substance Use Policy Laboratory

Thomas Clarke, PhD National Mental Health and Substance Use Policy Laboratory

Amanda Doreson, MPA National Mental Health and Substance Use Policy Laboratory

Daniel Gallardo, MPH National Mental Health and Substance Use Policy Laboratory

Neeraj Gandotra, MD Chief Medical Officer*

Tanya Geiger, PhD, MPH National Mental Health and Substance Use Policy Laboratory*

Kirk James, MD Center for Substance Abuse Treatment

Donelle Johnson, PhD, MHSA National Mental Health and Substance Use Policy Laboratory*

Expert Panel

Michael B. Blank, PhD University of Pennsylvania Perelman School of Medicine

Katie Biello, PhD, MPH Brown University School of Public Health, The Fenway Institute

Deb Bourne, MD, MSW San Francisco Health Network, San Francisco Department of Public Health

Redonna Chandler, PhD National Institute on Drug Abuse (NIDA)

Francine Cournous, MD Columbia University Mailman School of Public Health, Northeast/Caribbean AIDS Education and Training Center

Carlos Del Rio, MD Emory University School of Medicine, Rollins School of Public Health. Principal Investigator, and Center for AIDS Research

Antigone Dempsey, M.Ed Division of Policy and Data, HIV/AIDS Bureau, Health Resources and Services Administration (HRSA)

Traci Green, PhD, MSc, Opioid Policy Research Collaborative, Brandeis University

Douglas Krakower, MD Beth Israel Deaconess Medical Center, The Fenway Institute, and Harvard Medical School

Conall O’Cleirigh, PhD Harvard Medical School, Massachusetts General Hospital

Melinda Tinsley, MA Division of Policy and Data, HIV/AIDS Bureau, Health Resources and Services Administration (HRSA)

Glenn Treisman, MD, PhD Johns Hopkins University School of Medicine

Contract Staff

Olivia Bacon, Abt Associates

Korrin Bishop, Korrin Bishop Writing & Editing

Yvonne Cristy, Abt Associates

Margaret Gwaltney, MBA Abt Associates*

Alexis V. Marbach, MPH, Abt Associates*

Nikitha Reddy, Abt Associates

Cayla D. Roby, MA, MPH, Abt Associates

Daniel Jefferson Smith, Abt Associates

Sarah Steverman, PhD, MSW Abt Associates*

Christopher Weiss, PhD Abt Associates

Elyse Yarmosky, LISCW, Abt Associates

*Members of Guide Planning Team

Appendix 2: Evidence Review Methodology

The authors followed a rigorous, systematic evidence review process in the development of this guide. This appendix provides an overview of the evidence review methodology used to identify the ratings for the practices included in the guide: practices to increase uptake of and improve adherence to PrEP, syringe services programs, cognitive behavioral therapy, contingency management, and patient navigation. Reviewers, in coordination with SAMHSA and experts, conducted a four-step process to select practices, identify related studies, review and rate studies, and identify practice ratings.

Step 1: Practice Selection

The authors identified these five practices after a review of the literature and in consultation with experts. In an effort to include interventions that would be most useful to those seeking to prevent and treat HIV among people with mental illness and/or substance use disorders (SUD), eligible practices were required to meet the following criteria for evidence review:

- Be clearly defined and replicable
- Address the target outcome of preventing and treating HIV among people who use substances and/or have mental health concerns
- Be currently in use
- Have studies of their effectiveness
- Have accessible implementation and fidelity supports

At the conclusion of this step, SAMHSA and the guide's Expert Panel reviewed the proposed practices identified by the authors and agreed on five for inclusion in the evidence review and rating process.

Step 2: Study Identification

Once the practices were selected, the reviewers conducted a comprehensive review of published research on these practices to identify studies of the selected practices. This review only included studies from eligible sources (i.e., peer reviewed journals and government reports) that avoid clear conflicts of interest. The reviewers documented all potential studies identified through the literature search.

The studies identified in the literature search varied in type and rigor, so the reviewers assessed them further for inclusion in the evidence review. To be eligible for review and study rating, research studies had to:

- Employ a randomized or quasi-experimental design, or
- Be a single sample pre-post design or an epidemiological study with a strong counterfactual—a study that analyzes what would have happened in the absence of the intervention.

Literature reviews, descriptive studies, implementation studies, and meta-analyses were not included in the review, but were documented to provide context and identify implementation supports for the practices.

Additionally, to be eligible for further review and rating, studies had to:

- Be published or prepared in or after 2000
- Be a publicly available peer-reviewed paper or research report
- Be available in English
- Include at least one eligible outcome related to HIV prevention and/or treatment
- Have a comparison/control group that is treatment as usual or no/minimal intervention if using a randomized experimental or quasi-experimental design

Step 3: Study Review and Rating

Next, trained reviewers assessed each study to ensure the methodology was rigorous and therefore could demonstrate causation between the practice and the identified outcomes. Reviewers reviewed and documented each study to ensure that:

- Experimental and comparison groups were statistically equivalent, with the only difference being that participants in the experimental group received the intervention and those in the comparison group received treatment as usual or no/minimal intervention

- For randomized experiments with high attrition and for quasi-experimental designs, baseline equivalence was established between the treatment and comparison groups
- For randomized experiments, randomization was not compromised. For example, ensuring that reassignment of treatment status, usually made to balance the distribution of background variables between treatment and control groups, did not occur.
- Study did not have any confounding factors (factors that affect the outcome but are not accounted for by the study)
- Missing data were addressed appropriately
 - Imputation based on surrounding cases was considered valid
 - Complete case analysis was considered valid and accounted for as attrition
 - Using model with dummy for missing as a covariate was considered valid
 - Assuming all missing data points are either positive or negative was not considered valid
 - Regression-based imputation was considered valid; mean imputation was not considered valid.
- Outcome measures were reliable, valid, and collected consistently from all participants
- Valid statistical models were used to estimate impacts
- Practice demonstrated improved outcomes related to HIV prevention and treatment

Based on the study design and these study characteristics, reviewers **gave each study a rating** for causal impact. Reviewers used the following scoring metric for each study based on the eight factors above to determine if a study is rated:

- High support of causal evidence
- Moderate support of causal evidence
- Low support of causal evidence

Only randomized controlled trials, quasi-experimental designs, and epidemiological studies with a strong comparison were eligible to receive a high or moderate study rating.

Step 4: Practice Rating

After all studies for a practice were assessed for these criteria, the reviewers **gave each practice a rating** based on the number of studies with strong, moderate, or emerging support of causal impact. Causal impact is evidence demonstrating that an intervention causes, or is responsible for, the outcome measured in the study's sample population. The practice was placed into one of the following categories based on the level of causal evidence of its studies:

- **Strong Evidence:** Causal impact demonstrated by at least two randomized controlled trials, quasi-experimental designs, or epidemiological studies with a high or moderate rating.
- **Moderate Evidence:** Causal impact demonstrated by at least one randomized controlled trial, quasi-experimental design, or epidemiological study with a high or moderate rating.
- **Emerging Evidence:** No study received a high or a moderate rating. The practice may have been evaluated with less rigorous studies (e.g., pre-post designs) that demonstrate an association between the practice and positive outcomes, but additional studies are needed to establish causal impact.

The four-step process described above resulted in identification and rating of the five practices. The rating given to each practice is intended to inform decision making about adoption of new practices or clinical or system enhancements that will improve health outcomes for people with or at risk for HIV with co-occurring mental illness and/or SUD.



Photos are for illustrative purposes only.
Any person depicted in a photo is a model.

Publication No. PEP20-06-03-001
First released 2020

SAMHSA
Substance Abuse and Mental Health
Services Administration

SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.
1-877-SAMHSA -7 (1-877-726-4727) • 1-800-487-4889 (TDD) • www.samhsa.gov



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|---------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |



Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/

May 2021

Ryan White Part A/MAI Program and Miami-Dade HIV/AIDS Partnership Calendar

S	Monday	Tuesday	Wednesday	Thursday	Friday	S
	<p>All events listed on this calendar are free and open to the public. Meetings at the Miami-Dade County Library will be held in-person and via Zoom. <i>RSVP is required to attend in-person or via Zoom.</i> RSVP to cbontempo@behavioralscience.com, marlen@behavioralscience.com or (305) 445-1076.</p> <p>To request material in accessible format, a sign language interpreter, CART (Communication Access Real-time Translation) services, and/or any other accommodation to participate in this or any other Miami-Dade HIV/AIDS Partnership meeting, please contact Marlen Meizoso or Christina Bontempo at (305) 445-1076 or send an e-mail to hiv-aidsinfo@behavioralscience.com at least five (5) calendar days in advance to initiate your request. TTY users may also call 711 (Florida Relay Services).</p>					1
2	3 Miami-Dade HIV/AIDS Partnership Executive Committee **Cancelled**	4	5	6 Miami-Dade HIV/AIDS Partnership Care & Treatment Committee 10:00 AM – 12:00 PM Miami-Dade County Main Library 101 West Flagler Street Auditorium Miami, FL 33130	7 **NEW DATE** Miami-Dade HIV/AIDS Partnership Medical Care Subcommittee 9:30 AM – 11:30 AM Miami-Dade County Main Library 101 West Flagler Street, Auditorium Miami, FL 33130	8
9	10 Miami-Dade HIV/AIDS Partnership Strategic Planning Committee 10:00 AM – 12:00 PM Miami-Dade County Main Library 101 West Flagler Street Auditorium Miami, FL 33130	11 **NEW DATE** Miami-Dade HIV/AIDS Partnership Housing Committee 2:00 PM – 4:00 PM Miami-Dade County Main Library 101 West Flagler Street Auditorium Miami, FL 33130	12	13	14	15
16	17 Miami-Dade HIV/AIDS Partnership 10:00 AM – 12:00 PM <i>Rescheduled to May 26, 2021</i>	18  National HIV Vaccine Awareness Day	19  National Asian & Pacific Islander HIV/AIDS Awareness Day	20 Miami-Dade HIV/AIDS Partnership Housing Committee <i>Rescheduled to May 11, 2021</i>	21 Clinical Quality Management Committee 9:30 AM – 11:30 AM Zoom Meeting – RSVP Required*	22
23	24 Miami-Dade HIV/AIDS Partnership Community Coalition Committee 10:00 AM – 12:00 PM Miami-Dade County Main Library 101 West Flagler Street Auditorium Miami, FL 33130	25 MAI CQM Team 9:30 AM – 11:30 AM Zoom Meeting – RSVP Required*	26 **NEW DATE** Miami-Dade HIV/AIDS Partnership 10:00 AM – 12:00 PM Miami-Dade County Main Library 101 West Flagler Street Auditorium Miami, FL 33130	27	28 Miami-Dade HIV/AIDS Partnership Medical Care Subcommittee <i>Rescheduled to May 7, 2021</i>	29
30	31 Memorial Day (BSR Offices Closed)					



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|------------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/



MIAMI-DADE HIV/AIDS PARTNERSHIP

Medical Care Subcommittee Friday, April 23, 2021

9:30 a.m. – 11:30 a.m.

Miami-Dade County Main Library
101 West Flagler Street, Auditorium
Miami, FL 33130

AGENDA

- | | | |
|-------|--|------------------------|
| I. | Call to Order | Carlos Palacios |
| II. | Meeting Housekeeping and Rules | Marlen Meizoso |
| III. | Roll Call | All |
| IV. | Floor Open to the Public | Dr. Robert Goubeaux |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 22, 2021 | All |
| VII. | Reports -Q & A | All |
| VIII. | Standing Business | |
| | • Letters of Medical Necessity for Phenotypes | All |
| | • Letter of Medical Necessity for Testosterone | All |
| | • Work Plan Revision | All |
| IX. | New Business | |
| | • Cabenuva Update | Carla Valle-Schwenk |
| | • Anchor Study Update | John McFeely |
| | • Substance Use Disorder | All |
| X. | Announcements (copies on file) | Marlen Meizoso |
| XI. | Next Meeting: May 7 or July 23, 2021 at Main Library- Auditorium | Carlos Palacios |
| XII. | Adjournment | Carlos Palacios |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.aidsnet.org | facebook.com/HIVPartnership | twitter.com/HIVPartnership | instagram.com/hiv_partnership/